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Parkinson’s Disease (PD) is a neurodegenerative disorder that manifests 
with motor and non-motor symptoms. PD treatment is symptomatic 
and tries to alleviate the associated symptoms through an adjustment of 
the medication. As the disease is evolving and this evolution is patient 
specific, it could be very difficult to properly manage the disease.
The current available technology (electronics, communication,  computing, 
etc.), correctly combined with wearables, can be of great use for obtaining 
and processing useful information for both clinicians and  patients allowing 
them to become actively involved in their condition.
Parkinson’s Disease Management through ICT: The REMPARK 
Approach presents the work done, main results and conclusions of the 
REMPARK project (2011 – 2015) funded by the European Union under 
contract FP7-ICT-2011-7-287677. REMPARK system was proposed 
and developed as a real Personal Health Device for the Remote and 
Autonomous Management of Parkinson’s Disease, composed of 
different levels of interaction with the patient, clinician and carers, 
and integrating a set of interconnected sub-systems: sensor, auditory 
cueing, Smartphone and server. The sensor subsystem, using embedded 
algorithmics, is able to detect the motor symptoms associated with 
PD in real time. This information, sent through the Smartphone to the 
REMPARK server, is used for an efficient management of the disease.
Implementation of REMPARK will increase the independence and 
Quality of Life of patients; and improve their disease management, 
treatment and rehabilitation.
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Preface
Parkinson’s Disease (PD) is a neurodegenerative disorder that manifests with
motor and non-motor symptoms. PD treatment is symptomatic and tries to
alleviate the associated symptoms through a correct adjustment of the medi-
cation. As the disease evolves with time and this evolution strongly depends
on each patient, it could be very difficult to correctly manage the disease.
Currently available ITC technology (electronics, communication,
computing...) correctly combined with wearables can be of great utility to
obtain and process useful information for both clinicians and patients. In this
way, patients can actively involve in their condition and clinicians can obtain
complimentary information for helping purposes.
This book presents the work done, main results, and conclusions of
the REMPARK project (2011–2015) funded by the European Union under
contract FP7-ICT-2011-7-287677. REMPARK system was proposed and
developed as a real personal health device for the remote and autonomous man-
agement of Parkinson’s Disease, composed of different levels of interaction
with the patient, clinician and carers; and integrating a set of interconnected
sub-systems: sensor, auditory cueing, smartphone, and server.
The sensor subsystem, using embedded algorithmics, is able to detect the
motor symptoms associated with PD in real-time. This information is sent
through the smartphone to the REMPARK server and is used for an efficient
management of the disease.?
Implementation of REMPARK will increase the independence and Quality
of Life of patients; and improve their disease management, treatment and
rehabilitation.
xi
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1.1 Introduction
Parkinson’s Disease (PD) is a common neurodegenerative disorder that mani-
fests with motor symptoms (MS) and non-motor symptoms (NMS). These
symptoms vary from one patient to another and throughout the course of the
disease, affecting patients’ quality of life (QoL) progressively. Advanced PD
represents a public health problem, given that it leads to the reduction in the
capacity for self-care and deterioration of the QoL of those affected and their
caregivers. The economic cost, including lost productivity and informal care,
is about 20 billion euros in the world today.
Parkinson’s Disease treatment is symptomatic and aims to alleviate the
symptoms associated with the disease, through the precise adjustment of med-
ication. The most widely used drug, levodopa, is effective usually across the
lifespan. However, the onset of motor complications (MCs) a few years after
starting treatment (e.g., ON–OFF fluctuations and dyskinesias) detract from
its value. Symptomatic control of these complications is difficult and must be
often optimized because the obtained improvement after such adjustment is
not stable over the long term.
Treatment is primarily addressed to reduce the time that the patient is
in the OFF state (i.e., time without medication effects), while avoiding the
appearance of MCs and NMS, such as hallucinations or impulse control
disorder. Reducing OFF hours is, therefore, one of the main parameters used to
evaluate the effectiveness of therapeutic interventions, both in medical practice
and in clinical trials. Gathering accurate information about the patient’s
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condition throughout the day is essential in order to determine the optimal
treatment plan. In clinical practice, the only method available is based on
diaries filled in by patients and their caregivers about the ON/OFF hours and
dyskinesias. However, this method has certain limitations that make unreliable
medium and long-term monitoring: motor difficulties, memory failures that
hinder regular compliance and subjective evaluation. Therefore, solutions that
can improve disease management are of great interest and occupy important
part of current research.
Another important aspect of the symptomatic treatment of PD is the
multidisciplinary treatment (MDT). The multiple impairments occurring in
PD have diverse functional and psychosocial consequences. While the primary
treatment is pharmacological, many symptoms do not respond to medication,
such as on-period freezing and postural instability. Indeed, later stage disease
may be dominated by such symptoms. In addition, there is growing evidence
for the efficacy of rehabilitation therapies for specific symptoms, through the
involvement of the multidisciplinary team. There is also emerging evidence for
physiotherapy with external cueing for improving gait and balance; cognitive
movement strategies; and strength and balance exercises. Intensive speech
therapy [e.g., Lee Silverman Voice Treatment (LSVT)] has been shown to
improve the loudness and intelligibility of speech in PD. Unfortunately, the
MDT is only applied in a small number of PD patients for economical and
logistic reasons.
1.2 Impact and Strategies of PD at Different Stages
Parkinson’s Disease is one of the chronic disorders with the most impact on
patients’ lifestyle. Most patients survive many years after the first symptoms.
The mean survival rate of patients with this disease (when diagnosed after
age 50) is 26 years, not very different from the non-affected population.
This disease responds very well to treatment with levodopa and dopamin-
ergic agonists during the first years (between 3 and 7 years). As the disease
progresses, the patient encounters a limitation of the effect of medical treat-
ment due to the appearance of motor and non-motor complications. These
entail a progressive difficulty in carrying out activities of daily living and
leading an independent life. During the first year, the doctor establishes the
possible diagnosis and starts one treatment. In course of 2–4 years, there is a
relative normality and the medication is generally effective. Between the years
5 and 9, the effectiveness of medication usually decreases and treatment may
need to be modified. Problems with driving, finances, and work may appear
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Table 1.1 Modified Hoehn and Yahr scale
Scale Description
1.0 Unilateral involvement only
1.5 Unilateral and axial involvement
2.0 Bilateral involvement without impairment of balance
2.5 Mild bilateral disease with recovery on pull test
3.0 Mild to moderate bilateral disease; some postural instability; physically
independent
4.0 Severe disability; still able to walk or stand unassisted
5.0 Wheelchair bound or bed ridden unless aided
at this time. During years 10–13, there is an increasing disability: 60–75% of
patients present some intellectual deficit, worsening immobility, incontinence,
and increased risk of falling.
We can distinguish five evolutionary stages of the disease, although
patients may not go through all of them. These are the stages of Hoehn and
Yahr (Table 1.1).
The main problems presented by patients in the different evolution-
ary phases and the strategies currently recommended are explained in the
following subsections.
1.2.1 Patients in Early Stages
In stage 1 of PD, facial expression is generally normal and also the posture.
Tremor of a limb is the most common initial manifestation. It is often quite
annoying, and it is the symptom that draws the attention of both the doctor
and the patient. Tremor rarely interferes with the activities of daily living
(ADL), although it disturbs and distresses the patient. Patients sometimes
report difficulties in performing activities such as buttoning, typing, or cutting
food. In the careful exploration of these patients, other parkinsonian signs in a
limb, such as bradykinesia or slow movement, and stiffness, which contribute
to these fine motor difficulties, are detected in addition to tremor. Decreased
arm swing or dragging of a leg when walking can also be observed. These
symptoms, often present for several years, are better tolerated than tremor.
In Stage 2 of PD, the involvement is bilateral. There may be loss of
facial expression with decreased blinking. Slight flexion of the body may
be present and, in general, arm swing when walking is diminished, without
altering balance. Patients slow down when performingADLs, and they require
more time to dress, clean themselves up, get up from a chair, or tie their shoes
on their own.
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Depressive symptoms are also frequent, and these are detected in between
30–50% of the cases. Medical treatment, which is administered according to
the severity of the symptoms, often produces side effects.
In these initial stages, patients are advised to learn about the disease,
learn to speak naturally about their problems, learn to share difficulties, and
go to the doctor accompanied by someone. Standardized psychoeducational
programs, such as the “Edupark” program [1], are of great help during this
transition. From the diagnosis, it is recommended to initiate MDT, which
includes physical exercise and cognitive stimulation. It is better for patients to
continue doing things by themselves, even if it is slowly, without rushing and
with enough time. It is advisable to adapt the setting in which patients have to
perform their ADLs and to be physically and mentally as active as possible.
Family members should also be informed and should know how to convey
their support. It is recommended to see a doctor if depressive symptoms or
side effects occur with medications.
1.2.2 Moderately Affected Patients
People with PD in stages 3 and 4 already have a degree of moderate–severe
disability, as they experience difficulty walking and with balance. They explain
that their gait is shortened, and that sometimes they have difficulties to make
turns while they walk, in the corners of the rooms, or to cross doorways.
Balance problems can cause falls. Sometimes while walking, they develop
freezing of gait (FOG), or difficulty to stand, either forward, propulsion, or
backward, retropulsion. The feeling of fatigue is a very frequent symptom.
They have the feeling of needing a lot more effort to perform certain tasks,
and often notice pains in the cervical, lumbar, or shoulder region. Symptoms
of autonomic dysfunction may also be present in the form of orthostatic
hypotension, extreme sensations of heat or cold, sweating not related to
physical activity, sometimes in the form of crisis, and urinary or sexual
dysfunction.
Many patients, at stage 3 or 4, experience side effects to chronic dopamin-
ergic medication. The most annoying side effect for patients is the ON–OFF
phenomenon. This phenomenon is often disabling and causes fear and inse-
curity. During the ON phase, patients can enjoy good mobility and carry out
activities outside the home, such as shopping or social activities. However,
during the OFF phase the patient may be completely disabled, with difficulty
walking, getting up from a chair, or manipulating objects with hands. The
appearance of OFF phases limits the social activities of the patient, often
preventing them from going out. In this state, patients may find themselves in
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really dangerous situations, such as if this phenomenon occurs when crossing
a street.
Dyskinesia, or involuntary movements, are another important problem
that many patients present with during stages 3 and 4. In general, they have
a choreiform nature: creeping movements of the extremities, or masticatory
movements of the lower jaw, protrusion of the tongue, oscillations as they
walk, and head and neck movements. Dyskinesias are a secondary symptom
of dopaminergic medication, which usually occurs during the levodopa peak
dose. If they are mild, the family is more aware of these movements than the
patients themselves, who usually associate it with free time of parkinsonian
symptoms. When they are severe, they can become incapacitating as much as
the symptoms themselves.
Non-motor symptoms may appear in the form of sleep disturbances, vivid
dreams, and nocturnal vocalizations. Night-time vocalizations, reported by
the bed partner, consist of loud cries during sleep often accompanied by
agitation of arms and legs. It is called “Rapid eye movement (REM) behaviour
disorder”.These events can disrupt sleep. Other frequent behavioural disorders
in these stages are visual hallucinations, delusional ideas and confusional states
of the paranoid type. Visual hallucinations in general are not very threatening
in PD. They often describe the vision of family members, animals, or shadows
that become animated objects.
The strategies recommended in these phases are aimed at understanding
the MC’s and NMC’s and know how to monitor them. This will allow the
patient to adjust the activities in each period. In case of ON-OFF fluctuations,
dyskinesias, clinical worsening or behavioural disorders appear, the patient
may inform the neurologist who will consider the possibility of a drug
adjustment. It is, therefore, important to learn to do the patient’s diary. This
information will be crucial to optimize pharmacological treatment.
Patients, in these phases, should continue to maintain an active life and
perform MDT, such as physical exercise, occupational therapy, speech therapy,
and cognitive stimulation, according to individual needs. It is also recom-
mended to the patient to continue doing things by himself, as long as possible.
1.2.3 Severely Affected Patients
Patients with PD, stage 5, are severely affected. They are usually confined to
a wheelchair or in bed and require great assistance to make transfers. They are
totally dependent for the realization of ADLs and have a great limitation on
a personal level. Difficulties in speech and voice are often accentuated: these
patients are often difficult to understand due to their low volume and poor
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articulation of words. They may eventually develop contractures and present
decubitus ulcers or recurrent urinary tract infections.
Since the emergence of effective therapies for the cure of this disease, not
all patients reach a state of total dependence. However, they are experiencing
a progressive reduction in ON time and an increase in dependency time. In the
final stages of this disease, the presence of progressive dysphagia can cause
recurrent aspiration pneumonia, which is a possible cause of death. Other
conditions that may contribute to this outcome are infections of pressure ulcers
or urinary tract.
Since a causal treatment of the disease is still not possible, the objective
for an optimal treatment will be to obtain for the patient a good QoL
and the maximum of independence possible. In the advanced stages, it is
recommended to increase the hygiene, to take care of the mobilization, to adapt
the feeding and above all to take care of communication. The LSVT method
has demonstrated efficacy in the treatment of speech and speech disorders.
However, in very severe situations, it is advisable to maintain communication,
even if external technical support is necessary.
Possible conduct disorders should be addressed, while enhancing the
hobbies and pleasures that can still take place, such as listening to music,
reading, or watching movies.
Caregivers should make them feel their support, while they should seek
a replacement that allows them to have their own space and thus, avoid the
burden of care and better adaptation when the patient passes away.
1.3 QoL in PD
Quality of life means well-being or satisfaction with aspects of life that are
important to the person according to social standards and personal judgments.
Because of this latter characteristic (i.e., personal judgment), the QoL is
understood differently by each person and, therefore, it is difficult to define.
The World Health Organization (WHO) defines it as: “an individual perception
of the position in a person’s life, in the context of the culture and value system in
which he lives, in relation to his goals, expectations, standards and concerns”.
Quality of Life, as related to Health (QoLRH), is the self-perception and
assessment of the impact that the disease has on a patient’s life and what its
consequences are [2]. This assessment is extremely important because, when
it is not possible to cure, maintaining the QoL of the patient is a priority of
medical care. Among the different components of QoLRH, main attention
must be paid on:
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• physical aspects, which are related to symptoms and are functional (i.e.,
ability to perform activities);
• mental aspects in relation to mood and cognition;
• social aspects such as family role or social relations; and
• economic aspects.
In a recent study by Winter et al. [3], a baseline and 3, 6 and 12 months’
assessments were performed on 145 Parkinson’s patients. The average annual
cost was calculated at 20.095€ per patient. The direct costs involved an expen-
diture of 13.185 € on medication, 3.526 € on hospital care, and 3.789 € on
residences. The indirect costs accounted for 34.5% of the total costs (6.937 €).
The costs of home care for the family accounted for 20% of direct costs.
Factors associated with a higher total cost were fluctuations, dyskinesias, and
younger age.
To assess QoLRH in PD, 56 studies were reviewed [4]. The three most
important factors determining QoLRH in PD were depression, stage of the
disease, and the time that has elapsed since the onset of the disease.
In another study by Sławek et al. [5], performed with 100 patients,
the most important predictor for poor QoL was depression, followed by
motor complications. Motor complications, especially nocturnal akinesia and
dyskinesia, significantly decrease the QoL of Parkinson’s patients [6]. Not
only can dyskinesias affect QoL, but they can also increase health costs
in patients with PD. This should be taken into account when planning
treatment [7].
Despite the high impact of motor symptoms in Parkinson’s, non-motor
symptoms seem to influence patients’ QoL even more [8]. Non-motor symp-
toms tend to accumulate. The average was 10 symptoms per patient in the
populations studied and symptoms tend to intensify over time. Depression,
anxiety, fatigue, sleep disorders, pain, orthostatic hypotension, and profuse
sweating are some of those that have shown an individual relationship with loss
of QoL. In fact, any symptom that, due to its intensity, is installed as a central
problem in the life of the patient has a direct and important impact on his or
her QoL. For example: difficulty swallowing, persistent constipation, urinary
urgency and night-time urination, delusions and hallucinations, memory
problems, or a sense of choking when breathing. At the global level, the main
factors influencing the poor QoL of those affected by PD are (in order):
1. Depression
2. Overall disease severity (Hoehn and Yahr stage)
3. Dyskinesia
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4. ON–OFF fluctuations
5. Age
6. Insomnia
7. Tremor
8. Cognitive dysfunction
Another element that must be taken into account is the QoL in caregivers
of patients with PD [9]. 40% of caregivers indicate that their health suffers
from caring. Nearly half have increased depression, two-thirds report that
their social life has suffered. The caregiver becomes burned out more (burden
of care) if the patient has more disability, or affective problems, mental
confusion, or falls.There is a correlation between those caregivers that are most
affected and the degree of a patient’s depression. The conclusion is that more
attention should be given to caregivers’ care, particularly in advanced stages
and/or with psychiatric and fall complications. These findings demonstrate
that the QoL of both the patient and the caregiver depends, to a great extent,
on the inclusion of the burden of care as one of the problems associated
with PD [10].
1.4 State of Art of Current Trends in PD Management
The current treatment of PD is symptomatic and is applied through pharma-
cological and/or surgical treatment, associated with MDT.
The pharmacological treatment of PD aims to alleviate the symptoms
associated with the disease, through the precise adjustment of medication.
During the first few years of treatment, dopaminergic drugs are usually very
effective. When the ON–OFF phenomena are already present, this objective
is reached essentially by reducing the time during which the patient is in the
OFF state, while avoiding the appearance of MCs and NMS. The reduction
of OFF time is, therefore, one of the main parameters used to evaluate the
effectiveness of therapeutic interventions, both in medical practice and in
clinical trials. To determine the optimal treatment plan, gathering accurate
information about a patient’s condition throughout the day is essential. In
clinical practice, the method currently available is based on diaries filled in by
patients and their caregivers, recording hours of ON–OFF and the presence of
dyskinesia. However, this method has limitations that make it unreliable, such
as motor difficulties, failures in memory and in compliance, and subjective
evaluation. It is necessary to know precisely the effect of drugs on reducing
OFF hours and increasing the ON hours in Parkinson’s patients. Reliable tools
are, therefore, needed for detecting the motor condition of patients.
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In patients with advanced PD, in which it is very difficult to control
MCs and NMS through pharmacological adjustment, interventional therapy
strategies are increasingly applied. These treatment strategies are aimed at
obtaining continuous dopaminergic stimulation (CDS), either by using an
infusion pump to deliver medication or by deep brain stimulation (DBS).
However, these techniques are expensive, and often difficult to manage
by the patient. Well-designed clinical studies on these interventional thera-
peutic approaches provided evidence for the efficacy of DBS and CDS in
advanced PD and opened new perspectives for their use in earlier disease
stages also.
On the other hand, there is growing scientific evidence of the benefit of the
application of MDT, such as physiotherapy, speech therapy (e.g., LSVT), occu-
pational therapy, cognitive stimulation, and psychoeducation in the treatment
of Parkinson’s Disease. Intensive and multidisciplinary rehabilitation slows
the progression of motor decay, and slows the need to increase treatment with
levodopa, which is postulated to have a neuroprotective effect [11]. Therefore,
the application of MDT from the moment of diagnosis seems of great interest.
There are several studies of multidisciplinary care in PD comparing outcomes
before and after the intervention. Outpatient multidisciplinary care pro-
grams have reported short-term improvements in UPDRS (Unified Parkinson
Disease Rating Scale) motor score, gait speed and stride length, speech,
depression and health-related QoLRH. Long-term improvements in motor
function have also been reported, and the authors comment that a close
collaboration among members of the multidisciplinary team was essential
to obtain the best results.
Potential limitations to the implementation of effective MDT are:
distance, insufficient expertise among health professionals, poor interdisci-
plinary collaboration, poor communication, and lack of financial support
for a multidisciplinary team approach. Regular face-to-face team meetings
are important for effective functioning of the team. These meetings allow
sharing of pertinent information and ensure the team is working towards
shared goals for any given patient. The meetings can be a forum and stimulus
for staff education, driving up quality of care. This type of coordinated
multidisciplinary approach is sometimes referred to as interdisciplinary.
Most hospitals in Europe do not have a multidisciplinary service for the
care of people with PD. These types of therapies are expensive and in addition,
their application requires patients to frequently go from one place to another.
This entails a number of limitations, both economic and logistical, for those
affected with PD before having access to these therapies.
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1.5 Needs and Challenges for Optimal PD Management
Current management of advanced PD is complicated and problems arising
from poor QoL affect many patients. In 2001, the Committee on Quality of
Health Care in America Institute of Medicine provided an objective analysis
on healthcare. The report listed six aims, proposing that health care should
be: safe, effective, patient-centred, timely, efficient, and equitable. However,
current care for PD in the US, Europe, and likely the majority of the world,
frequently does not meet these six aims [12]. PD care is often not safe.
Individuals with PD who are hospitalized are often subjected to delayed
treatment, contraindicated medications, prolonged immobility, lengthy stays,
and high mortality [13, 14]. There are some comprehensive and distributed PD
care models that are quite effective, but only few patients receive such care.
Many PD-related hospitalizations are likely preventable. The patient-centred
care that is timely has been rarely studied. Despite the limited evidence, focus
groups and surveys suggest that individuals with PD want more personalized
information from multiple disciplines that is delivered remotely in a timely
manner [15]. PD care is very inefficient. Patients and their caregivers spend
hours travelling and waiting in the clinic for routine follow-up appointments
or for the application of complementary therapies.
Finally, and perhaps what may be most concerning, there exists inequity
of current PD care. A primary determinant of the care that will be received is
where you live. In the US, 42% of individuals with PD older than 65 and up
to 100% of individuals in some rural areas do not see a neurologist soon after
diagnosis [16]. In Europe, the first right expressed in the European Parkinson’s
Disease Association Charter is care from a physician with a special interest
in PD. However, 44% of Europeans do not see a PD specialist in the first
2 years after diagnosis. Beyond neurological care, access to specialist nurses,
occupational therapists, and counsellors is often more limited [17]. In less
wealthy countries, the situation is even worse. China only has approximately
50 movement disorder specialists to care for more than 2 million individuals
with PD and Bolivia only has 15. A door-to-door epidemiology study found
that none of the individuals identified with PD had ever seen a physician, much
less received treatment.
We can make the treatment safer, effective, patient-centred, efficient, and
equitable only with the application of two conditions: that the treatment is
applied mostly in the patient’s home and with the use of tools, based on new
technologies: sensors, communication platforms, and smartphones. This will
overcome economic barriers and physical distance.
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The simple fact of detecting accurately and reliably the clinical condition of
the patient can mean a significant advance in the QoL of the patient, as this will
affect a much more accurate adjustment of medication. In addition, with the
help of adequate platforms, many more patients, as well as their caregivers,
will receive more specialized medical care, complementary therapies, and
psychoeducation as often as necessary, regardless of where they live.
In addition, reliable detection of the motor status of PD patients throughout
the day can drastically change the value of drug clinical trials. Finally, the
careful selection of patients amenable to the semi-invasive therapy options
becomes more and more important and should be timely. An interdisciplinary
setting is required to account for optimal patient information and awareness,
selection of best individual treatment modality, training of relatives and
caregivers, management of complications, and follow-up care.
The application of this type of tool is also of great interest in this
section [18].
From a clinical point of view, the development of new technologies in the
management of Parkinson’s Disease must be validated so that the improvement
of the QoL related to health is the main objective. Symptom-monitoring
tools should be based on these premises: to provide a valid and accurate
parameter of a clinically relevant characteristic of the disease; to find evidence
that the parameter has an ecologically relevant effect on the specific clinical
application; that a target interval can be defined in which the parameter reflects
the appropriate treatment response; and finally, that the implementation is
simple to allow repetitive use [19].
Remote monitoring from devices, such as wearable sensors, smartphones,
platforms, disease management applications, smart beds, wall-mounted cam-
eras, smart glasses, and even utensils, can monitor a patient’s symptoms and
function objectively in their environment, facilitating the delivery of highly
personalized care.
Another aspect to improve PD care is that the most of it must be delivered at
home. Current care models frequently require older individuals with impaired
mobility, cognition, and driving ability to be driven by overburdened care-
givers to large, complex urban medical centres. Moving care to the patient’s
home would make PD care more patient-centred. Demographic factors,
including aging populations, and social factors, such as the splintering of the
extended family, will increase the need for home-based care. Technological
advances, especially the ability to assess and deliver care remotely, will enable
the transition of care back to the home. However, despite its promise, this
next generation of home-based care will have to overcome barriers, including
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outdated insurance models and a technological divide. Once these barriers are
addressed, home-based care will increase access to high-quality care for the
growing number of individuals with PD.
Emerging care models will combine remote monitoring, self-monitoring,
and multidisciplinary care to enable the provision of patient-centred care at
home and decrease the need for in-clinic assessments.
The demand for in-home care is likely to grow as a result of demographic,
economic, social, and technological factors. Both the absolute number and
proportion of older individuals with PD will increase.
1.6 Conclusion
A system for PD management will be necessary in the near future. It must be
able to reliably assess the symptoms, facilitate patient disease management,
and give them independence and the best QoL.At the same time, the tools must
help the patient to stay physically and mentally active as much as possible.
Finally, they must provide the neurologist with disease management tools to
optimize the treatment.
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2.1 Advancing Parkinson’s Disease: Motor
and Non-Motor Fluctuations
The triad of rest tremor, slowness of movement (bradykinesia), and limb
rigidity constitute the clinical hallmarks of idiopathic Parkinson’s Disease
(PD). However, the majority of patients will develop an increasing number
of more complex symptoms over time. These symptoms include variability
in the patient’s mobility, so-called motor fluctuations, as well as variability in
other non-motor symptoms (NMSs). Much of this variability is accounted for
by a change in the patient’s response to dopaminergic medication over time,
such that the duration of benefit for a given dose of dopaminergic medication
shortens. The following section will elaborate further on these motor and
non-motor fluctuations and how they affect patients’ ability to function. It is
important to note, however, that not all motor fluctuations are the result of
changing responses to dopaminergic medication.There is increasing recogni-
tion that several progressive motor symptoms such as postural instability and
freezing of gait (FOG) are the result of non-dopaminergic dysfunction and,
therefore, unlikely to respond to standard pharmacologic modifications. The
clinical picture of advancing disease is further complicated by the emergence
of other symptoms including cognitive dysfunction, sleep disturbances, and
blood pressure instability, all of which combine to contribute to the increasing
risk of falls in patients with PD. These emergent symptoms probably are a
reflection of the underlying pathogenesis in PD, which is thought to involve
spread of neuronal degeneration not only to dopaminergic neurons but also
autonomic and cholinergic pathways. The result of advancing PD, therefore, is
a tendency for patients to develop motor and non-motor fluctuations, postural
15
16 Objective Measurement of Symptoms in PD
and autonomic instability, cognitive impairment, and increasing falls risk. As
we shall see in the following section, the task for the clinician is to accurately
document the emergence of these symptoms, so that appropriate treatment
strategies may be initiated to restore patients’ quality of life (QoL).
2.1.1 Motor Fluctuations
Over 70% of patients with PD will develop increasing variability in their
motor response to dopaminergic treatment after 5 years [1]. These “motor
fluctuations” typically appear insidiously and are often initially unnoticed by
the patient. The first evidence of an emerging fluctuating medication response
is the “wearing-off” phenomenon, where the patient reports slowing up or
increasing stiffness as the time approaches for their next dose of medication.
This commonly is apparent overnight as the patient develops difficulty turning
over and getting comfortable in bed (nocturnal akinesia). Patients report that
they feel the first morning dose of medication “kick in” around half an hour
after taking it (“morning benefit”). Over time, patients may notice end of
dose “wearing-off”. This may be ultimately quite dramatic to the point where
they “freeze” and become effectively immobile until such time as their next
dose “kicks in”. Furthermore, the time needed for the subsequent dose to
start working may be strongly influenced by several factors including dietary
intake of protein, which may result in a delayed time before the patient turns
ON. Motor fluctuations can become so severe as to result in the ON–OFF
phenomenon, where the patient may cycle rapidly between being ON (mobile)
and OFF (immobile or frozen). As mentioned above, these fluctuations are the
result of alterations in dopamine receptor sensitivity to exogenous dopamine.
The increasingly attenuated motor response to dopaminergic medication is fur-
ther complicated by an exaggerated sensitivity of the motor response, resulting
in excessive involuntary movements (dyskinesia), typically during the time of
peak plasma levels of dopamine. Less commonly, painful twisting (dystonic)
movements occur as dopamine levels rise or fall (biphasic dyskinesia). The
OFF state may be so severe in patients as to cause painful “off dystonia” or
FOG. It will be apparent, therefore, that there is a wide repertoire of variability
in a given patient’s motor state, ranging from complete immobility to flinging
choreic movements, and that these fluctuations may occur cyclically many
times throughout the day. Furthermore, the occurrence of motor fluctuations is
influenced by many factors, including the dose and formulation of dopaminer-
gic drug, diet, anxiety, and use of concurrent medications. It is essential that the
treating clinician documents an accurate account of these motor fluctuations,
so as to guide further treatment to minimize their disruption to the patient
(Table 2.1).
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Table 2.1 Common motor and non-motor fluctuations in PD
Motor Non-motor
Wearing-off
• Morning benefit
• Nocturnal akinesia
• ON/OFF
Sensory
• Paresthesias
• Hyposmia
Freezing of gait (FOG)
• Start hesitation
• Festination
Autonomic
• Sweating
• Constipation
• Orthostatic Hypotension
Dyskinesia
• Peak dose
• Biphasic
Neuropsychiatric
• Anxiety
• Depression
• Psychosis
OFF dystonia Sleep
• Rapid eye movement (REM) sleep
behavior disorder
• Excess daytime sleepiness
2.1.2 Non-Motor Fluctuations
It has been increasingly recognized that while much of the day to day disability
in PD relates to motor dysfunction, many patients experience a variety of
NMSs, including paresthesias, fluctuating mood, and anxiety, autonomic
disturbances such as constipation, postural hypotension, sleep disturbances,
as well as cognitive slowing (bradyphrenia) [2, 3]. As alluded to above, many
of these symptoms reflect the underlying degenerative process, which affects
several neurotransmitter systems. However, it is also apparent that many of
these NMSs occur as a result of dopaminergic dysregulation, and are, therefore,
fluctuant in the same way as motor symptom fluctuation. NMSs typically affect
one or more of four domains: neuropsychiatric, autonomic, sensory, or sleep
(Table 2.1). Many NMSs are now recognized to precede the development
of motor symptoms in PD, and hence, can be seen as intrinsic to the disease
process. Other NMSs are likely to be due to medication effects. The importance
of recognizing fluctuations in non-motor dopaminergic symptoms (such as
OFF-related paresthesias or anxiety) is that their management will be entirely
different to similar symptoms that may not be dopaminergic in origin. For
instance, many patients will develop acute onset anxiety symptoms as the
first symptom of wearing-off of their dopaminergic medication. Treatment
of this symptom will involve modifications in their l-dopa intake rather than
prescribing anxiolytics. It will be again apparent that it is essential for the
18 Objective Measurement of Symptoms in PD
clinician to accurately document these symptoms so as make appropriate alter-
ations in therapy may be made. Teasing out non-motor symptomatology can
be challenging even for the experienced clinician.Adding to the complexity of
this assessment is the fact that cognitive dysfunction develops in the majority
of PD patients over time, so that after 15 years, 80% of patients experience
significant cognitive impairment [4]. Moreover, chronic sleep disturbances
due to nocturnal akinesia, rapid eye movement (REM) sleep behavior disorder
and psychosis frequently result in excessive daytime somnolence. Each of
these factors contributes to the difficulty that many patients have in recognizing
fluctuations in MS and NMS.
2.2 Challenges in Documenting “Real-World”
Fluctuating PD Symptoms
The complexity of evolving motor and non-motor fluctuations in PD poses
a significant challenge to the treating clinician. It will be apparent from the
previous discussion that accurate identification of true dopaminergic motor
and non-motor fluctuations is paramount to the future management strategy for
each patient. In the context of a busy hospital or clinic-based environment with
its restrictions on the face-to-face patient time, as well as patient anxiety and
fatigue, all contribute to the problem of accurate documentation of a patient’s
clinical status. The clinician has a number of well-worn skills at their disposal
so as to become informed of how a patient is coping. The traditional history
taking and detailed examination techniques provide invaluable information
not only about the patient’s motor function, but importantly about the patient’s
understanding of the different motor states. The latter is a critical aspect of the
clinical encounter. Is the patient able to distinguish tremor (a manifestation of
the OFF state) from dyskinesia (an ON phenomenon)? What is the patient’s
understanding of the terms OFF and ON? While the clinician examination will
usually help in determining the patient’s motor status, it is only a snapshot of
a patient’s daily life, and even at that, often not a particularly reliable one, as a
visit to the doctor’s office is not representative of a patient’s daily activity, and
the added burden of long travel to the clinic, a degree of patient anxiety about
the encounter, as well as forgotten tablets, may all contribute to a distorted
account of a patient’s “real-life” clinical status.
A number of additional tools are available to help the clinician acquire
the necessary data to inform therapeutic decision-making. The availability
of an informed family member provides a useful narrative regarding the
patient’s home life, although too often the patient may live alone or a spouse
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is unavailable or unable to provide helpful information. A variety of clinical
rating scales and questionnaires have been developed which provide a degree
of objectivity to the patient’s assessment, though all have their own limitations.
Although the Unified Parkinson’s Disease Rating Scale (UPDRS) remains the
gold standard clinical rating scale especially in a research setting, it suffers
from subjectivity and variable clinician competence in using it. For many years
patient diaries have provided the backbone of “real-world” interrogation of
patient motor states. Diaries allow for frequent recording of a patient’s motor
state (OFF, ON, ON with dyskinesia; and asleep) as determined by the patient
or caregiver. However, patient reported diaries are known to lack consistency
and can be associated with variable adherence. In addition, patients may
have physical difficulty filling in the diary due to micrographia and severe
akinesia. Similarly, many patients have difficulty distinguishing tremor from
dyskinesia, or may erroneously record the state they are in at the moment of
documentation, rather than their predominant motor state over the preceding
hour or two. What is certainly clear in relation to the accurate assessment of
motor fluctuations is that the patient’s motor state as determined in the clinic
is rarely representative of their quotidian state; indeed, it is not uncommon
for the patient to cycle from extreme akinesia to severe dyskinesias during the
course of the clinic encounter. The situation regarding accurate detection of
non-motor fluctuations is even more difficult, and relies mostly on obtaining
a careful history from the patient and their family regarding any possible
periodicity of such symptoms (Table 2.1). The NMS questionnaire [5, 6] is a
30-questions assessment tool which can be useful in highlighting symptoms
not previously recognized as potentially related to PD. Such questionnaires
may lack the ability to identify non-motor fluctuations as part of a medication
effect and are impractical for clinical routine use.
2.3 Emerging Technologies to Monitor Symptom
Fluctuations
In an attempt to improve the ability to detect and monitor the occurrence
of motor fluctuations, a variety of new technologies have emerged which
is beginning to transform the management of Parkinson’s Disease. Two
technologies have recently been combined which promise to radically change
the daily management of PD: so-called “wearables” and machine-learning
based techniques [7]. Suffice it to say here that these technologies can provide
objective, high frequency, sensitive, and continuous data on motor and non-
motor phenomena in PD [7]. In particular, the development of wearable inertial
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sensors has introduced a level of objectivity in the recording of patients’motor
function in daily life, so-called free-living monitoring [8]. The explosion
of interest in the quantitative assessment and management of PD using
technology-based tools has been usefully summarized in a series of reviews in
the journal Movement Disorders [9]. Several large-scale studies on wearable
technologies have reported preliminary results, along with over a dozen
smaller series using a variety of machine learning algorithms for wearable
sensor-based data acquisition in PD (summarized by Kubota et al. [7]). The
obvious appeal of wearable technology (WT) is that it allows for community-
based data acquisition over a continuous time period. In addition, the collected
data is free from observer bias and the so-called attentional compensation
(Hawthorne effect). The newer devices are relatively low cost with user-
friendly technology. Continuous monitoring allows for the accumulation of
large amounts of data, which may be analyzed at both a macro- or micro-level
[10]. At a micro-level, data is available on motor state, frequency and severity
of motor fluctuations, gait as well as response to medications. In the case of
patients with PD, data can be acquired on the number and intensity of multiple
activities, including the frequency and amplitude of movements throughout
the day and night, the frequency and duration of tremor, dyskinesia, as well
as impairments of gait including FOG and balance impairment [11]. There
is also the possibility that detailed interrogation of data obtained at regular
intervals may disclose important subclinical physiological changes that might
predict a subsequent clinical change in motor state, allowing potentially for
preemptive therapeutic intervention. This appears to be especially relevant in
the detection of FOG [12, 13]. A big challenge, however, for any emerging
sensor technology aiming to supersede existing clinical motor assessments
(such as the UPDRS) is the requirement for clinimetric algorithm validation.
Testing of such objective algorithms must include a test/re-test protocol to
ensure reliability.
At a macro-level, general levels of activity, inactivity or sleep are available.
The information obtained from WT is available both to the clinician and the
patient, and importantly it allows the patient to become actively involved in
their condition and learn about their level of activity as well as therapeutic
efficacy. An important aspect of a WT system is that it allows remote
monitoring of symptoms with its obvious potential advantage for patients and
health economics (REMPARK system, presented in this book, is an example).
It should be apparent that the ability to quantify clinical phenomena
using WT is not simply because “we can”, but that the ability to reliably
capture such data is a major advance on the standard qualitative clinical
examination. Espay et al. [11] point out that whatever is measured must be
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directed toward a therapeutic target. Despite these technological advances,
however, their application in a clinical setting has been slower to evolve.
As Del Din et al. [10] pointed out, there remains no gold standard against
which remote monitoring WT can be compared. Moreover, simply measuring
a litany of motor and non-motor phenomena should not necessarily lead to
reflexly acting on such data with therapeutic intervention. What matters for
one patient may cause little functional impairment for another. For instance,
a common experience for the clinician is to observe a patient with severe,
ballistic dyskinesias, but for whom the involuntary movements are non-
disabling [14]. This dichotomy becomes even starker when one attempts to
take into account various non-motor measurements (such as hyperhidrosis or
anxiety), which may cause substantial disability for the patient, but remain
less overt than motor recordings. A number of attempts have been made to
record non-motor symptomatology using sensor technology, chiefly relating to
sleep-related symptoms [15]. These sensors can provide valuable real-world
insight into a variety of nocturnal sleep difficulties including RBD (REM
sleep behavior disorder), nocturnal akinesia, and restless legs syndrome.
Moreover, information on excessive daytime somnolence is also recordable
on inertial devices. In recognition of this, several commentators have called
for a “multidomain” integrated technology as the template for individualized,
personalized therapeutic approach to care [11]. The REMPARK system is an
attempt to provide an integrated system of personalized management of PD.
2.4 Challenges in the Use of Inertial Sensor Technology
in Monitoring PD Symptoms
There exist some specific challenges in the use of technology for an objective
monitoring of PD and the contribution to increase QoL of patients. A set of
them are discussed below:
1. Limitations of Motor Sensors: Currently available commercial sensor
technologies have been demonstrated to accurately measure a variety
of motor symptoms in PD including tremor, bradykinesia, dyskinesia,
and gait impairment [16]. However, much of the validation testing of
such technology was derived from laboratory-based experimentation.
Clinicians have raised a concern that this is not an accurate reflection
of “real-world” situations. For example, sensor data fails to discriminate
accurately whether bradykinesia is the result of fatigue, anxiety, or motor
wearing-off [12]. Hence, the context in which sensor data is derived
has a large influence on its interpretation. While the freedom to record
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continuous data in an ambulatory home setting has obvious advantages
over the laboratory, the trade-off is a substantial loss of experimental
control over the data collection [7]. The REMPARK system and others
have attempted to provide a degree of context to the sensor data by the
provision of smartphone technology, which allows the patient or carer
to interact with a web-based application to input subjective data, such as
a non-motor questionnaire [13]. Another potential limitation of inertial
sensor measurements is that their resolution may be affected by their
anatomical location, and that while this may be mitigated to some extent
by the application of multiple sensors, this adds to the complexity of the
algorithms to interpret the data, as well as adding more complexity and
discomfort for the patient [17]. Currently, most available sensors rely on
single sensors applied to the most affected side in patients.
2. NMS Monitoring: The development of WT to monitor PD symptoms
has primarily focused on motor aspects of the disease [11]. However,
it has been apparent even using older established clinical scales of
motor disability (UPDRS) that there is at best only a modest correlation
between the degree of motor impairment and QoL. There is an emerging
recognition that a substantial daily burden for patients derives from
non-motor symptomatology [5], including symptoms such as anxiety,
sweating, fatigue, sleep disturbances, etc. While some technologies are
available to address this, such as sweat sensors, blood pressure and heart
rate monitors, as well as the application of inertial sensors to monitor
for sleep disturbances, clearly further refinement of this technology is
needed.
3. Clinimetrics and data validation: There is a natural tendency to consider
the development of “objective” sensor technology as ultimately replac-
ing previously validated subjective rating scales such as the UPDRS.
However, Espay et al. [11] have pointed out that the clinician integrates
many sources of “data” to reach a subjective score or opinion, and
that technological sensor measurements should complement clinical
measures rather than act as surrogate markers.
4. Disease Progression:The advent ofWThas opened the door to their use in
clinical trials of emerging therapies as surrogate markers of efficacy. But
investigators need to be cognizant that improved sensor “data” following
institution of a therapy may not translate into improved QoL for patients.
Moreover, use of WT longitudinally will need to take into account that PD
is a progressive disease and that the parameters by which improvement
must be measured will change over time. For instance, for many patients
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with advanced disease, the priority of maintaining cognitive function
may come at the expense of a desirable motor outcome, at which point
motor sensor data becomes moot.
5. Data Analysis: Existing technology-based objective measures require
a robust method of data analysis to ensure that the data collected is
an accurate reflection of the clinical phenomena under scrutiny. The
development of algorithms to appropriately interrogate the data requires
close cooperation between clinicians and technical personnel. For
instance, a sensor that detects “severe bradykinesia” at one measure-
ment and “severe dyskinesia” at a second measurement within a two-
minuteepoch is likely to be spurious, unless data from other sources can
be factored in. In this case, the data suggesting “severe bradykinesia”
is likely to be strengthened in its validity if such data is accompanied
by a contemporaneous finding of “severe tremor”. Development of
reliable algorithms to interpret data requires input from clinicians so
that appropriate weighting can be given to such data.
6. User Engagement: Despite enthusiasm from technologists and clinicians
for the incorporation of WT into practice, current research suggests only
modest patient and carer engagement [18]. Giving feedback to patients
on the relevance and importance of wearing sensors seems to influence
adherence.
2.5 Conclusion
There is little doubt that the rapid development of continuous WT with the
ability to generate objective measurements relating to the evolving clinical
state of PD patients has provided a tremendous opportunity to improve patient
care, as well as learn more about the disease as it affects patients in their own
environment. In the long term, these technologies will have to be sufficiently
reliable and robust to allow for the remote personalized management of PD,
including treatment delivery.
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3.1 Introduction
As it has been presented and described in previous chapters, Parkinson’s
Disease is a progressive neurological condition. Unfortunately, there is no
known cure for the disease and only treatments focused to the management
and mitigation of the different symptoms are available to patients.
A well-designed and adapted technological approach (mainly based on
WT and machine learning, as suggested in Chapter 2) can help both, the
patients and their neurologists, for a better management and follow-up of the
disease evolution. This will open the possibility to more effective therapies
in order to improve patients’ daily activities. From the beginning, with
this specific aim, REMPARK project proposed four main objectives to be
covered:
Objective 1: Real-time motor status identification.
To develop a minimum set of wearable inertial, electronic, intelligent sensors,
to register in real-time the ambulatory movements of the patient and to
clearly identify the relevant number of parameters, or types of motor disorders
associated with Parkinson’s Disease.
27
28 The REMPARK System
Objective 2: Gait improvement system.
To develop a self-calibrating gait guidance system to prevent the gait impair-
ments and therefore minimize the appearance of FOG episodes and falls. The
development will be mainly focused on auditory cueing, based on a system
able to generate an auditory or acustic signal when necessary (Auditory Cueing
System ACS), in order to help patients to improve their gait.
Objective 3: User interface to get patient’s feedback.
To develop and implement a specific user interface on a smartphone to collect
feedback directly from the patient. This feedback provided by the patient must
have, at least, the following functionalities:
• Introduction of routine information such as the medications’ intake time,
quantity and quality of the sleep and other NMS.
• Answer to specific prompts to validate some situations detected by
the REMPARK system. For instance, periodically completing medical
tailored tests designed by the doctors (based on the UPDRS scale) in order
to assess the evolution of the patient with time regarding the non-motor
symptoms.
Objective 4: REMPARK service for remote management of the disease.
Acentral server service (REMPARK Server) organized to act as a repository of
the processed ambulatory data of the patients, to ease the combination of these
data with the Electronic Health Record (EHR) and to facilitate interaction with
the neurologist (or medical service), the patient and/or the caregiver.
The present chapter introduces a deeper view of the presented approach,
describing the details of the implemented and used system for the works carried
out during the evolution of REMPARK project.
3.2 REMPARK System Overview
The developed REMPARK system has been worked-on and designed as
a Personal Help System (PHS) that provides a closed-loop detection and
treatment capabilities for an improved management of Parkinson’s Disease
(PD) patients.
From the beginning, the REMPARK architecture was conceived and
organized in two different levels:
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• The immediate level (BAN – Body Area Network). A minimum set
of wearable monitoring sensors should be able to identify in real time
the motor status of the patient. The identification of the status is made
autonomously using embedded algorithms in the sensor. The sensitivity
and specificity of these sensors are better than 80%. A gait guidance
system, based on an auditory cueing system ACS, was envisioned as part
of this level to help the patients in real time during their daily activities.
The immediate level is also including actuation capabilities that will be
triggered by certain conditions detected by the sensors:
• activation of the ACS;
• automatic administration of a questionnaire;
• possible remote control of a delivering medication pump.
A possible inclusion of a remotely-controlled pump was done in REM-
PARK project as a laboratory exercise with no real tests in the trials with
patients. This is a challenging work aiming to give a response to the need
of a more accurate and adapted dose control for infusion pump systems.
It must be considered as a step forward in the improvement of the QoL
of patients with advanced PD.
All the information from and to the immediate level are carried out by a
smartphone which is used as a gateway.
• The mid-term level (based on a server). This is where the data provided
by the sensors are partially analyzed, along with disease management
done automatically or/and by neurologists. This part of the REMPARK
system provides interconnection between analysis performed in the
sensor and data provided by the neurologist, caregivers or the patient.
An important tool at this stage is the Disease Management System
(described in Chapter 8) that opens the possibility to a high level manage-
ment of PD and to the establishment of interaction between concerned
people.
These two levels and their relationship are represented in Figure 3.1. Below,
Figure 3.2 shows a more detailed content of the described levels, together with
the associated functionality. In these levels, two different groups of algorithms
are running. The first group is located in the Immediate level (BAN), mainly in
the sensor and smartphone, and it is responsible for the ON/OFF detection, the
different symptoms identification and the implementation of the gait guidance
system. A second group of algorithms is responsible of the implementation of
the Rule Engine at the second level.
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Figure 3.1 Hierarchical organization of REMPARK system.
Figure 3.2 System architecture overview.
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3.2.1 The Immediate Level
The Immediate Level corresponds to the Body Area Network (BAN) and
acts in the short-term. It is composed of the sensors, the actuators and the
smartphone, which also acts as GPS for providing context-aware information
and as an interface for the PD patient, to record their direct feedback especially
regarding the non-motor symptoms.
Communications among the elements of the BAN is done through Blue-
tooth V2.1, allowing enough autonomy for the patient. This level operates
autonomously and it is a real operative closed loop. It is auto-adaptive by
means of a constant evaluation of the actuator’s effect, correcting its behavior
in the short-term. The configuration of this level can be changed according to
different patients’ needs.
Considering the details indicated in the Figures 3.1 and 3.2, the main
components or sub-systems having a direct interaction with the PD patient are
the following:
• Sensor module: It is in charge, using appropriate technology, of the
continuous monitoring of the patient’s movement behaviour. It is able
to detect and identify in real-time the different motor-related symptoms
suffered by the patient.
• Mobile gateway: As it is inferred from Figure 3.1, it plays a central role
in the system. It does not only interact with the remaining components,
but also drives their behaviour by setting their functional parameters.
In the REMPARK system the mobile gateway is implemented using a
commercial smartphone and specifically developed software.
• Drug pump: It is intended to administer an appropriate drug dose
depending on the patient’s movement parameters (in REMPARK project,
this part was only considered, for a feasibility demonstration and was
treated from a theoretical point of view with a laboratory proof of
concept).
• Auditory cueing system (ACS): This component provides an auditory
pattern intended to assist the patient in the case of abnormal movement
patterns (such as FOG or shortened stride length).
3.2.2 The Mid-Term Level
The Mid-term Level (also called the Level 2), refers to the actuation in the
medium-long term and constitutes a closed semi-automatic loop, as it will
allow the intervention of medical professionals. The system is able to send
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data to the server, allowing the patient’s neurologist to regularly follow the
evolution of the patient’s disease in a more effective manner, as well as being
able to take better informed decisions about the adjustment of the pharmaco-
logical treatment of the patient using the Disease Management System (DMS).
The system is also able to generate alerts, according personalized thresholds,
related to the status and evolution of the disease.
Data on the server can be automatically included in an Electronic Health
Record (EHR). This way, the correct intelligent data treatment will help to
evaluate and predict the evolution of the disease of a particular patient.
Below, the sub-systems responsible for the storage of the data generated at
Immediate Level as well as for its high-level analysis are listed. The results of
the high-level analysis are available to both the patient and the neurologist or
clinician. The clinician can also interact with the system by changing/updating
the medication profile of the patient.
• Mobile gateway: At this level, it is responsible for sending the data
generated at the first level to the REMPARK server and to get the feedback
test to be presented to the patient.
• REMPARK server: It is in charge of storing the data provided by the
mobile gateway and of making this data available to the Rule Engine,
described below.
• Rule Engine: This component filters the raw data stored in the server
and makes it available to the patient and the caregiver using an appro-
priate interface. Through this interface, both the PD patient and the
clinician/neurologist can be interconnected. The patient is able to access
the personal record stored in the server. The neurologist can access the
personal records of the supervised patients and eventually update their
treatment plan based on this information.
3.3 Definition of the REMPARK System Main
Characteristics
This section includes a description of the main characteristics of the system.
Some characteristics were included according considerations already con-
tained in the proposal of the project and after the analysis of the results obtained
from the answers provided by potential users of the REMPARK system
(patients, neurologists and carers) to specific questionnaires elaborated by
the consortium [1, 2]. These will imply concrete requirements and constraints
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for the system that were considered and included in the final version of the
tested system.
The indicated references [1, 2] are publicly available reports on these activ-
ities which contain details of the administered questionnaires, the constraints
of this administration, obtained answers and their analysis. As it is indicated
in [1], there are three main conclusions derived from the answers provided by
patients to the REMPARK questionnaire:
• The most prevalent motor disorders among patients are: ON/OFF
phenomena, dyskinesia and FOG.
• The most prevalent gait problems among patients are: “reduced walking
speed”, “small steps” and “shuffling”. These problems appear both at
home and outdoors, and nearly half of the patients use a strategy to
improve them.
• Over 80% of patients are familiar with the use of a mobile phone for
making calls and sending SMS. However, they are not so familiar with
smartphones based on a touch interface.
Regarding the answers provided by caregivers, as stated in [2], four main
conclusions can be derived:
• “Reduced walking speed” and “small steps” are the most clinically
relevant symptoms in the mild stages of PD. “Freezing of gait” and
“difficulty in turning” are the most clinically relevant symptoms in the
moderate stages of PD. In the advanced stages of PD, “falls” arises as a
new main clinical occurrence.
• Patients use strategies to improve symptoms mainly in the moderate-
advanced stages of PD. However, the strategies that PD patients adopt
(mostly the use of a stick) are not considered as useful as verbal cueing
(auditory).
• “Reduced walking speed” should be considered a symptom as relevant
as “freezing of gait”.
• The moderate stages of PD are the best target for the REMPARK
system. This means that the system should pay special attention to the
multifaceted clinical expression of PD during these stages.
Table 3.1 summarises the requirements for the REMPARK system derived
from the feedback got from the final users through the proposed questionnaires.
It is worth noting that first and third requirements in Table 3.1 were already
considered in the original goals and specifications of the REMPARK project,
but second one was only detected after the evaluation of the questionnaires.
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Table 3.1 Technical specifications derived from the user feedback
Requirement Heading Requirement Description
Symptom detection The system must be able to detect at least the following
symptoms: “reduced walking speed”, “small steps”, “freezing
of gait”, “dyskinesia”, “bradykinesia” and “falls”.
Patient interface The user interface in the mobile gateway must be operated by
a PD patient in any stage of PD.
Symptom mitigation The system must provide auditory cueing upon detection of
“reduced walking speed”, “small steps” and “freezing of gait”
symptoms.
Concerning the symptom detection requirements of the system, the motor
status of the patients will be evaluated based on the following parameters:
• Tremor
• Bradykinesia
• Freezing of gait (FOG)
• Stride length
• Gait speed
• Fall indicator
• Dyskinesia
The final conclusion on ON/OFF state is achieved by a real time execution of
the included algorithms and an evaluation of their combination or presence
during a given time period.
3.4 Subsystems Specification
In previous sections, main components of the REMPARK system and the
processes that enable their interaction have been identified. Based on this, the
present section elaborates the main technical specification for each individual
component: the sensor module, the ACS Auditory cueing sub-system, the
smartphone and the REMPARK platform.
As it will be discussed in Chapter 4, a very important part of REMPARK
project was devoted to the gathering and construction of a Database, with the
cooperation of a number of patients in order to extract the necessary knowledge
for the development and implementation of the corresponding algorithms to be
embedded in the processing part of the final sensor module. These embedded
algorithms in the sensor module will be able to process and to determine in real
time the presence of specific symptoms in a patient. It must be clarified here
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that the presented and mentioned sensors hereafter (the wrist and the waist
ones) have been used for data gathering and construction of the Database, but
after discussion and final conclusions of REMPARK, the wrist sensor was
finally not considered in the pilots, where only the sensor module located in
the waist of the patient was finally used.
3.4.1 Sensor Module
The sensor module is the subsystem in charge of determining in real time if a
specific indicator (of a concrete symptom) appears in the PD patient movement
pattern. The detection of the indicators is obtained after a local process of the
data acquired by the sensors included in the module. These indicators are sent
at regular time intervals to the mobile gateway subsystem, that will thereafter
decide the action to be performed based on their values.
The type and number of sensors to be used depend on the specific
movement disorders to be detected. As it has been stated in the previous
section, the movement disorders to be addressed by the REMPARK system
are the following: Tremor, Stride length, Gait speed, Bradykinesia, Falls,
Dyskinesia and FOG.
• Tremor consists in an involuntary, rhythmical, forward and backwards
movements of a body part, which are Caused by the rapid alternating
contraction and relaxation of muscles. For three out of every four
people who develop Parkinson’s Disease (PD), the disease begins with
a trembling or shaking in one of the hands. It can also appear in the feet,
face or jaw. This rhythmic movement of the extremities in PD patients has
a frequency typically between 4–7 Hz. Therefore, in order to detect this
movement disorder, the REMPARK system should include a sensor unit
to be placed in the wrist. This unit should contain a triaxial accelerometer
and a data processing unit. In order to provide an indicator whose value
is related to the presence of tremor in the hand the data processing
unit should be able to carry out sensor readings with a frequency of at
least 20 Hz.
• The determination of indicators related to stride length, gait speed and
bradykinesia are interrelated, since the gait speed is given by the number
of strides in a specified time window, and once stride length and gait
speed are determined it is possible to derive an indicator for bradykinesia.
Even if the stride length has been determined in the past using gyroscopes
placed in the leg [3], it has been demonstrated [4] that a single triaxial
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accelerometer placed on the patient’s waist can be used to accurately
measure stride length, gait speed, bradykinesia and falls.
• Dyskinesia is a medication side effect experienced by patients with
Parkinson’s Disease and shown in the form of involuntary movements.
There are many papers in the literature that manage to successfully
detect dyskinesia using inertial sensors. The most prominent research
work in this area is performed by Manson et al. [5] which uses a triaxial
accelerometer placed on the shoulder. The analysis is based on the com-
parison of a signal’s characteristic with the severity of dyskinesia assessed
by Abnormal Involuntary Movement Scale (AIMS) while the patient
performs the following activities: sitting, talking, writing, drinking,
preparing food, eating and walking. Characterizing the signal consists of
obtaining the average value of the accelerations in the range of 1 to 3 Hz,
obtained through a band-pass filter. This characteristic of the signal
is demonstrated to be correlated with the value of the AIMS score.
The study included 26 patients with Parkinson’s Disease who were
monitored for 20 minutes. Since a triaxial accelerometer placed on
the waist will be used to measure stride length, gait speed and falls,
the data provided by this sensor unit will also be used for detecting
dyskinesia.
• Regarding the detection of FOG episodes, the first work that analysed
the relationship between the frequency content of the signals gener-
ated by triaxial accelerometers and the presence of a FOG episode
was presented in [6]. Two accelerometers were placed in the ankles
of both healthy people and PD patients. It was observed that normal
walking has a principal frequency around 2 Hz, while FOG episodes
are characterized by a principal frequency in the range of 6–8 Hz. A
second study was carried out in [7] with PD patients. In this study,
a single triaxial accelerometer was placed on the patient’s shin, and
the signal was measured on the vertical axis (parallel to the leg). It
was found that FOG episodes caused the appearance of frequency
components in the range 3–8 Hz. This study was continued in [8,
9], where the analysis presented in [7] was extended to accelerom-
eters placed in the patient’s thigh and waist. Regarding the results
obtained when the sensor was placed on the waist, it was found that
they were similar and even better than those obtained when using
other body locations. Therefore, the REMPARK system will use the
waist accelerometer to derive an indicator related to the rising of a
FOG episode. In order to cope with the different measurements that
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this unit has to carry out the minimum sampling frequency should
be 40 Hz.
From the previous explanation, a decision was initially taken and the sensor
module to be used in the REMPARK system was constituted by two sensor
units. One of these sensor units must be placed on the patient’s wrist and the
other on the patient’s waist. These sensor units must contain, in principle, a
triaxial accelerometer and a data processing unit. However, in order to provide
additional contextual information to the acceleration data, it is considered
convenient to include sensors too providing information related to the speed
(gyroscope) and the orientation (compass). This information may improve
the sensitivity and specificity of the measurements related to the movement
disorder indicators to be generated by the REMPARK system.
As previously indicated, the sensor module has to communicate using a
wireless link, such as Bluetooth, with the mobile gateway of the REMPARK
system, in order to make the measurements accessible to both the patient
and the caregiver. Therefore, in order to simplify the overall system and to
make it more user-friendly it is envisioned that the sensor units placed in the
waist and the wrist should establish a communication using the same wireless
communication protocol.
It is important to bear in mind that during the construction of the already
mentioned REMPARK database the raw data captured by the sensors will not
be processed by the sensor units, since the goal of this project phase is to
get enough representative data in order to develop efficient processing and
detection algorithms. Thus, the sensor module should have some amount of
local storage in order to save the sensor recordings. This local memory unit
should be easily accessible in order to retrieve the data once the experiments
with patients are finished.
Another important aspect to be considered is that the sensor module has
to be operated by people with no technical knowledge. Hence, it has to offer
a very simple procedure to start/stop its operation and to analyse its status
at any time (preferably using visual information). Additionally, it has to be
worn during extended periods of time (approximately eight hours during the
experiments). This poses a constraint to the physical features (weight and
size) of the sensor module, to the materials that have to be in contact with the
patient’s skin.
According to the above considerations, Table 3.2 summarizes some of the
main requirements for the sensor module derived from operational features to
be exhibited by this subsystem.
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Table 3.2 Some important technical requirements for the sensor module
Requirement Heading Requirement Description
Structure The sensor module must contain a sensor unit placed in the
patient’s waist and a sensor unit placed in the patient’s wrist.
Size – waist sensor unit The dimensions of the waist sensor unit must be smaller than
150×70×30 mm.
Size – wrist sensor unit The dimensions of the wrist sensor unit must be smaller than
80×70×30 mm.
Weight – waist and
wrist sensor units
The weight of the sensor units must be low (around 200 g. for
the waist unit and 150 g. for the wrist one)
Battery capacity The battery on the sensor units must permit a normal
continuous operation for at least 8 hours.
Operation – waist and
wrist sensor units
The sensor units must be turned on/off using a single button.
User interface The sensor unit must use a single led to display its state.
Communication The sensor must be able to establish a wireless link with the
mobile gateway. This requirement is only for the operative
part and not used during the database construction phase.
Communication –
additional specs
The waist and wrist sensors must be able to send to the mobile
gateway its battery status. The waist sensor must be able to
send to the mobile gateway data containing indicators for the
following movement patterns: stride length, gait speed,
bradykinesia, falls, dyskinesia and FOG.
Communication –
security
The data sent by the waist and wrist sensor units to the mobile
gateway must be encrypted.
Sensors – waist sensor
unit
The waist sensor unit must contain a triaxial accelerometer, a
triaxial gyroscope and a compass.
Sensors – wrist sensor The wrist sensor unit must contain a triaxial accelerometer.
Data sampling rate The waist sensor unit must be able to sample data from the
sensors with a frequency of at least 40 Hz.
The wrist sensor unit must be able to sample data from the
sensors with a frequency of at least 20 Hz.
It must be noted that during the Database construction, used
frequency was higher (200 Hz for the waist sensor and 80 Hz
for the wrist sensor).
Data processing The waist sensor unit must contain a data processing unit able
to calculate indicators for the following movement patterns:
stride length, gait speed, bradykinesia, falls, dyskinesia and
FOG.
The wrist sensor unit must contain a data processing unit able
to calculate indicators for the following movement patterns:
tremor.
Comfort The parts of the sensor unit in contact with the patient’s skin
must be constructed with a biocompatible material.
(Continued )
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Table 3.2 Continued
Requirement Heading Requirement Description
Battery certification The Li-ion batteries used in the sensor module must have test
certificate according to standard UL 1642.
Battery charger
certification
The battery chargers used for the sensor module must have a
test certificate demonstrating compliance with IEC 60950.
3.4.2 Auditory Cueing Subsystem
This section describes the REMPARKAuditory Cueing System (ACS) system
for gait-cueing and FOG intervention. This system intends to be a self-
calibrating/adaptive gait guidance system for helping PD patients in real time,
during their daily activities.
PD patients are usually affected by symptoms associated with a reduced
motor performance and gait disturbances that affect their ability to walk
independently and safely [10]. One of the key problems of PD patient’s gait is
the particular difficulty with the internal regulation of stride length, reflected
as an inability to generate sufficient stride length, even though the control of
cadence (or step rate) is intact and can be easily modulated under a variety
of conditions [11, 12]. Some patients may increase the stepping frequency to
compensate the reduced stride length [12–14]. With the disease’s progression,
other episodic gait disturbances can appear, e.g. start hesitation and FOG
episodes [12]. Festination of gait, characterized by small and rapid steps, is
also a common symptom of advanced PD [15]. By applying adequate external
regulatory rhythmic stimulations, movements’ speed and amplitude can be
modified [16], so that gait performance is improved, even under complex
environments [9, 12, 17, 18].
The ACS systems would therefore be able to adapt the rhythm of cueing
to the specific needs of each patient and each situation, being activated and
deactivated at the adequate times, taking into account the real time feedback
sent by inertial sensors (i.e. relative to the gait’s quality), as well as the feedback
provided by the patient (i.e. a subjective feedback related with the quality of
cueing that is being applied).
3.4.2.1 Gait guidance ACS functional description
The cueing system is intended to be used every day, during daily activities.
The smartphone (seen at this point as a control unit) will be responsible for
the control of the auditory cueing actuator, and will be able to program the
cue parameters taking into consideration the specific needs of the patient in
each situation, in a self-adaptive way (Figure 3.3).
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Figure 3.3 Simplified representation of the ACS functionalities.
The system must be mainly controlled in a self-adaptive way and should
not require user intervention to trigger or adapt a cueing response. Thus, it is
required that the system operates in real time, together with the feedback
provided by inertial sensors.
Since continuous auditory cueing might not be acceptable for PD patients
[9] the system will provide the cueing automatically only when required, i.e.
when the patient is walking and a context of impaired performance or an
inefficient walking pattern is perceived (based on the available REMPARK
sensor subsystem measures).
In concrete, the final parameters and symptoms considered for triggering
of the ACS system are the presence of a bradykinetic walk and FOG episodes,
suffered by the patient (see Table 3.3).
The detection of gait impairments is performed through a real-time
comparison with the baseline data characterizing the normal range of walking
parameters values for a specific individual patient.
It must be clear that, according to the previous explanation, there exists
a very close relationship between stride length, speed of walking, cadence
and bradykinetic walk. Hence, changes in these parameters, characterizing a
bradykinetic walk, must be referred to baseline measurements of a patient [19].
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Table 3.3 Parameters/Measures considered by the ACS
Parameter/Measure Description
Bradykinesia Slow movements, slow walk
FOG episodes Transient period in which gait is halted.
This means that even if a low stride length is detected, this parameter can be
considered normal if the baseline walking speed is also low.
The determination of “normal values” needs to be done carefully, so
that meaningful values are considered for impairments detection. To get this
information, some initial tests (called here the calibration sessions) can be
performed with each patient before starting to use the REMPARK system. The
therapist/doctor must be the responsible for conducting these tests, in order to
accurately control the protocols and the results. The REMPARK system will
also be able to detect the FOG episodes, which are also considered as an input
for the ACS subsystem.
Based on the detection of the triggering symptoms and their comparison
with the baseline values, the ACS automatically activates or deactivates the
cueing. Also given these measures, the cueing rates must be automatically
adjusted to the specific needs of the patient in each situation. This autonomy
requires a constant evaluation of the effects of cueing on the patient, and the
automatic adjustment of cueing rates according to the patient’s response. The
requirements related to the specific situations are detailed on Table 3.4.
The ACS will provide the cueing in the form of sounds. Once the patient
hears these sounds, he/she will try to synchronize the rhythm of steps with
the rate of the sounds provided. Sound beats can be single (i.e. pace one step
per stride) or double (i.e. pace both steps per stride). According to [20], gait is
more effectively modulated when both footfalls are paced, which means that a
double beat must be used. Specific voice recordings of alerts and information
must be produced when the patient is not able to synchronize with the rhythm
of cues. These alerts must help the patient to synchronize with cueing rate and
ask for some patient’s feedback.
TheACS implemented and used in REMPARK (see additional information
in Chapter 7) is comprised of two physical components – headphones and
the smartphone – that will interact (directly or indirectly) with other sub-
systems. The smartphone will be able to decide when and how to actuate in
each specific situation; headphones are placed on the patient’s ear and will
produce the sounds acting as cueing. The above Figure 3.3 is presenting this
architecture.
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Table 3.4 General functional requirements of the ACS system
Requirement Heading Requirement Description
Cueing type ACS must provide cueing automatically, in a
self-adaptive, non-continuous way, taking into account
the specific needs of the patient in each situation.
Operation mode Cueing must operate only when the patient is walking.
System interaction ACS must be able to work in real time, together with the
feedback provided by sensors.
Functional requirements ACS must be able to detect a bradykinetic gait based on
walking speed, stride length and the occurrence of FOG
episodes, as measured by movement sensors.
Stimulus type ACS must provide stimulus in the form of sounds.
Sound rhythm Sounds must pace both left and right footfalls.
Alerts ACS must be able to provide voice recordings with
alerts and instructions, when required.
Configurability ACS must be able to program the activation and
deactivation of sound stimulus at the adequate
times/situations.
Adaptation ACS must be able to automatically adapt the rhythm of
cues (sound stimulus) to the specific needs of each
patient in each situation.
Evaluation and Rating ACS must be able to constantly evaluate the effect of
cueing on the patient and to enable the patient to rate the
cueing session.
A headset (ear-set) was selected to be included in the auditory cueing
system. Ear-sets are usually small and aesthetic and, as they are placed in a
single ear, they enable the patient not only to hear the auditory cueing but also
to perceive the auditory stimulus from the surrounding environment.
The auditory stimulus will be provided in the form of metronome sounds.
Since different rhythms of stimulus are going to be produced, the easiest way
to apply cueing is to use metronome sounds, because its rate is easier to be
adapted than, e.g., the music.
Since the headset will produce the sounds streamed by the smartphone,
it must therefore be compatible with Advanced Audio Distribution Profile
(A2DP). This profile defines how audio can be streamed from one device
to another over a Bluetooth connection. A2DP is designed to transfer a
unidirectional 2-channel stereo audio stream.
Alternatively, audio can be produced by a non-A2DP device, by chan-
nelling the audio to the stream that carries phone call audio to the headset.
This option was, also, considered as an option.
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3.4.2.2 Need of an adaptive ACS
When an external rhythmic auditory pacing is applied, the patient tries to
couple his/her footfalls with the beats, which helps to normalize the walking
pace (cadence) [20, 21].As stride length and stride frequency tend to change as
a function of walking speed, this adaptation of cadence might offer a strategy
to indirectly influence the stride length regulation in these patients, while
controlling for walking speed [19].
The effects of auditory cueing may, however, differ for patients with or
without FOG, referred as “freezers” and “non-freezers”, respectively [18].
It is well known that cueing rates higher than baseline walking rate are
contraindicated for freezers. Based on the study by [22], it is recommended
the use of a lower rate setting for freezers and an increase of up to 10%
for non-freezers. In both cases, the latest goal of training with the ACS is
to maximize stride length while walking at as fast a cadence as possible. If
these two variables are increased during training, then walking speed is also
increased [16].
The cueing rate settings need, then, a careful consideration, i.e. the intended
speed of walking and the quality of movements, and the different responses
to the cues by different subgroups of patients suffering from PD. Given these
conditions, a set of requirements related with the auditory cueing rate must be
carefully considered:
• Preference
• Safety
• Walking rhythm
• Different modalities
• Adaptation to the user
As the person can dictate his/her own preferred walking rhythm, the perception
of this baseline rhythm is crucial, so that REMPARK ACS can be the most
fitted and comfortable as possible to each situation. The comfortable walking
rate is used as a basis to establish the auditory cueing tempo being provided
if it is necessary.
The baseline rhythm can be perceived when gait is considered normal
(without evident motor symptoms). After the person has started to walk a few
strides, it is possible to estimate this rhythm (at least 3 strides are required
to reach a steady-state walking in healthy young subjects [23]). When this
estimation is not possible, the normal cadence at the preferred speed, as
calculated during the calibration session, can be used. When setting the cueing
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rates, it is important to guarantee that the applied rates will never compromise
the safety of the person, both during dual task and walk alone.
Therefore, gait cannot be stimulated beyond the person’s limits and the
stimulus cannot provide a negative effect on the walking pattern of the
individual. A too high cueing rate, for example, may lead to small steps (low
stride length) at a high cadence, which is an inefficient walking pattern.
As PD patients face different problems and intensities of problems
considering the different stages of the disease and medication states (i.e.
ON/OFF state and freezer/non-freezer classification) [24, 25], theACS system
must enable the introduction of different settings/configurations for different
patients.
The self-adaptive cueing system will have the possibility to be adjusted/
modified in several ways by the patient and by the doctor/therapist. The
ACS system must offer the following characteristics regarding user’s interac-
tion: configurability to the specific needs of different patients, configuration
of different parameters done by caregivers (rate, modality, baseline, rate
change . . .), voluntary deactivation, adjustment of the volume and the tone.
3.4.3 Drug Delivery Pump Considerations
The development of a wireless communication module for subcutaneous
infusion pumps of liquid medicines opens an opportunity for real-time control
of the applied dose. A system of closed-loop control would be possible for the
case of some diseases in which the result of treatment can be measured by a
sensor, i.e. the drug infusion could be adjusted to the needs of the patient in
real time.
This idea has been explored in the case of diabetes, in which the glucose
level in plasma can be measured accurately and thus this information may be
used to control the basal dose of insulin to be delivered via a subcutaneous
pump infusion. From this hypothesis, various feedback systems that include
automatic and semi-automatic (with a doctor in the decision loop) feedback
have been successfully developed, in which insulin infusion is controlled
according to the level of glucose in the blood. In contrast, drugs for Parkinson’s
treatment are often given using a pre-established scheduling and dosage.
However, regardless of the route of administration, intermittent delivery of the
programmed dosage produces fluctuations in the level of the drug in plasma
(known as ‘peaks and valleys’) that produce variations in the effects of the
drug in the central nervous system.
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The amount of drug in each administration and the time between admini-
strations is calculated so that the peaks of plasma do not exceed the upper
therapy limit (which may produce unwanted side effects) and that the valleys
do not fall below the lower therapy limit (which may cause the therapeutic
effect to disappear). Unfortunately, it is not always possible to maintain drug
levels in plasma within the therapeutic range. What is more, as the disease
progresses, the goal of staying in the therapeutic range is increasingly difficult
to achieve and therefore, the time intervals between administration of drug
become shorter and the doses higher. Contradictory to this, such doses and
time intervals seldom completely control symptoms and therefore, the OFF
periods and dyskinesias occur eventually.
Recently, it has been hypothesized that if the drug levels are maintained
within the therapeutic range, control of symptoms associated with Parkinson’s
Disease will be improved substantially [26].
To this end, therapeutic solutions are being developed, aimed at eliminating
the programming/intermittent administration of medication and replacing it
by a continuous, controlled administration. It is precisely for this reason that
subcutaneous administration of dopaminergic drugs was made possible by
the development of infusion pumps that maintain drug levels in plasma in the
desired range for as long as possible.
The purpose of using these pumps is to maintain the level of drug in plasma
within the desired range, and, at least, change the dose on a schedule based on
time (different doses depending on the time of day, assuming the needs of the
patient). The development of “automatic” infusion pumps, able to adjust the
drug dose based on the patient’s symptoms will be welcomed both by patients
and by doctors as a breakthrough in controlling the symptoms of Parkinson’s
Disease.
Apomorphine is an agonist dopaminergic with a very short average life,
which is administered subcutaneously. There is extensive experience in the
use of apomorphine for the treatment of Parkinson’s Disease, including its
administration in the form of bolus or flow for the release of “lock states” and
the corresponding basal treatment.
In order to address the symptoms in real time with apomorphine, a
subcutaneous infusion pump that can adapt to them is required, that is, it
should receive orders from a device capable of monitoring symptoms.
Even if drug infusion pumps were not tested with patients within the
framework of the REMPARK project, one of the project goals was to test if
the REMPARK system may be useful to create an automatic or semi-automatic
feedback loop that will improve the treatment of PD patients. For this purpose,
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a commercial apomorphine infusion pump was used in the REMPARK system.
The pump was modified with the necessary electronic components so that it
was able to communicate with the mobile gateway so as to receive commands
related to the drug dose to be administered. The pump should be able to operate
both in bolus and in infusion mode. Additionally, the electronic system added
to the pump should permit a manual user interaction.
In REMPARK project, the organization of a specific pilot action, with
real patients, using a drug delivery system control was discarded because it
was out of the real possibilities of the project activity. Alternatively, it was
decided to consider this effective possibility, preparing all the requirements
and conditions from a technical and functional point of view. This activity was
based on an already developed experience by some of the participants [27].
3.4.4 The smartphone Technical Requirements
The smartphone is at the core of the REMPARK BAN, receiving data from
sensors and sending instructions to actuators. Furthermore, it serves as a gate-
way between the BAN and the server, by receiving settings and preferences
from the server and sending the data gathered in the BAN. In consequence,
the smartphone is a critical device in the BAN, as without it the system would
be unusable. Figure 3.4 shows the connections of the smartphone on the
REMPARK system, as well as the directions of the information exchanged.
We split the requirements of the smartphone into hardware and software.
The hardware requirements are mainly related to the characteristics of the
smartphone including connectivity. It must provide battery life, as well as
other usability requirements.
Figure 3.4 Smartphone connectivity and information flows.
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Connectivity-wise, the smartphone should be able to form the BAN itself,
connecting to all sensors and actuators using Bluetooth protocol. To connect
to the caretaker server, it will need an Internet access enabled. Here, cellular
connectivity is mandatory (GMS or UMTS) and Wi-Fi will be used whenever
possible. Although most smartphones in the market today already come with
all these radio interfaces, we need to ensure that they are present and available;
for instance, we need to ensure that the smartphone has a SIM card with a data
plan enabled, so that cellular data is available. As this is a critical component
of the system, we need to ensure that it is always on, or at least minimize its
downtime. To this end, it is critical to have a suitable battery that will last for
the whole day while the patient is away from a power source. We expect the
system to last at least 8 hours working on battery power alone, as this is the
maximum expected time a person will be away from a power source.
With regards to the usability of the smartphone, we expect it to be big
enough and have enough resolution so that older adults with some visual
difficulties can use it. Furthermore, the device needs a touch screen interface
to provide direct interaction and a more reduced learning curve.
As a result of a review of relevant literature, and interviews with doctors
and relatives, we identified major changes on PD affected people’s fine motor
skills, changes that makes it very hard for them to do precise movements both
on ON and OFF stages. Hence, we need a screen large enough to accommodate
buttons as big as necessary in order to offer them good interaction experience.
• On/OFF state, they have their fine motor movements mostly conditioned
by Bradykinesia and rigidity. Causing slower movements and loss of
agility thus precise movements become very difficult. Possibly they can
do some precise selections but with great effort. Whereas tremor although
being generally a rest tremor, sometimes can still be active while on
movement, and thus makes a precise movement even harder.
• While on ON state even when most PD symptoms are gone, on later stages
of the disease, PD affected people have dyskinesia which can be impairing
as the other symptoms, since it make them do involuntary movements
and thus making it very difficult to do precise selections as well.
Moreover, with the aim of interacting with a touch screen, a user does not need
to apply much pressure to activate it, which is also beneficial to PD affected
people since they also have lack of strength and are much more comfortable
with smooth gestures.
In order to ensure these preconditions and to guarantee that we can extend
the smartphone functionality in any way we require it to have an open-source
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operating system and main drivers, so that we can access, change and compile
them to any software version we need.
Concerning the smartphone related software aspects, they will consist of
distinct components:
• Server Communication: The smartphone will need to exchange infor-
mation with the REMPARK Server.
• End-user Applications: The smartphone will provide a number of
applications related to the management of the disease or the REMPARK
system.
• Data Processing and Event Detector: The smartphone will analyse the
data received from the sensors and will raise specific events.
• Sensor Communication: The smartphone will gather information from
waist sensor.
• Actuator Communication: The smartphone will control the actuators
upon receiving orders from the Server, an input from the user or after
processing the data gathered by the sensors.
In regards of the Server Communication, the smartphone must guarantee the
communication with the REMPARK server, establishing a communication
channel with the caretaker server whenever needed, and use encryption
methods that must ensure:
• Data integrity: both the smartphone and the server must guarantee that
the information they receive was correctly transmitted and unaltered.
• Data security: the mechanism must ensure that no one else can have
access to the information being transmitted, as well as ensure that no one
can alter the information while it is being transmitted.
• Authentication: both the smartphone and the server will be able to
authenticate themselves to each other, thus guaranteeing that information
is being transmitted to the right party.
• Non-repudiation: tightly coupled to the authentication mechanism, non-
repudiation aims at guaranteeing that: (1) every message is signed, so
that the sender cannot deny that it had sent the message; (2) no one else
can impersonate the sender. This will guarantee that every message is
accounted for.
The final set of the smartphone requirements is related to provide a set of
applications, both giving users and medical caretaker’s tools to better manage
this disease. To the users, it provides assistive applications to help them with
their daily lives and to the medical caretakers it provides valuable medical
information of the state of the disease. These applications range from actuators
controllers (e.g. for auditory cueing), assistive applications to help the users
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with their daily living (e.g. medication reminders) questionnaires to input
medical or routine information and prompts to validate specific situations
detected when acute events are detected.
The smartphone is also the interface to the caretaker server, so it must
provide a way for patients to use the services provided by the server, e.g.,
check health status, contact the doctor, see appointments. Table 3.5 provides
an overview of these requirements.
The REMPARK smartphone must receive and process the data from the
sensors. The processing will be achieved through a set of algorithms to assess
the status of the patient and control the BAN actuators. These algorithms will
be adapted to the particular needs of each user. As such, the smartphone will
fine-tune the algorithms by updating its information with the caretaker server.
Furthermore, after analysing the data, the smartphone should decide on the
action, or event, to trigger. These actions can be:
• to enable an actuator for the interaction with the patient
• to raise an alarm so that medical staff can respond
• to ask some input, or confirmation, to the patient.
The smartphone will also provide an Actuator Communication component to
interact with the actuators. The actuator actions must be triggered either by
the smartphone in the cases described above, or directly by the server if, for
instance the medical staff decides that the patient should receive some input in
real time (e.g., a medical questionnaire). Furthermore, when communicating
with the actuators, the smartphone must ensure that: (1) messages sent to the
actuator are not replicated, so that the actuator does not trigger the same action
twice; (2) no messages for the actuator are lost, to guarantee that the actuator
really acts; (3) actions of the actuator are personalized for each patient, for
instance, the auditory cueing system uses the frequencies that better suit the
patient.
Table 3.5 Requirements of the smartphone end-user applications
Requirement Heading Requirement Description
Questionnaires The smartphone must enable the user to answer medical
questionnaires sent by the doctor.
User answers The smartphone must enable the user to answer specific prompts
to validate alerting detected situations.
User input The smartphone should enable the user to input routine
information such as the time of intake of the medications,
quantity and quality of the sleep or other information.
Actuators The smartphone should enable the user to adjust the behaviour
of the auditory cueing.
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3.4.5 The REMPARK Platform Architecture and Functionality
The REMPARK platform is composed of all the services that will store and
process information, namely, the server and the Rule Engine blocks. While
the so-called server will have the role of keeping the database and hosting all
the services, the Rule Engine will use these data to make further analysis and
store new processed-data. All this information will be used by the medical
application to show relevant information to clinical professionals that is why
it is got an interaction with the server. Likewise, the Mobile Gateway will also
interface the server to store measures and alerts. Figure 3.5 shows an overall
architecture view of the main blocks that make up the REMPARK’s platform
and its main interactions.
An important element of the REMPARK platform is the server, enabling
the potential service. There are two main functionalities. The first one deals
with measures and the second one with alerts. Both functions are deployed
as REMPARK’s services in the server and they will provide also methods to
insert and extract both measures and alerts of any type. These services will be
exposed so that the blocks that interface the Server (i.e. Rule Engine, Medical
Application and Mobile Gateway) can use them.
Other identified service is the Patient Service. The Server must provide a
way to register new patients and associate them with their information (i.e.
measures, alerts) as well as providing some basic information report about
them and their associated hospital, if necessary. Finally, it might be useful to
have questionnaires’ information available and that is why a specific service
dealing with this functionality should be implemented. Figure 3.6 shows the
services that the server will expose to their interfaces.
Figure 3.5 Platform functional architecture.
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Figure 3.6 Server services.
Table 3.6 summarizes the main technical requirements of the REMPARK
server
Table 3.6 Technical requirements for the REMPARK server
Requirement Heading Requirement Description
Service Server must expose some public services so that the
Mobile Gateway, the Rule Engine and the Professional
Application can access the generated data.
Service Server must provide services that are able to store and
extract for each specific patient.
Measures Server must provide a service to store measures which
will be used by the Mobile Gateway, Rule Engine and
the Professional’s application.
Measures New measures must be able to be added in a simple
fashion.
Getting Measures Server must provide a service that allows receiving
measures and is accessible by the Mobile Gateway, Rule
Engine and Professional Application.
Alerts Server must provide a service to notify about alerts
which will be used by the Mobile Gateway, Rule Engine
and the Professional’s application.
Alerts New alerts must be able to be added in a simple fashion
Storing Alerts – Mobile
Gateway
• Patient has fallen.
• No connection with motion sensor.
• Emergency button.
• Sensor is running out of battery.
• Mobile phone is running out of battery.
Storing Alerts – Rule Engine • Mobile Gateway has lost connection with the
platform.
• Mobile Gateway has resumed connection with the
platform.
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3.4.5.1 Important functional parts
As it was indicated in Figure 3.2, there is a set of important functional pieces
embedded in the REMPARK server that are crucial for the implementation of
its final functionality. They are the Rule Engine sub-system (RE), the Disease
Management System (DMS) and the user-Web interface.
3.4.5.1.1 Rule Engine
The Rule Engine (RE) is a subsystem which is intended to analyze and process
data from sensors at regular time intervals. The main idea is to perform tasks,
such as post processing (e.g. filtering and transformation) or data analysis
(e.g. verify that the most recent pulse and/or blood pressure measurement
was within an acceptable range), at regular time intervals. The tasks and their
timing were defined by medical and technical partners along the project.
Four components make up the RE: (1) a timer, (2) a processing service,
(3) a task manager and (4) a data manager. The data manager encapsulates the
access to the main REMPARK database. It is the main interface to REMPARK
system and provides the means to read and write data (i.e. measures and alerts).
The task manager will decide when a task needs to be executed at a certain point
in time. The processing service is fed with a set of tasks which it executes. A
timer is used to (re-)initialize the processing of tasks at regular time intervals.
In order to implement the tasks, it must be specified: (1) how often a
particular task needs to be performed (e.g. every minute, every five minutes),
(2) the data that the performance of this particular task requires (e.g. pulse
data or data from the inertial sensor), (3) how recent the data needs to be (e.g.
last fifteen minutes, at least two hours old or just the most recent value) and
(4) the task itself (e.g. check whether pulse is within acceptable range).
3.4.5.1.2 Disease Management System
The Disease Management System (DMS) is an application for managing
the patient’s health by the medical staff. Data and medical information are
integrated into the DMS to support medical decisions. These decisions have
influence on changes in the treatment plan and raising alerts to the medical
team who has to take care of it. The DMS for REMPARK was developed
as a web application using the .NET platform with C# as the programming
language.
The DMS is based on the REMPARK database as the resource for
every data coming from the patient. The information is sent through the
communication module and written to the database. The DMS will have access
to the data as a raw data and to the processed data coming from the RE.
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Every user of the DMS will be linked to a specific user profile. Every profile
will be exposed to the relevant data according to pre-defined specifications.
Four profiles have been defined:
• Supervisor – The main authority in the site (Doctor, nurse or other) that
will have access to the management parts of the system. The supervisor
can register new users and manage the profiles.
• Doctor – The Doctor is the highest medical authority in the call center/
point of care. Therefore, the doctor will have full access to the treatment
plans of the patients related to the specific patients’ doctor.
• Nurse – Every nurse will be assigned to several patients who will be
monitored by another specific nurse. The supervisor will have the ability
to allow one nurse to access another nurse’s patient in case of absence of
the nurses. This exceptional access will be time limited. A nurse can be
assigned also to all patients at the call center.
• Patient – The patient will be related as a DMS user in order to allow
the patient access a web interface/web site for watching the information
related to him/her. A patient cannot be deleted from the database. Instead,
the patient’s status can be changed to “Not Active” and it will not be
shown in the DMS lists (or report) but will remain in the database.
Important operative tools, included in the DMS are:
• Patient’s Record. The patient’s record must include the patient details,
patient relative details (a contact person in case of emergency), a technical
part with documentation of the equipment implemented in the patient’s
home (ID, IP, etc.) and a treatment plan.
• Treatment Plan. For each patient registered in the REMPARK program a
treatment plan is created by the neurologist according to the patient’s
evaluation and clinical history. The treatment plan will include the
necessary exercises, medications, normal ranges for every measurement
the patient will have the sensors connected to the Mobile Gateway at the
patient’s home.
• All of the above will be documented in the DMS. The treatment plan can
be viewed by any of the medical team assigned to the patient but only the
doctor can change an existing medication treatment plan. In some cases,
a nurse could also be able to change the treatment plan. These special
cases, if any, will be defined in the Clinical Protocol. A change in the
treatment plan can be a result of changes in the patient’s health, patient’s
environment, etc.
• Alerts. The alerts will be raised in two ways.
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1) Alerts that were sent by the Rule Engine after processing raw data.
2) Alerts that came directly from the Mobile Gateway without any
pre-processing.
• Clinical protocols. The clinical protocols can be described as set of
flow charts allowing the neurologists to make decisions according to
the collected information. It is actually a set of medical instructions for
every situation, change (or lack of change) in the patient status. These
protocols can be updated or changed from time to time according to the
medical considerations.
Table 3.7 compiles the requirements of the DMS according to the description.
3.4.5.2 Platform technical constraints
Before analysing the different services that must be supported by the server,
it is important to estimate important parameters that can compromise the
performance of the whole system, such as the maximum storage, the maximum
number of simultaneous transactions and the bandwidth.
Just as an example, calculations were made considering the constraints
imposed by the pilots organized in REMPARK project. Final technical
decisions were:
• Maximum storage requirement of 100 Gbytes, permitting to operate with
60 patients during 1,5 years, considering that a probable transmission rate
of 1 Kbyte per minute should be necessary, with the sensor connected
during 12 hours a day.
Table 3.7 Compiled requirements for the DMS
Requirement Heading Requirement Description
BAN data DMS will store all data from the BAN.
Medical monitoring DMS will monitor medical aspects of the patient.
Technical monitoring DMS will monitor technical aspects of the patient regarding the
REMPARK project.
Alerts DMS will raise alerts when information about irregular
behaviour or measurement will come from the gateway.
Questionnaires DMS will allow managing questionnaires.
Treatment plan The treatment plan will be created in the DMS.
Data integrity No data could be deleted from the database.
Monitoring interface The DMS will have a monitoring interface.
Data interface The DMS will have an interface for showing patient’s data.
Website The DMS will have a patient personal website.
Reports The DMS will be able to publish reports.
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• Concerning the bandwidth, it was estimated that 1 Mbps channel is more
than enough for the requirements of REMPARK.
• The maximum number of parallel transactions, considering the previous
figures, overcome the necessary characteristics.
3.5 Conclusion
The present chapter has presented and described the architecture, functionality
and technical requirements of the REMPARK system, organized along some
different sub-systems specifically designed for fulfilling the functional objec-
tives of the proposed project, finally implemented and tested in real piloting
experiences.
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4.1 Introduction
This chapter describes the methodology developed and used to obtain the
elements of the REMPARK system devoted to monitor the related PD motor
symptoms, according to the specifications discussed in the previous chapter.
The monitoring part basically consists in the waist-worn device and its
embedded algorithms for the analysis of the PD patients’ movement and gait.
The development of such a device to assess motor symptoms has been
divided into several steps that are summarised below:
• First, different questionnaires were administered to professionals and
cargiveers to identify some system requirements and the most important
symptoms to be monitored. This step has been already partially presented
and used for the purpose of Chapter 3. The present chapter describes the
details of these questionnaires and the obtained results.
• A methodology was developed to detect these symptoms, which is based
on inertial sensors and machine learning techniques. This methodology
is presented in Section 4.3.
• A database of signals was collected in order to develop automatic
detection methods based on the mentioned methodology. The design of
the experiment to collect such data and a summary of the data obtained
are also detailed in Section 4.3.
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• The algorithmic approach to exploit the database of signals based on mac-
hine learning techniques is presented in Section 4.4. Each symptom and
parameter detected by an algorithm is described in a different subsection.
• Finally, some conclusions are drawn.
4.2 Decision on the Most Relevant Symptoms to Be
Detected and Assessed
During REMPARK project, specific tasks were devoted both to the collection
of clinical information and to understand aspects that may be relevant for
the REMPARK system. These tasks were carried out during the first months
of the project through the administration of two questionnaires addressed to
patients and related professionals [1]. Their results were included in the system
design to set the technical specification of the system (partially discussed in
Chapter 3).
The most relevant issues addressed in the questionnaires administered to
professionals are summarised below:
• First, on the salient clinical features of PD in the different stages of the
disease. Here, for instance, professionals were requested to indicate the
symptoms with higher priority for treatment, to report which monitored
symptoms may have a greater impact on daily living, and which are the
most frequent symptoms according to a mild, moderate or severe PD.
• Second, information was collected on how the professional expects to
be helped by REMPARK system in the therapeutic management of the
individuals with PD. “At which PD stages do you think REMPARK may
be useful?”, “For the improvement of which symptoms do you think
REMPARK may be useful?”, are examples of the related questions made to
the professionals to acquire valuable information at this level of analysis.
• The third issue addressed consisted on how data had to be organised for an
optimal use and updating of the PD treatment in the disease course.At this
level professionals were required to express their opinion on the usability
of REMPARK in PD patients as a function of symptoms severity.
Furthermore, the interviews helped the consortium to understand the perspec-
tive, the expectations and the general attitude of the care service (i.e., clinical
professional) against the REMPARK approach. At this regard, emphasis
was paid in capturing different perspectives. For this reason, the question-
naires were administered to different kind of professionals belonging to the
medical (i.e., neurologists, geriatricians) and technical rehabilitative (i.e.,
physiotherapist, occupational therapist) areas.
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Figure 4.1 Illustration of the number of professional who filled the questionnaire divided
according to their country of origin. Years of clinical practice in PD area are also reported in
the average, also in this case individually for each country. Vertical bars represent the standard
deviation.
4.2.1 Subjects
Some characteristics of the 57 professionals recruited for the administration
of the questionnaires are reported in Figure 4.1. The average number of
years of clinical expertise with PD patients was 13.7 (SD=4.6). Most of the
clinicians were employed in Public Health Service (n=36) while 18 of them
were employed in private or “intermediate” health care system.
Across the different countries/sites, it must be noted that the three kinds
of professional who took part in the study were neurologists, geriatricians and
physiotherapists.The majority of participating professionals were neurologists
(n=23), followed by physiotherapists (n=22) and, then, by geriatricians (n=10).
4.2.2 Questionnaire
The characteristics of the questionnaire including the formulation of the
items and methodology for answering questions were developed through a
continuous consultation between the four medical partners participating in
REMPARK: Centro Medico Teknon (Spain), Fondazione Santa Lucia (Italy),
Maccabi Healthcare Services (Israel) and the National University of Ireland
at Galway (Ireland).
The questionnaire is composed of three main sections.
• An initial social-demographic section in which the participant is required
to provide personal information regarding, for instance, own specialty,
the country of origin and the years of clinical experience with PD patients.
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• A second central section that addresses clinical issues related to PD. This
is the section in which participants indicate the clinical relevance of PD
symptoms according to the three disease stages (i.e., mild, moderate and
advanced). Questions such as the following ones were posed:
• What do you consider are the three most characteristic motor
symptoms of this phase?
• What do you consider are the 3 motor symptoms that interfere the
most, with the quality of life of people with Parkinson’s at this stage
of the disease?
• What do you consider are the three priorities to treat symptoms at
this stage of the disease?
The professional was asked to answer by ticking a square box in a mixed
multiple alternative forced choice paradigm. In fact, for most questions, if
the professional feels that the right answer does not fit with the proposed
alternatives he can tick the square box corresponding to “other” and, then, is
allowed to better specify his response.
• The third and final section of the questionnaire aimed at investigating
the potential utility of REMPARK system for the clinical management
of PD, as it is perceived by professionals. Questions like the following
ones were proposed here:
• Do you consider that a system such as REMPARK would be useful
to improve motor problems of your people with Parkinson’s?
• In your clinical practice, do you consider that a system such as
REMPARK would be a useful system for monitoring motor problems
of your people with Parkinson’s?
In the case of the professional expressing a positive judgment about
REMPARK utility by ticking the “yes” box, he is required to indicate both the
PD stage for which REMPARK could be better applicable (i.e., mild, moderate
or advanced stages) and which PD symptoms would benefit from REMPARK
utilisation. Also for these questions the professional has to respond by ticking
a square box in a mixed multiple alternative forced choice paradigm.
4.2.3 Results
4.2.3.1 Analysis of the correlation between responses
on clinical questions
A first item analysis was performed to investigate the coherence of the
professionals’ response relating the clinical answers. More specifically, the
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participant is required to evaluate the clinical relevance of a PD symptom by
indicating:
• The three most characteristic motor symptoms of PD.
• The three motor symptoms that interfere more with the quality of life of
people with PD.
• The three symptoms that have priority for treatment.
All three questions were individually addressed for mild, moderate and
advanced PD stage. The three questions are apparently related since it can
be reasonably posited that the most characteristic symptoms of PD have a
great probability to be those symptoms that interfere with quality of life and,
furthermore, those for which a treatment is imperative. Therefore, from the
statistical point of view, the existence of a significant correlation between
the responses on these items could be a parameter to verify the reliability of
responses themselves.
In order to examine the correlation between the professionals’ responses
on the above three items/questions, Pearson’ r statistic was performed. For
the purpose of these analyses, in order to quantify the relative weight of
each symptom, the responses were classified according to a Likert-type scale
ranging from 0 to 3, resulting in most of the correlations analysed being
significant. In these cases, the r value ranged from 0.27 to 0.72 being >
0.40 in about 67% of all cases. The significance of the correlation was only
approached in one case relating to the analysis that involved the “Difficulty in
Turning” symptom (i.e., the correlation between the score attributed to “most
characteristic symptoms” and to the “priority for treatment items”).
Therefore, the correlation analyses, by confirming the existence of a
significant relationship between the professionals’ response, indicate a global
coherence of the responses themselves.
4.2.3.2 Investigation of the clinical relevance of the motor
symptoms in the three PD phases (i.e., mild, moderate
and advanced)
The clinical relevance of the PD symptoms as reported by professionals
was investigated by means of descriptive analyses firstly without taking into
consideration the particular country/site where the data were collected and,
then, in a second step, individually for each country/site. This was made in
order to have both a general view on data and to evidence possible differences
as a function of the country/site the professional belongs to.
For the purpose of these analyses, a unique score was computed by
collapsing the score attributed to each individual item in the three clinical
questions mentioned in the previous sub-section:
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An index of clinical relevance for each symptom was, thus, computed by
averaging the score attributed by professionals to that symptom in the three
questions. For instance, the index of clinical relevance for “small steps” was
represented by averaging the scores attributed to it in questions 1), 2) and 3).
Also in this case, for the purpose of these analyses, in order to quantify the
relative weight of each symptom a score of 3 was attributed to the symptoms
the professional indicated as first, a score of 2 was attributed to a symptom
indicated as second, a score of 1 was given to the symptom indicated as third
and, finally, a score of 0 was attributed to the symptoms not included in the
first three symptoms list.
As showed in Figure 4.2, independently from the countries/sites where
data were collected, the analysis of the index of clinical relevance computed
for PD motor symptoms evidence some differences according to the PD stage
considered.
In fact, in the mild stage (represented by blue columns in the figure),
“reduced walking speed”, “small steps”, “difficulty in turning” and “shuffle”
were the four symptoms with the higher index of clinical relevance with and
index value of 1.74, 1.24, 0.68 and 0.66, respectively.
In the moderate stage (represented by red columns in the figure), the most
clinically relevant symptoms were “freezing of gait”, “difficulty in turning”,
Figure 4.2 Indices of clinical relevance for each PD motor symptoms examined referred to
the mild (blue columns), moderate (red columns) and advanced (green columns) PD stages.
Vertical bars represent standard errors.
4.2 Decision on the Most Relevant Symptoms to Be Detected and Assessed 65
“falls” and “reduced walking speed” with an index value of 1.19, 1.05, 0.91
and 0.87, respectively.
Finally, as for the advanced stage (represented by green columns in the
figure), the symptoms with a higher index of clinical relevance were “falls”,
“freezing of gait”, “difficulty in turning” and “shuffle” with an index value of
1.91, 1.50, 0.84 and 0.56, respectively.
According to the majority of professionals, patients with PD adopt some
specific strategies to improve gait difficulties particularly in the moderate-
advanced stages of the disease. More specifically, more than 80% (n=48) and
about 91% (n=52) of professionals indicates that PD patients use strategies to
improve gait in the moderate and advanced phases, respectively, compared
to the 33% who report this behaviour in the mild stages of the disease.
The strategies more frequently adopted by patients in the moderate-advance
disease stages would be stick use, verbal cueing, attention focus on walking
and steps counting. These strategies have been indicated by about 79% (n=38)
of professionals for the moderate stage and by the 80% (n=42) of them for the
advanced stage.
However, according to professionals, the most useful strategies to be
adopted in the moderate-advanced PD would be the use of verbal cueing
for about 32% (n=18), steps counting for about 16% (n=9) and stick use for
about 14% (n=8) of them. As for the advanced stage, also in this case the
majority of professionals indicated verbal cueing as the most useful strategy
to be adopted (about 26% of responses; n=15) followed by stick (about 23%
of responses; n=13) and metronome (about 12% of responses; n=7) use.
4.2.3.3 Analysis of REMPARK utility for PD patients
A large majority of professionals considered REMPARK potentially useful
for PD management. More specifically, about 96% of professionals (n=55)
judged REMPARK a useful system for symptoms improvement and 93%
(n=53) considered REMPARK potentially useful for symptoms monitoring.
The REMPARK utility for both symptoms improvement and monitoring, was
perceived by professionals for the intervention in the moderate stages (49%
and 40% of responses, respectively) and at a lesser extent in the mild (about
21% and 23% of responses, respectively) and advanced (about 9% and 19% of
responses) stages. However, the presence of missing data (n=13) related to the
lack of responses on the specification of the PD phase for which the application
of REMPARK system would be more useful, reduces the reliability of these
findings.
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Figure 4.3 Subjective judgment expressed by professionals about the utility of REMPARK
system for both improvement and monitoring of motor symptoms. Vertical bars represent
standard errors.
In order to quantify the professionals’ judgements about which symptoms
REMPARK system would be more useful, in terms of both improvement
and monitoring, the professionals’ responses were classified on a Likert-type
scale ranging from 0 to 3, where 0 represents the minimum value assigned to
the effect of REMPARK system on a specified symptom and, conversely, 3
indicates the highest value.
As Figure 4.3 illustrates, a substantial coherence is noted about the
symptoms that would better benefit from the application of the REMPARK
system in terms of symptoms improvement and monitoring. Indeed, according
to professionals’ opinions, the symptoms on which the REMPARK system
would have a greater positive impact would be “freezing of gait” and “reduced
walking speed”.
4.2.4 Discussion and Conclusive Remarks
A first critical issue the questionnaires are focussed on is the understanding
of the salient clinical features of PD in the different stages of the disease. The
answers should also give valuable information about clinicians’ expectations
on the REMPARK utility and usability in the clinical management of PD.
A first preliminary comment has to be devoted to the reliability of the
professional’s answers. Regarding this aspect, some indicators such as the
absence of missing data on content questions as well as a substantial coherence
of responses on clinical questions suggests that the questionnaires have been
filled correctly and congruently.
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The descriptive and inferential statistics applied to data allowed us to
evidence some main points of interest.
• First, as expected, different symptoms achieve a clinical relevance and
require a therapeutic intervention as a function of different PD phase con-
sidered and, thus, in particular in the mild stage of PD “reduced walking
speed” and “small steps”, were the most clinically relevant symptoms
whereas in the moderate stages “freezing of gait” and “difficulty in
turning” appear to be more important clinical signs. Moreover, in the
advanced stages, “falls” arises as a new main clinical occurrence. As
mentioned above, this finding is expected on the basis of the neurological
characteristics of PD [2]. Indeed, PD is a neurodegenerative disease
that progressively affects different motor and non-motor brain circuitries
with a related modification of both the qualitative and quantitative (i.e.,
severity) clinical features of the disease [3–5]. An interesting aspect to
be remarked is that according to professionals, PD patients use strategies
to improve symptoms mainly in the moderate-advanced stages, rather
than in the mild ones. This finding is obviously expected on the basis
of the greater impact that symptoms severity progressively exerts on
daily living. However, according to professionals, the strategies that
PD patients seem to adopt for improving their gait difficulties do not
appear to be the most useful . In particular, professionals judge to be
useful strategies to be adopted in both the moderate and advanced stages
the verbal cueing whereas it seems that PD patients tend to use stick more
frequently.
Furthermore, the analysis of questionnaires outlines a substantial convergence
of the professionals’ clinical judgements between the different countries/sites
for mild and advanced stages of the disease. However, it should be noted
that the same judgements appear to be more heterogeneous when applied to
moderate PD stages. A possible interpretation of this heterogeneity is related
to the objective difficulty to clinically define the moderate stages in respect to
mild and advanced ones.
• A second main point evidenced by the analysis is that REMPARK system
is perceived by professionals as a potentially useful instrument for
the management and treatment of PD. This is particularly observed
in the moderate stages of the disease. As a matter of fact, the majority
of professionals indicated the moderate phases of the disease as the best
target phase for REMPARK. In this regard, it should be noted here that,
as previously discussed, the moderate stage of the disease is the stage
68 Assessment of Motor Symptoms
for which the judgment on the clinical relevance of symptoms is more
heterogeneous. This provides a clear indication for REMPARK. Indeed,
the multifaceted clinical expression of PD during this phase should be
taken into account carefully to develop a functional system.
• Finally, as for the advanced stage, the symptoms with a higher index
of clinical relevance were “falls”, “freezing of gait”, “difficulty in
turning” and “shuffle” with an index value of 1.91, 1.50, 0.84 and 0.56,
respectively.
In conclusion, from the analysis and considerations done, the REMPARK
system appears to be perceived particularly useful to be applied for both
monitoring and improving PD symptoms in the moderate-advanced stages
of the disease.
REMPARK system might be a useful and well accepted instrument for
the therapeutic management of PD. Additionally, there exists evidence that
PD patients spontaneously adopt strategies to improve gait disorders by using
external aids.
4.3 Methodology and Database to Monitor Motor
Symptoms
This section presents the implemented methodology in REMPARK system
for the detection of the main motor symptoms discussed above. As this
methodology will be based on an artificial intelligence approach, it is necessary
the construction of a specific database for the required knowledge extraction.
4.3.1 An Artificial Intelligence Approach and the Need
of Relevant Data
The main objective of the REMPARK project is to obtain a system capable of
assessing PD motor and non-motor symptoms. This is a clinical goal that is
intended to be solved through technological solutions.
Firstly, REMPARK system involves inertial sensors to monitor PD motor
symptoms given their nature. Since motor symptoms affect movement, inertial
sensors capable of measuring such movement are used to automatically detect
these symptoms. Secondly, the techniques used to determine their presence
come from the Artificial Intelligence (AI) field; more concretely, machine
learning techniques are well-known to provide high accuracies in these tasks.
In this case, REMPARK work was focused on supervised learning methods.
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Supervised learning techniques for classification tasks are mathematical
and statistical methods that are capable of recognising patterns to associate
them with specific classes. These methods require sets of labelled data in
which patterns and their corresponding class labels are given. In the case
of REMPARK, inertial signals labelled with the presence of symptoms are
needed. In consequence, a specific data capture is required to gather such
labelled datasets.
Machine learning techniques require the maximum amount of data and the
most variability in them in order to properly generalise an automatic detection
from them. In addition, labels must be as accurate as possible. Through these
data, highly accurate models capable of automatically classifying the patterns
can be obtained. In consequence, REMPARK envisaged the construction of
a database of labelled inertial signals from 90 PD patients from 4 different
countries.
It must be taken into account that the usage of supervised learning
techniques creates some restrictions into the algorithmic development, which
will be carried out after the database collection. Data collection must follow
a strict protocol designed according to clinical restrictions in order to capture
the required variety of PD symptoms in different severities. The statistical
representability of the data will enable supervised learning techniques to
extract the embedded knowledge and, thus, precisely detect the presence of
symptoms into the signals provided by inertial sensors.
4.3.2 Protocol for the Database Construction
The data for the database were collected in the most homogeneous possible
way, and under the best conditions to ensure good enough generalization
capabilities. It is a very relevant task since the validity of the REMPARK
system for assessing a patient’s motor status relies on the quality of the data
in the database.
A specific clinical study was designed and carried out in order to collect
the database. It was a multicentre international study that was conducted in
four European settings: Centro Médico Teknon (Spain), National University
of Ireland, Galway (Ireland), Fondazione Santa Lucia (Italy) and Maccabi
(Israel).
The primary objectives of the study that collected the data were:
• To obtain a database of properly identified inertial signals, which will
allow the training of processing algorithms for motor phase detection
(ON/OFF) in PD patients.
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• To obtain a database of properly identified inertial signals, which will
allow to train processing algorithms for motor symptoms detection in
PD patients.
• To obtain identified inertial signals of hand tremor.
• To obtain identified inertial signals of freezing of gait.
• To obtain identified inertial signals of bradykinesia of the lower and
upper limbs.
• To obtain identified inertial signals of dyskinesia of the trunk and
limbs.
• To obtain a database of properly identified inertial signals correspond-
ing to movements and activities that can be mistaken for PD motor
symptoms (potential false positives).
• To obtain a database of properly identified inertial signals corresponding
to gait parameters.
• To obtain identified inertial signals of gait speed.
• To obtain identified inertial signals of step/stride length.
• To obtain a database of properly identified inertial signals corresponding
to movements and activities that can be mistaken for falls (potential false
positives).
The reference population was that formed by Parkinson’s patients with mod-
erate to severe disease and motor symptoms (Hoehn and Yahr greater or equal
to 2.5 including ON/OFF phases, FOG or dyskinesia). The total number of
recruited patients was 92, distributed among the clinical centres (26 in Spain,
16 in Ireland, 24 in Italy and 26 in Israel).Aconvenience sampling stratified by
symptoms was conducted, keeping desired minimum proportions of patients
with different motor symptoms. At least 50% of the sample were set to have
ON/OFF motor fluctuations, with the OFF state characterized by bradykinesia.
Furthermore, at least 25% of the sample had to present FOG episodes and,
finally, at least 25% of the sample was set to present dyskinesia (at least 15%
will present trunk dyskinesia).
The inclusion criteria for these patients were:
• to have a clinical diagnosis of Idiopathic Parkinson’s Disease according
to the UK Parkinson’s Disease Society Brain Bank [6]
• disease in moderate-severe phase (Hoehn andYahr greater or equal to 2.5)
with motor fluctuations with bradykinesia, FOG and/or dyskinesia
• aged between 50 and 75 years and willing to participate in the study and
wanting to co-operate in all its parts
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• accepting the performance regulations and procedures provided by the
researchers.
Patients fulfilling the following criteria were excluded from the study:
• other health problems that hamper physical activity
• rheumatologic, neuromuscular, respiratory, cardiologic problems or
significant pain
• carriers of implanted electronic devices: cardiac pacemaker, implantable
automatic defibrillator . . .
• patients receiving continuous therapy using intestinal duodopa or
apomorphine
• patients who have received deep cerebral stimulation therapy
(neurosurgical procedure)
• chronic consumption of psychotropic drugs and/or alcohol
• known mental disease, such as dementia, according to clinical criteria
-DSM-IV-TR and MMSE score ≤ 24 or neuropsychiatric disorders
• patients who are participating in another clinical trial
• patients unable to fully understand the potential risks and benefits of the
study and give informed consent
• subjects who are unable or unwilling to cooperate with study procedures.
The data capture was conducted in two visits. The first visit comprised both
the inclusion and basal visit, where the inclusion criteria were confirmed, and
initial clinical and socio-demographic data of the patient were gathered. The
second visit was devoted to the experimental procedures, where the maximum
number of physical signs related to the disease were recorded using the inertial
sensors and standard methods. This visit had two types of experiments that
will happen in interleaved manner (according to the symptoms that the patient
may present in each moment).
• The first type of experiments consists in short controlled tests, where the
patient was asked to perform certain activities, with the aim of capturing
specific motor symptoms (bradykinesia, dyskinesia, freezing of gait,
etc.). These tests were closely controlled, using video recording as a
gold standard.
• The second kind of experiments that took place in this visit involved
monitoring of the free activity of the patient, and recording the
natural symptoms that he/she spontaneously may present. This mon-
itoring lasted hours, and the activity and symptoms were electron-
ically recorded by trained observers (using a tabled and specific
software).
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Figure 4.4 Design of the experimental visit.
The two types of experiments took place alternatively, according to the motor
state and the symptoms that the patient presented. That is to say that when the
patient was in an OFF phase, the specific controlled tests for the OFF symptoms
were conducted (e.g., FOG) and the remaining OFF state time was used
for monitoring their free-natural activity. Similarly, when the patient entered
the ON phase, some specific short tests for capturing ON symptoms (e.g.,
dyskinesia) were performed, with the rest of the time devoted to monitoring
the free natural activity of the patient in this state. Figure 4.4 summarizes the
experiment done.
All participants were trained to follow the specific study procedures,
according to a common protocol that was the same for all the study sites.
Patients also received specific training for recognizing their own OFF state.
For this purpose, specific videos showing other patients in ON and OFF
states were displayed, and detailed explanations on symptoms defining the
OFF state were provided.
The investigators received a 3-day training session, comprising theoretical
sessions including guidelines and instructions of all the instruments and ques-
tions of the Case Report Form (CRF), and practical sessions with pretended
patients who behaved according a number of pre-established situations which
served an example of the most relevant cases. The entire experimental test was
performed at least twice by all the researchers, and every researcher conducted
an example free monitoring session of at least 60 minutes.
During this training session, investigators were also trained into the usage
of the designed labelling tools:
• Labelling for the controlled experiments was done once the data capturing
with the patients had finished. Researchers were trained into the usage
of the tool, that allowed, first, the synchronisation of the inertial signals
with the videos, and, second, the labelling of the different symptoms that
were listed in the objective of the study.
• Labelling of the free-monitoring experiment was done in-situ by the
investigators. A tablet with a specific application were used by them.
This application enabled the annotation of the different symptoms at the
same time that the inertial signals were captured.
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Finally, the Principal Investigator, or his designee, in accordance with institu-
tional policy, obtained an Informed Consent that was reviewed and accepted
by the Ethics Committee. A written consent form bearing the full name, date
and signature of the patient and the local investigator were obtained from each
patient. The signed Informed Consent constitutes a confidential document and
therefore was archived in the study binder.Acopy of the consent was also given
to the patient.
The inertial signals captured during this data collection phase were
obtained through two sensors: a waist sensor and a wrist sensor. The waist
sensor was worn inside a pocket within a neoprene belt. The wrist sensor was
worn through a strap. Figures 4.5 and 4.6 present both devices.
Figure 4.5 Waist sensor.
Figure 4.6 Wrist sensor.
74 Assessment of Motor Symptoms
4.3.3 Gathered Database Description
The following data were included in the database for each patient:
1. Socio-demographic data: Age, Sex, Educational level and Marital status
2. Parkinson’s Disease related information:
• Parkinson’s severity, as measured by Hoehn and Yahr scale
• Date of symptoms’ onset
• Date of PD diagnosis
• Motor section of UPDRS in OFF phase
• Motor section of UPDRS in ON phase
• Information on OFF periods characteristics and duration (UPDRS
motor complications section – motor fluctuations)
• Information on FOG presence, characteristics and duration (FOG
questionnaire)
• Information on dyskinesia presence, characteristics and duration
(UPDRS motor complications section – dyskinesia)
• List of treatments
3. Co-morbidity related information. Cognitive status: Mini-Mental State
Examination, Test of Attentional Performance and List of conditions.
4. Inertial signals labelled according to the following motor symptoms:
• Motor phases. Signals were labelled among the three following
options: ON, OFF and Intermediate state.
• Dyskinesia severity and location. Dyskinesia is a side effect of medi-
cation, not a PD symptom, and signals were labelled according to the
following modalities: Weak Trunk dyskinesia, Weak Foot/Leg dysk-
inesia, Weak Hand/Arm dyskinesia, Weak Head dyskinesia, Strong
Trunk dyskinesia, Strong Foot/Leg dyskinesia, Strong Hand/Arm
dyskinesia, Strong Head dyskinesia.
• Bradykinetic gait (presence/absence). This symptom describes a
difficulty to walk and slow gait, including small steps, shuffling
and difficulty to turn.
• FOG type. Episodes were labelled according to their type: Start
Hesitation FOG, Straight Line FOG, Turning FOG, Tight FOG,
Destination FOG.
• Tremor location and severity: Modalities labelled were: Right
Hand/Arm tremor, Right Foot/Leg tremor, Trunk tremor, Left
Hand/Arm tremor, Left Foot/Leg tremor.
5. Inertial signals labelled according to body postures and activities: sitting,
standing, walking, going upstairs, going downstairs, elevator (down),
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elevator (up), walk with FOG, carrying delicate object, carrying heavy
object, lying, jumping, running
6. Other information from inertial signals:
• Falls
• Walking aids: scooter, walking stick, walker, crutch, crutches, lean
on furniture, tripod walking stick
Organization of the complete set of data from each patient is summarised in
Figure 4.7.
Database contains clinical data from 92 participants with idiopathic
Parkinson’s Disease. Regarding the sociodemographic data, as Table 4.1
shows, fifty-six of them are male (60.9%) and 36 (39.1%) are female. The
average age of the participants is 68 (SD 7.9). Seventy-four patients are
married or live with a couple (80.5%), 10 (10.8%) single or divorced, and
8 (8.7%) widow.
All the participants in the database construction are patients with moderate
disease, having a Hoehn and Yahr scale of 2 or more. Average Hoehn and
Yahr score is 3 (IQR 0.5). The average time from diagnosis of the disease
was 10.5 years (SD 12.2). Eighty-nine patients (96.7%) of the database have
OFF periods, according to the “motor complications” section of the UPDRS.
Sixty-eight (73.9%) had predictable off periods, 54 (58.7%) had unpredictable
Figure 4.7 Data structure collected from each patient.
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Table 4.1 Sociodemographic data
Age (Mean ± SD) 68 (7.9)
Gender
Female 36 (39.1%)
Male 56 (60.9%)
Marital Status
Single 5 (5.4%)
Married/partner 74 (80.5%)
Widowed 8 (8.7%)
Separated/divorced 5 (5.4%)
off periods and 33 (35.9%) had sudden off periods. Most of them spend less
than a quarter of the day in OFF. 34.7% of the total declared to spend more
than 50% of the daytime in off.
Sixty-four patients (69.6%) present some degree of dyskinesia, being non-
disabling dyskinesia in 54.3% and non-painful in 78.3%. Twenty-five patients
have dystonia (27.2%). Only 5 patients have a 0 score in the FOG-Q, meaning
that the rest of them present some gait problems.
The database contains inertial signals properly identified and labelled
according to Parkinson’s motor symptoms and body postures and activities.
In total, the database contains 406 hours of inertial signals. Information on the
motor status of the participant is available for 346 hours of inertial signals of
the database (see Table 4.2).
A total of 175 hours of motor symptoms are recorded and identified in
the database (including bradykinesia, dyskinesia, FOG and tremor). Thirty-
two of them correspond to inertial signals labelled against a video record
gold standard, and the rest correspond to inertial signals which have been
labelled using the real-time notations of an observer (tablet-PC annotations).
Table 4.3 summarizes the time (hours) of symptoms recorded and labelled in
the database.
Table 4.4 shows the amount of motor symptoms (bradykinesia, dyskinesia,
FOG and tremor) recorded in each motor phase (ON, OFF or “Intermediate”),
according to the gold standard used (video records vs tablet-PC annotations).
Table 4.2 Recorded time of the different motor periods
Motor Phase Time Recorded (hours)
ON 163
OFF 111
Intermediate 72
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Table 4.3 Video recording duration per symptom in the database
Dyskinesia Bradykinesia FOG Tremor TOTAL
Video 8,10 h 15,78 h 2,45 h 5,60 h 31,92 h
Tablet-PC 62,82 h 31,82 h 2,96 h 45,82 h 143,43 h
Total 70,93 h 47,60 h 5,41 h 51,42 h 175,36 h
Table 4.4 Summary of motor symptoms per motor phase
On Off Intermediate Motor Phase TOTAL
(minutes) (minutes) (minutes) Not Available (minutes)
Video Tablet Video Tablet Video Tablet Video Tablet Video Tablet
Dyskinesia 355 2500 28 431 18 712 85 126 486 3769
Bradykinesia 50 122 790 1394 25 308 81 85 947 1909
FOG 21 33 113 76 7 36 6 34 147 178
Tremor 94 789 224 1200 15 680 2 80 336 2749
Total 520 3444 1155 3100 65 1737 174 325
4.4 Algorithmic Approach and Results
Once presented the complete scenario of the objective motor symptoms to be
studied from a clinical perspective, it is necessary to propose an algorithmic
methodological approach to bring all this knowledge closer to the achievement
of machine-learning classifiers (algorithms) for the motor states monitoring
tasks.
The methodological proposal to estimate the motor state (ON or OFF
periods) of a PD patient wearing an inertial device is based on the use of
a hierarchical system. In a first level, the system permits to put in context
the patient’s activity and a second level is in charge of the detection of the
symptomatology of interest. The hierarchical system uses the output of the
detection algorithms in this second level for the assessment of the patient’s
motor status. Some details are presented in Figure 4.8.
The contextualization of the patient’s activity and posture is very important
because the evaluation of the different PD symptoms is related to the activity
developed by the patient. Thus, evaluation of bradykinesia will only be
performed when the patient is walking, since it is during self-executing
activities when this symptom is clearly manifested. In this way, the inertial
signals from the primary accelerometer sensor are analysed using temporary
windowing with a set of algorithms that determines if the patient is walking
and, if so, signals are analysed to determine the presence of Bradykinesia.
This strategy is applied in a similar way for Dyskinesia, where the detection is
performed only in the case that the contextualization algorithms determine that
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Figure 4.8 Outline of the structure defined for the algorithms for detecting symptoms of PD.
the patient is not walking during the windowed analysis, since it is considered
that the gait hides dyskinetic movements.
The information obtained from the detectors of bradykinesia and dyski-
nesia, together with the FOG detector results will be analysed through a set
of additional algorithms, which will determine the final motor state of the PD
patient (ON/OFF states). At this stage, as it is indicated in Figure 4.8, it is
necessary to use some personal parameters of the patient (basically obtained
from previous medical history information).
The development of the different detection algorithms, corresponding to
each considered symptom was done independently, taking as a starting point
some relevant papers published so far, analysing them, exploiting the acquired
signals contained in the REMPARK database and trying to improve, when
possible, the previous published results. As it has been already mentioned,
the methodology used is based on a machine-learning approach, mainly using
supervised learning techniques. The available database described in the above
Section 4.3 was used for this purpose.
In the machine-learning area, it is a common practice to divide the Database
into different sub-sets. One sub-set is strictly used for algorithmic training
purposes and other sub-set is only used for testing. Related works performed
in REMPARK project used this approach and the results of the different
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techniques were evaluated with the patients’ data not used in the training
process of the supervised learning algorithms.
The signals labelled according to the symptoms listed in Table 4.4 were
used to train the different supervised learning models. It must be considered
that all the included algorithms process accelerometer measurements sampled
at 40 Hz. In addition to the symptoms listed in Table 4.4 (dyskinesia,
bradykinesia, FOG, and tremor), there is another subsection devoted to
describe the estimation of gait parameters. A description of the algorithmic
work done is presented in the following subsections.
4.4.1 Dyskinesia Detection Algorithm
A processing method based on a frequency analysis of the signal was imple-
mented and used for Dyskinesia detection. The method considers the power
spectrum of the concrete band between 1 and 4 Hz for the detection of Dyskine-
sia, provided that information corresponding to higher frequency band (from
8 to 20 Hz) could correspond to false positives such as walking or climbing
stairs. Additionally, a number of conditions are added in order to allow a better
contextualization of the patient’s movement and consequently, to improve the
specificity of the algorithm. The algorithm has been subdivided into two steps
(detailed below), one at window level and one at the minute level.
• In the first step (at window level), the evaluation of the presence of
Dyskinesia is done through the analysis of three separate frequency
bands:
• Dyskinesia Band: A high spectral power density in this band is a
clear indication that the patient is suffering Dyskinesia, although it
may also mean that the patient is walking or climbing stairs. This
band is covering from 0.68 Hz to 4 Hz.
• Non-dyskinetic band: It is considered that this band covers from 8
to 20 Hz. This frequency band allows to discriminate if an increase
of spectral power in the band of Dyskinesia is due to the appearance
of a Dyskinesia or because the patient is walking (or doing similar
activities).
• Postural transition band: This is the band from 0 to 0.68 Hz. The
posture transition is a very common action and involves very low
frequencies that can generate harmonics in the Dyskinesia band,
which may provoke false positives.
• The detection of Dyskinesia, based on frequency band analysis allows
us to know, in a given time window, whether or not the patient has
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Table 4.5 Dyskinesia algorithm results
Type of Choreic Num. of Patients
Dyskinesia with This Type of Equal Weight per Minute
Severity Body Part Choreic Dyskinesia Specificity (%) Sensitivity (%) Total Minutes
Weak Trunk 16 95 78 953
Strong Trunk 4 95 100 895
Weak No-trunk 32 95 39 1110
Strong No-trunk 7 95 90 917
Dyskinesia. However, Dyskinesia is a symptom that is repeated over
time for many minutes, this fact can be used to minimize, using an
aggregation process, the presence of false positives. This method of
aggregation allows us to examine the appearance of Dyskinesia in several
consecutive windows over time by performing an aggregation of the
output of each window providing a unique output in a given time slot (it
has been considered a period of 1 minute in the implemented algorithms).
This signal processing method was applied to the database of signals by using
a leave-one-patient-out scheme on the minute-basis output of the algorithm.
The main reference for this work is [7] and a summary of the results
obtained is provided in Table 4.5. The results were obtained with REMPARK’s
database of video-labelled signals from 92 PD patients.
Specificities and sensitivities are provided for each different type of
dyskinesia. With regards to the most important in the clinical sense, i.e. the
strong trunk dyskinesia, the algorithm achieves a specificity of 95% and a
sensitivity of 100%.
4.4.2 Bradykinesia Detection Algorithm
Bradykinesia appears when plasma’s dopamine level is low, seriously compli-
cating the general mobility of the patient and, in particular, causing changes
and compromising the way of walking.
The analysis done has been based on the gait cycles characterization. The
detector algorithm identifies, on the one hand, the strides that the patient is
currently carrying out and, on the other hand, characterizes these gait cycles,
allowing the analysis of Bradykinesia through specific characteristics that
correlate with the presence of a pathological alteration.
In the analysis of the database, it was concluded that the most important
feature that helps to diagnose the occurrence of Bradykinesia is the fluidity
of movement when walking. Fluidity is a highly subjective variable that
is not currently objectively measurable. When a patient presents a very low
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movement fluidity, the probability of manifesting Bradykinesia is very high.
This principle allows to generate an algorithmic approach that objectively
measures characteristics associated with the fluidity of the movement and,
furthermore, enables the detection of the symptom based on comparative
thresholds, which determines when the symptom is present.
The bradykinesia detection algorithm is structured using a three-stage
scheme (see Figure 4.9). In the first one, the contextualization of the movement
is realized, detecting if the patient is walking or not. In the second block, a
process of recognition and identification of strides/steps is performed, and the
last block performs the analysis of the characteristics of strides/steps that may
be representative of the occurrence of Bradykinesia.
The walking detection done at the first stage is performed through a process
of pattern recognition from the obtained accelerometer signals. A binary-
classification procedure has been approached to detect gait through the use of
Support Vector Machines (SVM). The input of the SVM consists of a group
of features, which are extracted from a temporary window of signal obtained
from the accelerometer. The training set for the SVM was generated through
the windows obtained from the signals corresponding to a group of 10 patients,
which were acquired from a previously obtained database and its associated
gold standard. It should be noted that these patients were not used, later, in
the validation group of the final implemented algorithm. The most relevant
considered characteristics for the detection of the gait are the power spectra
in the three spatial axes, for the bands from 0.1 to 3 Hz and from 0.1 to 10 Hz.
The step detection process is launched when the SVM walking detection
has been positive on a given window. This step detection is carried out by
recognizing the biomechanical characteristics of walking in the acceleration
measurements taken from the sensor (located in the waist).
Figure 4.9 Scheme of the bradykinesia detection algorithm.
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Table 4.6 Bradykinesia algorithm results
Specificity Sensitivity PPV NPV
81% 88% 89% 84%
The interest of the analysis focuses on the strides (two consecutive steps
of each feet) and their characterization, in order to represent the fluidity of
the patient’s movement. Several statistical markers have been studied and
evaluated for this purpose, bearing in mind that the best marker is the one
maximizing the separation between the presence and absence of Bradykinesia.
Additionally, it must be considered that the states (Bradykinesia presence
or not) are very dependent on the user and, therefore, the threshold that
correctly separates the states of a particular patient may have a value different
from the threshold of another patient. The main reference of this work is [8]
and a summary of results is provided in Table 4.6. These results were obtained
by analysing the data from the 92 PD patients who participated in the database
construction.
4.4.3 Tremor Detection Algorithm
Tremor was evaluated by analysing the signals provided by the wrist sensor
included in the REMPARK system. A frequency analysis of the signals was
performed, permitting the extraction of several characteristic features in order
to determine the presence of the symptom. The process is based on a SVM
model.
The signal processing approach is divided into two different phases: the
window level in which tremor is recognized based on short duration signals
and the meta-analysis level that aggregates several window detections.
1. At the window level, frequency related features of the signals are used,
because this is one of the most common methods. We observed that
frequencies in the band from 4 to 6 Hz appear when Parkinsonian tremor
is present, and these frequencies are not observed when this type of tremor
is absent (which is in agreement with current literature).
Given the main frequency behaviour of this sort of tremor, it could
be theoretically detected only using frequency characteristics. However,
a list of other features has been used in the literature for this purpose
(for instance, Fast Fourier Transform (FFT), Peak frequency and its
amplitude, Entropy of signal, Sum of first, second and third harmonic . . .).
In order to measure the impact of non-frequency features in the accurate
detection of tremor, two approaches were defined. On the one hand, a first
method only used frequency features while, on the other hand, the second
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approach also included non-frequency features that were previously used
in the literature (see reference [9] for additional details).
Both approaches are composed of two phases in order to determine
if tremor is present in a certain time window:
• Feature extraction phase. Features are defined depending on the used
approach: frequency features alone or combined with those men-
tioned above. Frequency features from three axes were obtained,
and their amplitudes were summed up without taking into account
the amplitude of the zero-frequency harmonic. Thus, dependence
on the sensor’s orientation is avoided. From this, the previously
described features were acquired.
• Learning phase. An SVM classifier is trained to distinguish tremor
and non-tremor windows based on the chosen feature set.
2. At the meta-analysis level, since it is very important to minimize the
resources needed for tremor detection, time windows must be as short
as possible (i.e. about few seconds). However, short windows are likely
to produce false positives (e.g. a single segment with tremor surrounded
by non-tremor segments) since short movement may be confused with
tremor (e.g. teeth brushing). Thus, a meta-analysis is added in order to
enhance the reliability of the proposed approaches.
The employed meta-analysis method considers the algorithm’s out-
puts in a set of several consecutive windows covering a period of several
seconds. These outputs are aggregated into a value representing the
probability of having tremor in the corresponding period. This period is
considered as tremor if the probability is greater than a certain threshold.
Following the common procedure in the field, the database was split into three
non-overlapping sub-datasets: training, holdout and test.ASVM classifier was
trained to distinguish tremor and non-tremor windows, using the training sub-
dataset. The final evaluation was done on the test dataset and indicates the
performance of the developed algorithms.
In total two feature sets (i.e. only frequency features vs. commonly
employed features) and two SVM kernels (i.e. linear vs. Radial Basis Function
(RBF)) were evaluated.
The main reference for the tremor algorithmic approach is [9] and a
summary of results is provided in Table 4.7, where each column represents a
different learning model: “RBF+ Freq.” corresponds to a SVM with RBF
kernel and frequency features, “Lin+Freq.” corresponds to a SVM with
linear kernel and frequency features, “RBF+All” corresponds to a SVM with
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Table 4.7 Tremor algorithm results as presented in [9]
RBF+Freq. Lin.+Freq. RBF+All Lin.+All
Sensitivity (holdout) 100,00% 100,00% 100,00% 90,00%
Specificity (holdout) 98,50% 99,50% 99,30% 97,20%
Data Usage (holdout) 57,70% 41,10% 42,00% 82,10%
Sensitivity (test) 97,30% 91,00% 98,10% 92,10%
Specificity (test) 96,90% 99,00% 98,60% 97,50%
Data Usage (test) 55,50% 40,80% 42,00% 79,90%
Geometric Mean (test) 97,10% 94,90% 98,40% 94,80%
Accuracy (test) 96,90% 98,60% 98,60% 97,30%
RBF kernel and both frequency and temporal features, and, finally, “Lin+All”
corresponds to a SVM with linear kernel and both temporal and frequency
features. These results were obtained by training the method with data from
18 patients and validating it with data from 74 patients.
4.4.4 Freezing of Gait (FOG) Detection Algorithm
Freezing of Gait (FOG) is a widely studied and evaluated symptom from
the point of view of automatic detection methodology, since it is one of the
most disabling symptoms for the patients and one of the most difficult to be
evaluated by clinicians.
As it is clear from the current literature, detection techniques for the
laboratory setting are highly developed at the moment, and they have had
relatively high success rates. However, many problems arise when we tried
to apply these methods to the daily living activities, because many false
positive appeared due to the new situations and movements appearing under
non-controlled scenarios.
In the literature, it has been identified a frequency band on the acceleration
signals from the lower limbs of PD patients associated with FOG episodes and
ranged between 3 and 8 Hz. In consulted work, a freezing index is defined
based on the ratio of the square of the spectral power of these frequencies
associated with the freezing band to the square of the spectral power of the
frequency band corresponding to the act of walking, (between 0.5 and 3 Hz).
Since FOG mainly occurs when starting, during or at the end of the gait,
it is essential to contextualize the patient’s activity through a gait detection
algorithm. We can take advantage of the gait detector based on the SVM
presented in the Subsection 4.4.2 (for Bradykinesia detection). Some points
must be considered:
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• Contextualization was implemented in the sense that positive FOG
detection is validated when the algorithm detected that the patient is
walking or has been walking for the last 5 seconds.
• The onset of gait is a complex detection since, in the case of a posteriori
detection, the condition that validates the detection may never occur
because probably the patient would experiment a fall, or because the
patient’s FOG lasts longer than the imposed temporary condition.
• In addition to adding the validation condition of 5 seconds walking to
the formulation, some significant detectable events were considered to
know when a patient is rising from the sit position (transition from sitting
to standing). This action is very important for the contextualization of
FOG since a large number of episodes occurs some moments after the
patient is performing this action and try to walk. With this objective, the
postural transition band was used for the detection of these events.
In summary, this symptom is detected based on a set of both temporal and
frequency features, similarly to the tremor detection algorithm, although the
presented contextualisation is added. The main reference for the algorithmic
approach is [10] and a summary of results is provided in Table 4.8, where each
column represents a different learning model: “RBF freq.” corresponds to a
SVM with RBF kernel and frequency features, “Linear Freq.” corresponds to
a SVM with linear kernel and frequency features, “RBF All” corresponds to a
SVM with RBF kernel and both frequency and temporal features, and, finally,
Table 4.8 Freezing of Gait algorithm results
Kernel RBF Linear RBF Linear
Features Freq. Freq. All All
Sensitivity (train) 100,00% 92,30% 100,00% 92,30%
Specificity (train) 100,00% 100,00% 100,00% 100,00%
Data Usage (train) 69,60% 89,10% 90,60% 98,60%
Geometric Mean (train) 100,00% 96,10% 100,00% 96,10%
Accuracy (train) 100,00% 98,70% 100,00% 98,50%
True Positives 9 8 9 12
False Positives 0 0 0 0
True Negatives 55 82 65 65
False Negatives 1 1 1 1
Sensitivity (test) 90,00% 88,90% 90,00% 92,30%
Specificity (test) 100,00% 100,00% 100,00% 100,00%
Data Usage (test) 82,30% 91,90% 94,90% 98,70%
Geometric Mean (test) 94,90% 94,30% 94,90% 96,10%
Accuracy (test) 98,50% 98,90% 98,70% 98,70%
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“Linear All” corresponds to a SVM with linear kernel and both temporal and
frequency features.
In this case, a subset of the whole REMPARK database was used. More
specifically, these results were obtained by using signals from 15 patients as a
training set and the resulting model being evaluated with signals from other 5
patients. Training was done with patients who had FOG episodes. Validation
was done with both patients with FOG and patients without FOG.
4.4.5 Gait Parameters Estimation
Algorithms for the correct estimation of the gait parameters were included in
the sensor embedded software. Some previous activity and the collection of
a labelled database was performed in order to implement the most suitable
approach.
As part of a series of controlled tests, patients performed a gait test in
which their average step length and average step velocity was measured. These
values were estimated through the waist-sensor signals and a novel inverted-
pendulum model. The sensor location used in REMPARK provides a different
kind and shape of signals than those previously obtained in the literature, that
commonly are using the Anterior Superior Iliac Spine position for the reported
experiments.
Figure 4.10(b) and 4.10(c) show the acceleration signal from lower back
(around L4–L5) and left lateral side (near ASIS) of waist, obtained with the
REMPARK sensor. It can be seen that the symmetry among left-right steps
is lost in signals obtained from the lateral side. Signals from the left leg are
more prominent than those from the right leg which impose new restriction
on step detection and step length estimation.
Figure 4.10 (a) The inertial system prototype (9 × 2, Version 6) positioned in a neoprene
belt on left lateral side of waist. Acceleration signals obtained from (a) Lumbosecaral point of
waist and (b) left lateral side of waist.
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The signals from the lateral side differ from those from the lower back
of waist. A newly developed step detection method called SWAT [11] was
developed, combined with an adapted step length estimator based to accurately
estimate the step lengths from this position. From the left lateral point of view,
the proposed gait model considers vertical displacement of waist as an inverted
pendulum (IP) model during right step and during single support phase of
left step.
Step detection performs an average window that is calculated over the
magnitude of the acceleration signals. Mean is removed from this average
window signal, and, then, the resulting signal is used to identify left and right
initial contacts (IC) and toe-offs (TO) events. When the foot’s heal touches
the ground, the event is called as IC, and when the foot leaves it is called as
toe-off (TO).
The initial contact and toe-off events of left and right legs are noted here
as LIC, LTO, RIC and RTO respectively. As the sensor was placed on the left
lateral side, the local maximum lateral signal can be used to identify incidents
of LICs immediately before or after it. For every local maximum in the SWAT
signal, if there was no incident of LIC in the lateral signal immediate before
or after it, then it is determined to be a RIC. If there is an incident of LIC,
the mid-point from the local maximum to zero is considered to be a LIC. For
each detected RIC, the next zero crossing point is considered as a LTO. For
each LIC, the mid-point of next zero to the local minimum are searched and
considered as a RTO.
The main reference for this work is [11], where it is shown that the results
obtained by the proposed method in 28 patients from the REMPARK database
show that gait parameters can be estimated with an average RMSE error below
0,04 meters.
4.4.6 Fall Detection Algorithm
The set of algorithms developed and implemented in the REMPARK project
is complemented by a fall detection algorithm that was previously developed
by one of the partners (UPC). This algorithm enables the detection of falls
based on specific computations through accelerometer measurements sampled
at 40 Hz. This algorithm is included in the set of algorithms implemented in
order to provide more information through the REMPARK system and include
the possibility of raising alarms.
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The fall detection algorithm has been successfully validated in the “Fall
Detection for the Elderly” (FATE) project (CIP-ICT-PSP-2011-5-297178)
[12]. It has shown a sensitivity and specificity above 95% along a pilot in
which more than 200 users from three countries (Spain, Italy and Ireland)
participated.
4.4.7 ON/OFF Motor State Estimation
The algorithmic part for determining the motor state (ON/OFF state) of a
person with Parkinson is very complex, because the high degree of subjectivity
included in the construction process of a correct model to be used. A main
problem is due to the fact that patients, sometimes, are not able to correctly
identify their own symptoms and, in some cases, may confuse them with non-
motor symptoms. Additionally, when non-motor symptoms are present, it is
even more difficult for these persons a correct identification.
This could be a very compromising situation when a machine learning
approach is intended to be used, since the most common gold-standard, in these
cases, is the patient-diary where the patient should annotate the experimented
symptoms every hour, along the day.
In order to be able to implement an objective algorithmic approach to the
problem, the related medical literature was reviewed and useful discussions
were organized with professionals for determining as much as possible the
set of objective conditions characterizing the ON/OFF states. The most
widespread definition of the OFF state is to refer to those periods in which
low dopaminergic levels occur, in which Bradykinesia is the most correlated
symptom. In addition, one can also use the fact that the appearance of Chorea
Dyskinesia is commonly produced by high levels of dopamine.
This approach makes possible, based on the algorithms of motor symptoms
that have been discussed along this section, to approximate the motor states
of the patient with the help of a decision tree technique:
• The algorithm determines that the patient is in ON state when either
non-bradykinetic gait or Dyskinesia are detected.
• OFF state is assumed when bradykinetic gait is detected.
This algorithmic approach was tested in the final pilots of REMPARK and
its output was compared to the diaries annotated by patients during 3 days.
Results are presented in the Chapter 9 and the original public deliverable
document (with the reference D9.2) is available at the REMPARK website.
The specificity and sensitivity on detecting OFF and ON motor states in 33
PD patients was 89% and 98%, respectively.
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4.5 Conclusions
This chapter has presented a huge effort made by REMPARK consortium
in order to develop a system capable of monitoring PD motor symptoms
in ambulatory conditions. A highly accurate database of labelled signals and
clinical questionnaires were collected from 92 PD patients, with more than 340
hours of recorded signals. The labelled signals have been used to train different
machine learning methods. The resulting approaches have shown that the
selected PD motor symptoms can be accurately monitored through the corre-
sponding sensors, with specificities and sensitivities about 90% in most cases.
Many different algorithms and their results have been presented. The
algorithms covering Bradykinesia, Dyskinesia, Tremor, Freezing of Gait
(FOG) and gait parameters, employing the collected REMPARK database
have been commented and their results presented. However, the ON/OFF
algorithm was only tested in the final pilots, since it had to be validated with
ON/OFF diaries filled by the patients, used as gold-standard.
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5.1 Introduction
The sensor is an important part of REMPARK since it is in charge of capturing
relevant inertial data from the patient’s movement pattern. The location of the
sensor is the left side of the waist and its operation is autonomous and done in
real-time. The sensor, described along the present chapter, has an embedded set
of algorithms, already introduced in precedent chapters, and able to determine
indicators for specific movement disorders related to PD, mainly Dyskinesia,
Freezing of Gait (FOG) and Bradykinesia.
Following the requirements derived for this sub-system (discussed in
Chapter 3), the main design principles, among many others, are:
• the achievement of a device with a reasonable operating autonomy
(adjusted power consumption), but keeping a small physical size;
• a device capable of being worn comfortably, permitting the regular
activities along the day; and
• the local execution, in real-time, of the embedded algorithmic set for
symptoms’ detection.
The system includes the classical elements of an Inertial Measurement Unit
(IMU), together with a dedicated part for battery control and energy consump-
tion optimisation. The battery level and the status of the main application
process are indicated to the user using a LED.
Amicrocontroller (µC) is in the nucleus of the sensor, being responsible for
the real-time and local execution of the developed algorithms on the acquired
data. This microcontroller is also responsible for handling and controlling the
rest of the components.
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5.2 Sensor’s Data Processing Flow
Before entering into the details of the sensor sub-system, it is necessary to
establish the Processing Data flow implemented within the sensor device for
executing the symptoms’ detection algorithms in real-time.
Developed algorithms operate on acquired samples on inertial sensors,
and Figure 5.1 shows a data flow compatible with the previously presented
processing specifications. Since many of the implemented algorithms are
based on a windowed analysis of the related signals, the figure distinguishes
three main parts:
• A first one is a set of calculations performed after acquiring a sample,
which mainly consist in the filtering of the signals to condition them,
followed by the execution of the fall detection algorithm.
• A second one comprising the calculations performed at the end of a
window time, which comprises the main computations for the monitoring
of the motor symptoms (detection of Bradykinesia, Dyskinesia and FoG).
• The third part comprises the computations done once per minute, in
which the final output of the algorithms is obtained and shared through
the mobile phone.
5.3 Hardware Requirements
According to the introductory section, the internal organization of the sensor
sub-system used in REMPARK appears in Figure 5.2. This section will
introduce the requirements of some critical hardware parts, together with a
timing analysis before the specification of the concrete components chosen
for the physical implementation.
It must be noted that during the REMPARK database collection phase, the
indicated three triaxial sensors (accelerometer, gyroscope and magnetometer)
were used to collect a complete set of signals from as many physical magni-
tudes related to movement as possible. However, in the algorithm development
phase, acceleration signals were identified to be enough to monitor motor
Figure 5.1 Data flow for the algorithms implementation.
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Figure 5.2 Internal organisation of the sensor unit.
symptoms. In this way, it must be indicated that the final sub-system only
includes the 3D accelerometer as a sensor.
The most relevant requirements are:
• The concrete component chosen as the correct accelerometer must fulfil
the needed range for the acceleration measurements (i.e. full scale values)
and to be able to operate at the necessary sampling frequency.
• A main constraint for the concrete microcontroller to be used is the
online implementation of the algorithms, so the most important charac-
teristics are memory capacity and the exhibiting computational capacity
(throughput).
Memory needs were determined by estimating how many resources should
be used by the algorithmic set, in terms of program and data memory. An
additional space managed by the firmware, necessary for the storage of the
acquired data was also considered.
The theoretical approximation of the required microcontroller computa-
tion time is difficult to be done, and for this reason a measurement strategy was
organized at the laboratory. Measurements were done around a microprocessor
based platform allowing the equivalent simulation of the algorithms.
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5.3.1 Memory Requirements
The calculations of the memory size required by the execution of the algo-
rithms and the firmware operation were performed by estimating the online
deployment of the algorithms, according the different blocks indicated in
Figure 5.1. In concrete, it was considered:
• Acombination of algorithms executed on each acquired sample (detection
of a fall, conditioning and filtering of the signal).
• A set of algorithms executed per window.
• An estimated need of the window management and the communication
system.
• An estimation of the local storage system, using a local μSD card.
Table 5.1 shows the results of these estimations, in terms of necessary
minimum size and type of memory (program or data memory).
5.3.2 Sampling Frequency and Full-Scale Values
Sampling frequency and full scale values are key characteristics for choosing
the correct accelerometer. Frequency also imposes specific time restrictions on
the online implementation of the algorithms, which finally creates important
constraints on the specific microcontroller to be used for the implementation.
Table 5.1 Estimated memory usage
Description Memory Type Memory Usage (bytes)
Basic System with window Management
and communication
Program Memory 6,5 KB
Data Memory 5 KB
Bradykinesia Algorithm Memory Usage Program Memory 3,5 KB
Data Memory 0,5 KB
FoG Algorithm Memory Usage Program Memory 3,5 KB
Data Memory 0,5 KB
Dyskinesia Algorithm Memory Usage
(FFT included)
Program Memory 3,5 KB
Data Memory 0,7 KB
Filters+FallDetection Algorithm Memory
Usage
Program Memory 1,2 KB
Data Memory 0,5 KB
µSD for Debug purposes Memory Usage Program Memory 2,8 KB
Data Memory 4,2 KB
TOTAL Program Memory 20 KB
Data Memory 11 KB
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Going along the different developed algorithms, it is necessary to evaluate
the necessary sampling frequency to be applied. For this purpose, and also for
considering the main frequency characteristics related to human movement
the following points are considered:
• In the case of Dyskinesia, it was observed that this symptom increases
the power spectra in the lower frequencies up to 4 Hz.
• In the detection of FOG episodes, it was observed that normal walking has
a principal frequency around 2 Hz, while FOG episodes are characterised
by a principal frequency in the range of 3–8 Hz.
• The developed method for detecting Bradykinesia uses the accelerometer
signals associated with the patients’ gait. The frequency content of gait
is known to be below 20 Hz.
According the Nyquist theorem, the minimum sampling frequency should be
40 Hz. Therefore, the waist sensor must incorporate an accelerometer with a
sampling frequency of at least 40 Hz. In order to keep the computing resources
as low as possible, this minimum frequency is set as the real-time acquisition
frequency.
Moreover, regarding the full-scale range of the sensor, according to
the measurements obtained in the signals collected along the project, it is
determined that a Full Scale of 6 g (where 1 g = 9,8 m/s2) for the accelerometer
is enough for the analysis of human movement with a sensor worn in the waist.
5.3.3 Time Restrictions on the On-Line Implementation
As previously mentioned, the estimate for the processing time requirement was
made on a set of measurements of processing time spent by a microprocessor,
configured to work at 40 MIPS, and running specific algorithms that have an
equal or greater burden compared with the algorithms developed in the project
for symptoms’ detection. This is an indirect way to fix minimum processing
requirements for the microcontroller to be included in the sub-system.
Considering that some operations must be done after acquiring a sample
or when a time window has been completed, Figure 5.3 shows the temporal
organization of the different computations included in the online implemen-
tation of the algorithms, according the data flow presented in Figure 5.1.
The timing of the accelerometer data collection is represented in orange
(related to a sampling frequency of 40 Hz, with a time between samples of
25 ms). In the sample zoom (top section of the figure), it is shown the time
necessary to both acquire the accelerometer measurements and to perform the
algorithm’s calculations that are done at every sample.
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Figure 5.3 Timing for the online algorithms implementation.
The duration of a window, which is 3.2 seconds corresponding to 128
samples, is represented in blue at the bottom section. Note that a new window
starts every 64 samples (every half a window), as described in Chapter 4. In
the zoomed window, the computations done at the end of an acquired window
are shown. These computations start from those provided by the processing
done after each sample. Most of the time spent in the window computations
correspond to the feature extraction. Once obtained, the bradykinesia, dyski-
nesia and FoG algorithms are applied. In order to ensure a correct processing,
their results are obtained before the end of the next window is reached.
Table 5.2 presents an estimation of the processing time for each part in
which the algorithms are divided. This estimation is based on the necessary
Table 5.2 Estimated processing time
Description Timing Time (ms)
Sampling Frequency Between Samples 25
Adquisition Every Sample 0,014
Filters + Fall detection algorithm Every Sample 0,0318
Windowing time Between Windows 1600
Feature Extraction Every Window (max) 151
Bradykinesia Algorithm Every Window (max) 55
FoG Algorithm Every Window (max) 3
Dyskinesia Algorithm Every Window (max) 3
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operations to accomplish each computation in terms of memory usage and the
inherent complexity of the calculus.
5.4 Sensor Device Components
This section describes the selection of the components for the sensor sub-
system according to the presented requirements.
5.4.1 Microcontroller
The microcontroller (labelled as dsPIC33F in Figure 5.2) is responsible for the
management of the data acquisition with a fixed sampling frequency, the anal-
ysis of the raw data applying the corresponding online algorithm and sending
the processed data (or, alternatively, the creation of a local log in theμSD card).
The selected microcontroller in the project, for these purposes, was the
Microchip r© dsPIC33FJ64MC804. One of the main advantages of this device
is the availability of an integrated DSP engine, which enables advanced
computations in short time, when compared with regular microcontrollers
(e.g., 32F, 24F, 18F and 16F). The microcontroller memory includes 44KB
for program memory while the memory dedicated to RAM reaches 16KB
(both are according the requirements indicated in Table 5.1).
This dsPIC architecture is known as “Modified Harvard” which uses
16 bits-long data and 24 bits-long instructions and it processes 40 Mega-
instructions per second (MIPS). The DSP engine enhances the operational
capacities of the µC. It allows 16-bit data multiplications for both fractional
and integers, and it also allows inverse multiplication among 32 and 16
bits of data. The DSP, despite its relative small size, becomes useful when
computation power is required, saving time to the main µC threat.
The dsPIC operational voltage range is 3.0 to 3.6 V (the whole system volt-
age supply is 3.3 V). Working at 40 MIPS and supplied with 3.3 V, the micro-
processor consumption is 60 mA in “run mode” (normal operation mode),
while in “idle mode” (special waiting state) its power consumption drops to 20
mA, and in energy safe mode (“sleep”) maximum current peaks reach 28 µA.
An internal DMA (Direct Memory Access) module allows the communi-
cation between the CPU, the memory and the peripherals independently from
the process being executed in the main thread of the program, enabling the
execution of this process in parallel. The dsPIC has 8 DMA channels that
may be associated to any peripheral I/O port. The DMA allows the parallel
execution of various processes interrelated among them through asynchronous
events (interrupts).
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The whole operation of the system is effectively managed by the CPU
using some internal specific peripherals, allowing:
• Data acquisition.
• Communication with the wireless module.
• Communication with the digital sensor.
Each peripheral has two associated DMA channels (transmission and recep-
tion) that provide access to a shared memory block.
5.4.2 Accelerometer Details
The selected accelerometer is the LIS3LV02DQ (LIS) manufactured by ST
Microelectronics [1] which was, at the moment of the design, the only available
Microelectromechanical System device (MEMS) using a digital interface
within the device. The inclusion of the sensors, the signal conditioning and
the converters within the same packaging ensures a very good performance
against perturbations. Besides, the inclusion of the three axis (3D) in the same
package also provides a better functional and geometrical symmetry. Finally, it
is important to highlight that the accelerometer includes a signal compensation
based on internal calibration curves, which compensates the measured signal
based on the temperature sensor also included in the accelerometer integrated
circuit.
The bandwidth used by the LIS is 640 Hz for each axis. Given the
particularities of human motion, the sample frequency required for it is 40 Hz,
therefore, an excessively small sample period is avoided. One of the main
advantages offered by LIS is that the full scale may be chosen between two
values (±2 g or ±6 g). The higher full scale allows a sensitivity of 340 LSB/g,
which is the selected one for the device. The precision of the accelerometer is
2.9 mg for every bit change.
5.4.3 Bluetooth Module
According to the REMPARK system requirements, the movement sensor
device has to communicate wirelessly with, at least, a mobile phone to share the
output of the algorithms. The system has been developed including a wireless
communication Bluetooth v2.1 + EDR (IEEE 802.15.1) chip to implement the
communication channel. For this purpose, the sub-system includes a WT12
Bluegiga r© communication module, with an on-chip integrated antenna.
The communication is organised through the UART port of the system.
When the system boots the connection and communication parameters are
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configured; once communication is established, and because the SPP profile
is used, the module works as a bridge between the UARTport and the Bluetooth
unit. This module works at 115200 bps and its consumption is 31.5 mA
according to its technical specifications [2].
5.4.4 Power Management
The sensor includes a battery management system that tries to save as much
energy as possible. As shown in Figure 5.4, the operation is based on 3
low-dropout regulators and each of them powers selected parts of the sensor:
first regulator supplies energy to the microcontroller, which manages the
operation of the remaining regulators. The additional two regulators supply
the analogue and the wireless circuitry.
The system is powered by an 1130 mAh Lithium-Ion battery. According to
the functional requirements for REMPARK system, sensor usage is suggested
to be similar to a mobile phone. The system has a peak of 100 mAinstantaneous
current consumption; therefore, the worst case estimated life of the battery is
a minimum of 20 hours. Then, the device should be charged a maximum of
once per day, and normally during night.
The system incorporates a battery charger and a battery monitor. The
battery monitor indicates to the user its current state through a RGB-LED.
Figure 5.4 Power Management block diagram.
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When the battery is very low, an interrupt is produced in the microcontroller
and the system automatically closes all its peripherals and communications
and enters in the “sleep” mode.
5.4.5 External Memory Unit
The sensor system contains an external memory unit in the form of a
μSD card, as it has been introduced, managed through one of the available
microcontroller SPI channels. This memory unit is intended to store, if desired,
the raw data captured by the sensors. After extracting the μSD card from the
sensor unit, it is possible to get the generated log file in order to analyse the
inertial data. This functionality was especially useful during the REMPARK
database construction process.
5.5 Sensor Casing and Operation
All the described electronic components of the sensor unit plus the Li-ion
battery are encapsulated in a 99 × 53 × 19 mm plastic case. The total weight
is 125 g (including the battery). The prototype also includes a wall battery
charger. Figure 5.5 shows the casing view of the sensor unit.
As parts of the user interface, four elements can be externally identified in
the unit: the main switch, an action button, the indicator LED and a charger
connector. Figure 5.6 indicates the location of these components.
The behaviour of the sensor unit is determined by two states: Off and
On. These states are mutually exclusive; a third state, related to the battery
supervision, is compatible with the previous ones and may be understood as
Figure 5.5 Sensor unit casing.
5.5 Sensor Casing and Operation 101
Figure 5.6 External components of the sensor unit.
an independent state. Figure 5.7 represents graphically the relations between
the states of the sensor unit.
In the OFF state the sensor cannot work, no battery consumption exists
and no battery level may be presented. Besides, the device does not react
when the action button is pressed. In the ON state the sensor initializes the
microcontroller. When the sensor has already initialized all the internal devices
it is ready to start the sensing process. When ready, the sensor reads inertial
signals and processes them. Data are sent every minute to the mobile gateway
as described above.
The state of the sensor is indicated using a unique multicolour LED by
taking advantage of its blinking light. Different states can be distinguished
due to the diversity of the colour code of the LED. For example, a blinking
green/yellow light means the sensor is in a sense and analysis process. A
blinking green/blue light means the sensor is sending data. If the sensor is
Figure 5.7 Status of the sensor unit.
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Figure 5.8 Special belt and REMPARK final sensor.
charging the battery, it will be indicated with a fixed orange light. Otherwise,
a fixed green light will notify battery if fully charged. Finally, error state will
be indicated by means of a fixed red light.
The sensor unit case is surrounded by a retention mechanism (belt) able to
fix the sensor unit on the patient’s waist, as depicted in Figure 5.8. The part of
the belt that is in direct contact with the patient’s skin has been manufactured
using a biocompatible neoprene material.
5.6 Conclusion
The specification of the concrete requirements has been done along the chapter,
allowing the selection of the most convenient components integrating the
sensor unit of the REMPARK system. The microcontroller is capable to embed
all the developed algorithms and to execute them in real-time and considering
all the restrictions related with the data capturing timing.
The system is light and small, being suitable to be worn in a belt without
being intrusive for the patient. Furthermore, the system is capable to store raw
data and to send messages to an external device. In this way, the developed
sensor complies, thus, largely with all the established requirements, becoming
the heart of the REMPARK system.
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6.1 Introduction
One of the components of the REMPARK system is the smartphone, which
represents the main communication channel between the system and the user.
Within the project, the main goals in the development of the smartphone
applications were to complement and confirm information coming from the
system’s sensors through patient feedback tests and to design user interfaces
specifically tailored to the needs and abilities of users with Parkinson’s
Disease (PD).
Given the nature of a device such as the smartphone and its potential
benefits in daily life outside a medical scope, the design and development
went beyond the single focus on medical issues to encompass other services,
such as the usual communication features offered by a smartphone.
The need for a strong collaboration with end-users was defined at the
project onset, which led to an iterative design process. This not only informed
choices about patterns of interaction suited for people with Parkinson’s
Disease (PwP), such as target sizes or suitable gestures, but also about the
kind of features main stakeholders would like to see in the REMPARK
smartphone. The structure of this chapter will then reflect the two main blocks
mentioned above: 1) the research on guidelines regarding visual, interaction
and navigation patterns; and 2) the design and validation of the smartphone
applications.
The smartphone is increasingly recognized as a viable instrument to be
applied in medical diseases with movement disorders [1]. Main applications
currently refer to the possibility of monitoring symptom changes over time
through the use of relatively economic software. This could potentially
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represent a significant advance particularly for the management of chronic
conditions.
The direct use of smartphones with PD patients should take into account
the presence of the motor and non-motor symptoms that could potentially
affect the usability of the smartphone applications. It should also be noted
that people involved in REMPARK were, mainly, older adults. It was then
taken into account that these individuals might not show high familiar-
ity with smartphones, and, more generally, with the use of most modern
technologies.
With the exception of a few studies regarding interaction of PwP with
desktop solutions or desktop peripherals [2, 3], software [4] or pen-tablet
devices [5, 6], at the beginning of project activities, there were few studies
on the interaction of PwP with smartphones. There were official guidelines
for the sizing of target buttons for people with disabilities and studies on
both the sizing and element gap for people with disabilities [7]. Nevertheless,
none specifically focused on PwP. This, then, constituted an opportunity for
relevant research on and beyond the scope of the REMPARK project, which
would likely:
1. help future practice in the development of ICT solutions for this particular
target group;
2. help the development of more inclusive guidelines;
3. help contribute to reducing the digital divide through promoting enhanced
access to smartphone solutions.
The sub-goals defined for this task were:
• to find suitable patterns for the REMPARK smartphone applications
which would enhance accessibility and usability;
• to design the applications themselves under collaborative processes with
users so that these applications would be: easily used by people with
PD, non-stigmatizing, user-friendly and foster adherence to the medical
treatment.
All the user interfaces were successfully designed and the most relevant
issues evaluated with end-users. The process also took into account possible
extensions to the REMPARK services, which led to specific user interfaces
leaving room to future features and additions. The results from the field
trials are listed and discussed in this chapter, followed by possibilities for
future work.
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6.2 State of the Art/Competitive Analysis
As part of the REMPARK activities, a systematic search was conducted in
order to capture and analyse relevant information about mobile applications
that could assist PwPin managing the disease. The search was organized to find
market products and Research & Development (R&D) technology related to
this topic, including technology being developed and described in published
and publicly available papers and conference proceedings. The search also
included currently registered patents to verify the existence of innovative
solutions. In terms of products or prototypes, the search was limited to mobile
solutions for either Android or iOS smartphones.
Table 6.1 summarizes the results of said search for R&D and market-ready
products. The different evaluated parameters are those appearing in the top
row of the table.
Some applications, like Parkinson’s Central, the Parkinson’s Disease by
WAGmog and Parkinson’s Disease Facts are small applications that provide
very useful information about the disease, but do not contemplate any kind
of interaction with the user. PD Warrior also offers information about the
disease and combines it with rehabilitation exercises. Parkinson’s Home
Exercises focuses on the physical side of the disease, providing rehabilitation
exercises and cueing support. It does not address the psychological and disease
managing sides. Parkinson’s Disease Manager is an application that provides
a relation between the doctor and the patient. It has doctor reminders and
questionnaires that allow the doctor to better diagnose the state of the disease
continuously.
DAF Professional, Speech Companion and Parkinson’s Speech Aid solely
focus on speech therapy, and no other application has approached this method
in conjunction with other features. It is an innovative method that is rising
among the possible therapies for PD. The Apple Health Kit is the only solution
we found that can assess PD stage by analysing the voice of the patient. It also
covers other features like recording all motor data, questionnaires and, like
REMPARK, the Tap games.
Parkinson’s Easy Call is the only solution we have found that overhauled
the default smartphone applications and adapted them to users with PD.
However, it does not include any other extra feature.
Some applications, like ListenMee, Musical Therapy Service Portland,
MoveApp and Beats Medical Parkinson’s Treatment contain an auditory
cueing solution; however the last two also incorporated a few extra features.
Beats MedicalTM also tracks medical intake history and the MoveApp is one
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of the most complete solutions found that includes medication reminders,
information about PD, a diary, rehabilitation exercises, an auditory cueing
solution and questionnaires. There seems to have been less focus on the
usability of the system in favour of the rehabilitation methods.
The Fox Insight App focuses on the daily management of the disease with
medication reminders and a diary. This information is combined with a record
of all motor data detected by the smartphone.
In the course of the chapter, it will become clear that, overall, the REM-
PARK system offers most of the features represented by all solutions, however
it has more focus on the management of the disease, physical and psychological
monitoring and improvement of patient Quality of Life (QoL) while using the
smartphone applications actively or passively. It does not have any kind of
approach regarding rehabilitation or speech related techniques. It also does
not provide any kind of general information about the disease. While the lack
of these features may be seen as a downside of REMPARK, it is important to
state that the REMPARK system was developed as a monitoring system with
an Auditory Cueing System (ACS) as actuator that offers assistance in case
motor symptoms are detected.
The search in patent databases retrieved the following relevant examples:
• WO2011088307 A2 (Application, filing date 2011) [8]. “Amedical mon-
itoring and surveillance system uses a server communicating with a
general purpose personal device running an application. The application
may be downloadable. The application is configured by the server, i.e.
the application configures the device to perform medical tests using
the sensors, pre-existing capabilities, and functionality built into the
device. The device may be a cellular phone with data communication and
other functionality, a personal digital organizer, a portable entertainment
device, or another similar personal device. The application reports the
results of the medical tests to the server or a third-party device. Various
trigger events and associated tasks may be incorporated in the server or
in the application residing on the device. A trigger event may occur, for
example, in response to the test results meeting one or more predeter-
mined criteria. Once a trigger event occurs, a task associated with the
trigger event is performed.”
• US8669864 B1 (Grant, filing date 2013). [9] “A mobile terminal is used
to assist individuals with disabilities. A mobile terminal such as a
“smartphone” or other commercially available wireless handheld device
may be loaded with software. The software may be configured to: (i) store
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criteria for managing communications between a disabled user of the
mobile terminal and a remote caregiver, (ii) determine whether a criterion
is satisfied, and if so (iii) initiate a communication from the mobile
terminal to the remote caregiver, and (iv) receive a response from the
remote caregiver. Thus, through this software, the mobile terminal may
dynamically facilitate communications with specific remote caregivers
based on specific situations that may confront disabled individuals.”
• US20130345524 A1 (Application, filing date 2013). [10] “Methods and
systems are disclosed for sensing and assessing patients’ responses to
tests using a device that may include tactile input, voice input, still image
analysis, and responses to visual and auditory stimuli. In one example,
a method includes obtaining interactive clinical assessment data using a
remote client device and a computer-based control device, the method
including providing on a display of a remote client device one or more test
prompts for conducting an interactive clinical assessment, each displayed
test prompt instructing a user to perform an action using the remote client
device in response to the test prompt, and providing on the display of the
remote client device one or more potential responses of actions that may
be performed in response to the test prompt.”
Analysing the patents found, it is possible to see that none is completely
oriented to PwP, however all three describe different methods to manage a
system similar to REMPARK. WO2011088307 A2 describes a system similar
to REMPARK where a smartphone gathers data from different devices and
sends it to the server. After that, some triggers may be configured in both the
server and the smartphone. The REMPARK system works differently, as
the triggers are preconfigured and the server only calculates the thresholds
that activate them. The US8669864 B1 patent describes a simple system of
communication between caregivers and patients, also not focusing in PwP.
Their focus was in general disabled people, and therefore the applications
are adapted accordingly. Given that REMPARK is a monitoring system,
the communication between the caregiver and the patient, using the tools
developed for REMPARK, is strictly restricted to the management of the
disease (medication intakes, medical appointments scheduling, etc.), even
though the patient may use REMPARK’s smartphone as a normal phone in
his/her daily living to establish and receive phone calls, text messages, access
the Internet, etc. The last patent (US20130345524 A1) describes the usage of
a device’s input methods, like touch, voice, gestures, etc. and how they can
be used to perform an interactive clinical assessment. The REMPARK system
makes use of this method in the Tap games.
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6.3 Interaction Guidelines for Users
with Parkinson’s Disease
The first step towards the design of adequate user interfaces for PwP was
understanding which and how specific symptoms of the disease affect the
interaction with touchscreen handheld devices such as smartphones; secondly,
understanding how said interaction with the smartphone can be improved in
order to accommodate the characteristics of the disease [11].
After an intensive literature review on the topic, eight semi-structured
interviews with health care professionals who worked with PwP on a daily
basis were organized. They were complemented with observation sessions
in which two PwP showed their symptoms to their neurologist, as if it was a
consultation. The interviews were audio-recorded, coded and analysed, which
enabled to understand which symptoms of PD could affect the interaction with
the smartphone. Table 6.2 shows some interesting Interview Results (IR) to
be considered.
To actually measure the extent to which PD symptoms affect the inter-
action with the smartphone, usability experiments were created. Thirty-nine
participants (17 females, 22 males) took part of the usability experiments.
Participants average age was 64 (Median: 66; STD: 7.4) and had been
diagnosed as having PD since for at least 10 years (Median: 8; STD: 5.8).
Table 6.2 Some important interview results
Motor Characteristics
IR1 Bradykinesia can slow repetitive movements.
IR2 Rigidity makes interaction more imprecise and slower.
IR3 Dyskinesia can make the interaction very difficult.
IR4 PD may hinder speech.
IR5 Some PwP may experience visual disabilities.
IR6 PwP are likely to use the phone while standing still or sitting.
IR7 The impact of PD hands’ tremor is limited.
Cognitive Characteristics
IR1 Short-term memory loss is accentuated on PwP.
IR2 Thought is slowed by PD.
IR3 Depression and apathy are common in PD.
IR4 Dementia cases are often observed on later stages of the disease.
General Characteristics
IR1 Symptoms significantly vary across different PwP.
IR2 Symptoms vary between ON and OFF phases.
IR3 The disease progresses differently from person to person.
IR4 Autonomy is gradually lost.
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All participants took part of the experiment while in ON phase. Regarding
participant’s self-reported motor symptoms: 59% had tremor, 59% had rigidity,
and 26% had dyskinesia. Some of them (13%) had undergone deep brain
stimulation surgery. The recruitment was done through two delegations of the
Parkinson’s disease patient association in Porto and Lisbon, as well as the
Hospital of São João (Porto) in Portugal.
As it can be seen in Figure 6.1, four different tests were developed to
evaluate the following PwP abilities:
1. select targets of different sizes using the Tap gesture
2. do swipes
3. perform repetitive taps
4. accomplish drag gestures
Tap and Swipe were chosen due to their heavy use on today’s smartphones.
Multiple-tap and Drag were chosen because they were adequate for building
smartphone interfaces for medical questionnaires with scales, a requirement of
Figure 6.1 Sequence of interaction of different experiments. a) Participants had to touch the
target, which appeared in different sizes, at different positions and surrounded by distractions
of different sizes; b) Participants had to slide a rug which appeared in different heights with
different spaces to the distractions; c) Participants had to control the water level, by filling the
pipette by touching the arrow up until the water reached the green mark; d) Participants had to
use the seek bar with a ball as a selector to drag the ball to the boy; scale and mark’s position
changed with test progression.
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the REMPARK project. Experiments were developed for theAndroid platform
and designed to run on the Samsung Google Nexus S (4-inch capacitive
touchscreen, with 480 × 480 pixels of resolution and 123.9×63×10.9 mm
dimensions). All relevant interaction data were logged during the experiments
and conveniently analysed.
The results of the usability experiment showed that Tap test results were
significant both regarding touch accuracy and reaction time. The results
showed that mean touch accuracy tends to decrease with button size, and
the highest accuracies were observed with targets with 14 mm size (98% of
accuracy). Results also showed that the spacing to surrounding elements does
not influence the accuracy of the Tap.
It was observed that PwP are able to perform swipes and distinct partici-
pants swipe at very different speeds. Despite target size and spacing between
the target and surrounding elements being irrelevant, our results showed that to
accommodate 95% of the participants’ swipes one should accept movements
of 24 mm/s.
PwPwere also able to perform successive taps with no significant reduction
in speed, which challenged the data from the interviews that anticipated
PwP would be strongly affected by bradykinesia. However, as participants
performed the tests while in ON phase, this might not be the case.
Regarding the Drag gestures, it was shown that participants were able to
drag objects with precision, but they were slow to reach the goal. However,
the increased frustration expressed by the participants with the Drag, allows
us to say that Multiple-tap is more comfortable to perform than Drag.
By reflecting on the findings of this short study, 12 user interface design
guidelines (DG) for creating smartphone applications for PwPwere considered
and are listed in Table 6.3.
Table 6.3 User interface design guidelines
Design Guidelines
DG1 Use tap targets with 14 mm of side.
DG2 Use the swipe gesture, preferably without
activation speed.
DG3 Employ controls that use multiple-taps.
DG4 Use drag gesture with parsimony.
DG5 Prefer multiple-tap over drag.
DG6 Adapt interfaces to the momentary
characteristics of the user.
DG7 Use high contrast coloured elements.
DG8 Select the information to display carefully.
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Table 6.3 Continued
DG9 Provide clear information of current location at
all times.
DG10 Avoid time dependent controls.
DG11 Prefer multi-modality over a single interaction
medium.
DG12 Consider smartphone design guidelines for
older adults.
6.4 User Research and User-Centred Design Processes
The choice was to provide the users of the REMPARK system not only with the
REMPARK applications, but also common functionalities of mobile phones.
The REMPARK applications could have been designed as stand-alone appli-
cations which could be downloaded and be amongst the smartphone’s existing
applications. Two performance-based reasons discouraged this approach:
1. The REMPARK system is a medical one containing sensors and actuators
which play a serious role in users’ lives. Therefore, the system should
have some control over its performance, which means having, amongst
others, control over battery duration or some means of preventing external
applications’ interference with REMPARK’s applications.
2. As described in the previous sections, users with PD are generally older
adults who, nowadays, are likely to be less tech-savvy and who, addi-
tionally, due to the disease itself, have motor and non-motor constraints
which might hinder the interaction with the smartphone. These users
then require simple user interfaces which are furthermore adapted to
their abilities.
These reasons have led the partners to develop a set of applications which
would work within a launcher. In a nutshell, launchers enable developers to
create a custom home screen through which one also has the possibility to
control what the user will or will not see and interact with. The advantage
of the launcher is that it answers the above listed reasons in the sense that it
allows to control which applications the user has access to and, furthermore,
in what usability and user experience are concerned, it allows for the design
of a single interaction experience. All applications within the launcher obey
the same principles and patterns and, once the user has learned how to use
one, he or she will most likely be able to use the others, as the language is
kept identical.
The processes followed a human-centred approach in that main stakehold-
ers were called to be part of the design process from onset. Following the above
114 User Interaction
described reasoning, the initial list of applications to design and implement
within REMPARK was set amongst the partners in the consortium as follows:
• Messaging
• Emergency call
• Calling
• Contacts
• Show disease status
• Medication
• Agenda
• Auditory Cueing System (ACS) controller
• Medical questionnaires
• My data
• Settings
• Tutorials
After this definition, a process of interaction with users was scheduled in order
to cope with main usability requirements, not previously considered.
Apart from the health-related benefits arising from the ACS, the value
proposition for this set of REMPARK applications would be that PwP could
have all their Parkinson’s-related mobile needs satisfied, while not hindering
the use of the main purpose of a smartphone: communication. All aspects of
the applications – ranging from button sizes to workflows – were taken into
account from users’ perspective in order to insure a positive user experience.
After informal discussions with the experts within the REMPARK project,
who provided insights about PwP’s needs and abilities, app design was
approached first through an exploratory methodology, in semi-structured inter-
views to people with Parkinson’s disease, informal caregivers and physical
therapists. The analysis of these results informed a second phase for which
a collaborative and participatory approach was considered, mainly involving
people with Parkinson’s disease and their caregivers.
The results were not conclusive regarding most issues (medication/
appointment reminders, preferred activities or physical therapy). On the one
hand the samples were fairly small and, on the other hand, participants with
PD gave ambiguous answers to the questions posed by the researcher. Never-
theless, there was a clear concern with moving around outside (especially in
places further away from home) and with having emergency mechanisms at
PwP’s disposal in case something happens.
These interviews helped to structure the next steps in user research and to
add a new requirement for the smartphone: that it should provide others the
information that the smartphone owner has PD.
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The material up until this point had enabled the design of the user interfaces
and some screen flows. The choices for the UIs and, specifically, the GUIs were
made based on Fraunhofer Portugal’s existing knowledge and expertise on UIs
for older adults, topped with the findings regarding specific requirements for
users with PD.
The background was kept dark to prevent glare and increase battery
life and all buttons size complied with the recommendations mentioned in
Table 6.3. The approach was to avoid the need for scrolling actions to the
widest extent possible. Therefore, activities were sometimes divided into
layers and, consequently, sub-activities. All screens consistently displayed the
same Back button, appearing at all times and in the same location. All action
buttons were consistent in displaying, whenever possible, an icon along with
an action verb + name, so that the user would be surer of his or her input. For
instance, whenever possible, instead of “Save”, the button would read action
verb plus the element being saved, e.g. “Save Appointment”.
Regarding navigation, the screen flows were kept with as few layers as
possible, wording was sought to adapt to terms which were familiar to users
and which could have relation to the physical world. For the composition
of the screens we have opted to design a set of patterns for a number of
situations/functions, which allowed to be grouped according to each situation.
Figure 6.2 shows some examples of the designed patterns.
In order to allow for as simple as possible an interaction, the text input
created a new activity so as to allow for a simple screen which would not
demand too much of the users’attention.As seen in Figure 6.3, once activating
a textbox, the user is led to a screen with a title reminding the input action,
a textbox, a save button and the keyboard. In this way, the user was offered
step-by-step guidance on information input.
Scoping sessions with stakeholders provided additional ideas for features
which would enhance the REMPARK smartphone, such as the different ways
to trigger an emergency alert, the importance of showing information about
the disease, along with some clues on what to show, the importance of having
clear information on medication reminders in order to reduce error, or the
usefulness of keeping a detailed record which both the medical doctor and the
PwP/caregivers can consult.
With all the compiled information and generated inputs, the partners
proceeded to redefine parameters in the REMPARK applications. At this time,
the screen flows for the following applications had been re-defined:
• Medication
• appointments
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Figure 6.2 Some examples of UI patterns and gestures.
Figure 6.3 Sequence for text input.
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• calls
• messages
• contacts
• ‘my data’.
A specific interaction session with PwP was organized at this point with the
objective of clarifying some issues within the medication application, namely
the amount and type of information being displayed (in medication, disease
status, appointments and my data applications) and to check whether or not
the flow was easily followed. The session also aimed to discuss the options
for emergency calls with the participants, the option of having SMS templates
and the option for the appointments application to have a rough prediction of
OFF states. Finally, participants were asked about what they thought would
be the best icon for the Auditory Cueing System controller. Some comments
on this session:
• About the medication. Participants were asked to state their opinions
regarding the proposed solutions and also to contribute with their critical
thinking and experience with the disease. For the most part, the solu-
tions were welcomed by participants with minor remarks. For instance,
regarding the ‘Medication Details’, participants thought there would be
no point in displaying the name of the active substance along with the
medication name. Participants agreed that the possibility to add notes
to the medication details was useful and that these should show on the
reminders (e.g. ‘Sinemet 10/100 mg, Take before eating’).
• About emergency situations. Facilitators discussed the ideas of having
one lateral hardware button reconfigured to act as quick dial to an
emergency number on long press. They also discussed the quick dial to
a caregiver and the permanent presence of a quick dial to an emergency
number through an icon on the smartphone’s main screens as it is shown
in Figure 6.4. Participants tried out long presses to the lateral hardware
buttons and agreed that it would be an easy action for them to complete.
They envisioned that a possible use case would be an emergency during
bathing.
• On “My data”. Participants were also happy about the possibility to have
a quick access to their health information under ‘My Data’. At this point
in time, the ‘My Data’ flow would first show a pop-up with a warning to
inform that the smartphone owner had PD, followed by a screen with the
owner’s picture, a quick dial button to the caregiver and a list of current
medication. Participants mostly cherished the possibility to carry with
them the list of medication they were under at any point in time.
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Figure 6.4 Screenshots of the home screens: Applications screen (to the left) and Favourites
screen (to the right).
After the advice of medical partners, the adopted solution is presented
in Figure 6.5, where all relevant information is shown at once (preferable
avoiding scroll).
• On the Disease Status. Participants welcomed the idea of visualizing
their disease status. They would appreciate it if the application would be
able to record involuntary movements (dyskinesia). One caregiver in the
Figure 6.5 Screen flow for the ‘My Data’ application.
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group had already her paper version of this disease status visualization,
which she would take with her every time she accompanied her sister
(PwP) to the doctor.
According with medical partners, one of the main drivers for choosing
to include such an application was to promote treatment compliance.
Several studies show the nefarious consequences brought about by non-
compliance with medical treatments [12, 13]; nevertheless, controlling
medical compliance without being intrusive and tiresome to users is
a difficult task. Our hypothesis was that, by allowing users to easily
visualize the relation between their disease status and their medical
treatment adherence, they would be compelled to follow the medical
prescriptions and advice. However, medical doctors pointed out that, if
a PwP is not doing well, visualizing a poor health state might have the
contrary effect.
Therefore, the choice was to present simple data gathered by the
system, which PwP usually try to collect in order to show to their
physician. The features to be shown in this application were: ON/OFF
periods, FOG, dyskinesia, festination and falls. Along with this, the
visualization tool would also show failed medication intakes, rather than
all data about medication. The final result may be seen in Figure 6.6.
Figure 6.6 Screenshot of the ‘My Day’ app.
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• On the Appointments. The idea brought forth about warning the user
whenever he or she was setting up an appointment which most likely
overlapped an OFF phase was not popular. After some initial discussion,
participants agreed this might be dangerous not only because – given
the several variables involved – it is quite difficult to predict an OFF
timeframe, but also because having this information beforehand could
most likely create unnecessary anxiety.
• On the ACS icon. Participants decided the best icon to convey the idea
of auditory cueing between some elaborated and proposed ideas.
Despite the effort placed onto adopting inclusive design for UI design, the
users’ concerns about the response of the touch screen led to conduct more
research into the touch patterns of PwP in order to try to define what charac-
terizes an intentional tap, and thus optimize interaction with the smartphone
by reducing error. For the purpose, a specific test was designed and carried
out with 4 participants with PD.
The tests were designed to explore the possibility of creating an algorithm
to differentiate voluntary from involuntary taps using the touch data provided
by the Android API. For that a little game was designed to persuade PwP to do
voluntary taps on the smartphone’s screen, consisting in basic math operations
where the user had to answer a question by tapping one of 3 possible answers
(Figure 6.7a). This game allowed to easily observe when a person would
intentionally tap an option or tap on another part of the screen by chance.
It was planned to achieve at least 11 voluntary taps per participant, in this
way 11 questions were presented and if they failed solving the problem at
Figure 6.7 a) Initial screen; b) Number indicating the tap counting; c) Custom display of a
tap event.
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the first time they would need at least one more tap to get the next question.
However, we could not induce any involuntary taps from the participants;
therefore, no minimum number of involuntary taps per participant was set.
The tests were recorded on video and each tap would increment a number
on the screen (Figure 6.7b), so after the test was done it was possible to
discriminate if a tap was voluntary or not.
The data provided by the Android API consisted of tap time, area of touch,
pressure of touch and dislocation of the finger during the tap event which could
be used to both perceive the orientation of the finger. The area of touch and
pressure were only estimated by the Android API by measuring the change in
capacitance on the screen, therefore not corresponding to real measures. As
a result, a visual representation on the screen of these measures was created,
as a means to test their correspondence to real measures. The pressure was
represented by an ellipse that we then stretched and rotated accordingly the
perceived orientation of the tap event, the area by a square and the orientation
by a red line (Figure 6.7c).
Despite inconclusive, the results suggested that there should be room for
improvement and that this analysis should be pursued further in the future. An
interesting correlation between the contact time in voluntary and involuntary
taps was found. However, the pressure and area had little fluctuations; the
direction of tap also did not prove effective because PwP lacked a consistent
movement that was necessary to detect correctly the orientation of the tap
gesture. But nevertheless, the information about the dislocation of the finger
could be used to mark involuntary taps if the finger moves too far away from
the first point of touch. Hence, the most probable outcome of future tests will
be a time-distance frame where a voluntary tap is considered as a tap that
respects that time-distance frame, and involuntary tap as one that does not
respect that time frame. This timeframe would be necessarily adjusted by the
user in order to better suit his/her needs.
Following these very concerns in optimizing interaction and preventing
errors, the velocity of scroll was adapted in order to better control for the
presence of dyskinesia. Furthermore, it was added the option to replace the
scroll gesture by tap buttons with upward and downward (Figure 6.8).
6.5 Final Usability Tests
For the purpose of conducting comprehensive usability tests with PwP, partic-
ipants were recruited through Hospital de São João, in Oporto (Portugal). The
documentation was sent to the Ethics Committee and approval was obtained
in due time upon documentation submission.
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Figure 6.8 Arrow buttons as an alternative to the scroll gesture.
6.5.1 Research Questions
The main questions left unanswered were related to touch interaction, ease of
navigation and the affordances of particular patterns. Regarding navigation,
most questions were brought about by the two most complex applications:
Medication and Appointments. These, it was supposed, will be frequently
used and imply an array of activities and tasks which might be difficult to
handle, such as interacting with reminders, introducing new data, browsing and
searching for specific data, amongst others. Therefore, usability tests focused
on evaluating the ease of understanding of the navigation experience, while,
assessing the touch and gesture interactions on the background.
6.5.2 Sample
The sample was recruited from the neurology department, a group of a
physiotherapist’s patients and a day care centre. No exclusion criteria were set,
except for the presence of concomitant health conditions which caused motor
or cognitive impairments beyond those owing to PD. A total of 12 participants
were recruited, although three were excluded for not being able to finish the
usability tests due to poor mental state. Consequently, the sample was reduced
to nine participants, which resulted on five tests forAppointments, five tests for
Medication and four tests for scroll accessibility. The sample had an average
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age of 71.3 years old, ±STD 10.4, (median: 73) and participants had had PD
for an average of 9 ±STD 8.6 years (median: 6).
6.5.3 Protocol, Script and Metrics
As there were many items in need of evaluation, there was the risk that
usability sessions would be too lengthy and hard on participants. Therefore, the
session was devised into two different session tests, one for each application:
Medication and Appointments. In this way, beyond avoiding wearing out the
participants, bias was also avoided to some extent, as participants would not
learn visual and interaction patterns from one application to the next.
The protocol followed the usual steps in usability testing: researcher
presentation, project presentation, material presentation, study presentation
and goals, obtaining informed consent, session tasks and debrief.
The variables being measured were as follows: tap button precision, tap
length time (evaluated with FUSAMI [14]), task completion, number of errors
and scroll errors (measured afterwards through video observation and with
the specific test). Additionally, in order to continue to adapt the sensibility
of the screen to better fit PwP the touch data from the appointment tests was
catalogued in voluntary taps and involuntary taps.
The scroll test was done at the end of the ‘Appointments’ session and it
had a simple design, it consisted of a contact list with thrice the number of
contacts supported by a screen with no need for scroll and the person had to
tap on a contact which was only accessible through scrolling. For the 3 types
of scroll all the names of the contacts changed, but in all of them the contact
was in the last position of the second scrolling panel, thus being required to do
an entire scroll to see it; scrolling all the way to the end of the list would hide
the referred contact once more. The measures used were: number of touches
on the screen and time to find the contact.
The test material, protocol and script were subjected to pilot testing
with two participants with PD for each test, who were recruited through
Fraunhofer’s contacts with day-care centres and who signed the informed
consents to take part in the pilot tests. After the pilot tests the session plan was
refined.
6.5.4 Results
Some results obtained on the main issues addressed during the set of usability
tests are discussed:
124 User Interaction
6.5.4.1 Appointment test
Using the calendar and reading an appointments list. Overall the par-
ticipants recognized which days contained appointments (Figure 6.9), even
though some had more difficulties than others. In the end, all participants
identified the days correctly. Current day is also visually distinct from the
remaining month days, but only one participant noticed this.
As expected, when asked to see more information about an appointment
they had on a specific day, participants tried to press on that day, despite being
too small for participants to accurately tap it. Participants were able to read
the correct event. They only had difficulties when the event did not show
immediately on the list and they had to scroll to get the correct appointment.
When the facilitator scrolled to the right position they read it without effort.
Tapping on an appointment to see more details. In general, the par-
ticipants were able to correctly identify the name of the appointments as a
clickable element and tapped them without almost any problem (Figure 6.9).
Editing/creating an appointment. Here the participants had more dif-
ficulties to know what they had to do in order to edit an appointment
(Figure 6.10). Creating a new appointment was the most complex task on
the tests and the participants were only able to accomplish it with assistance.
Generally, the editable elements were easy to identify, however when they
were ‘hidden’by the scroll, participants needed help to find them.Additionally,
the pop-ups confused some participants. When the pop-ups of date and hour
Figure 6.9 Calendar screens: a) Calendar; b) Week list.
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Figure 6.10 New/Edit appointment screen.
appeared on the screen some participants instinctively tried to tap on ‘Set’
before using the controls on the pop-up to set a different hour/date.
Using scroll. No participant, with the exception of the one who was used
to touch technology, had the initiative to use scroll. After its use was shown
to them, participants were able to replicate it in that situation but rarely used
it afterwards. Even though they were able to do the gesture, they would only
perceive the information currently displayed on the screen and would not seek
more information. Participants did not notice the visual marking on the screen
indicating the scroll.
6.5.4.2 Medication test
Reading the medication list. Almost all participants correctly identified the
medication names and notes with almost no effort (see Figure 6.11).
Tapping on a medication to see more details. When asked to see more
details, the majority of the participants correctly tapped on the medication to
disclose more details about it, but they had difficulty in correctly reading
the intake hours for that particular medication. As the intakes were on a
different list from that of other elements, only after reading all the details
regarding that medication (or getting some hints from the facilitator to seek
more information), did they finally read the intakes; again, with difficulties.
Edit intake hour and frequency.After understating the concept of intake,
it was easy for the participants to tap over the intake event to edit it. Concerning
126 User Interaction
Figure 6.11 Medication apps screens: a) medication list; b) medication details; c) edit intake.
the editing mechanisms, and despite some initial confusion, participants were
able to use them correctly. After some taps they understood what the ‘+’ and
‘–’controllers were for and used them. Participants were also able to recognize
the spinner to change the frequency of the intake, and choose the correct days
although with hesitation on what the options: “Custom interval” and “Custom
week days” would do. Again, they were not able to scroll down to tap the
‘Save’ button.
Read the medication schedule and list of missed intakes. Despite
the majority of the participants having correctly identified the hours and
medication which they had to take, some had difficulties associating the hours
appearing on the list with the correct medicament. Generally, participants that
understood the concept of missed intakes were able to say which medicaments
were not taken.
Interact with the medication alerts. Overall, the participants understood
clearly which medicaments they had to take, but some had difficulty under-
standing what they had to do in order to inform the system that they only
had taken one medicament of the displaced list (Figure 6.12). However, with
the help of the facilitator showing them how tapping on a medicament would
mark it with a check icon, they would then proceed to tap over ‘Taken’ to
finish the task.
Voluntary and involuntary taps differences. The test allowed us to
observe differences in touching times between some involuntary and voluntary
taps (Table 6.4), though many times those differences were not present, making
it not possible to differentiate them in an automatic way. However, it is possible
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Figure 6.12 Notification pop-up screen (medication reminder).
Table 6.4 Mean duration of a single tap for each participant
Involuntary Voluntary
Mean Std. Deviation Mean Std. Deviation
Participant of Time (ms) of Time (ms) of Time (ms) of Time (ms)
1 166.62 197.38 133.19 90.64
2 355.00 295.57 373.06 250.11
3 322.78 481.36 241.67 217.59
4 413.53 456.89 193.50 87.46
5 703.25 281.18 292.92 178.22
to do it if the PwP intentionally changes his/her behaviour while touching the
screen. Since most of the time the involuntary taps are quick (when one has
tremor and just passes the finger over the screen, or low dexterity and notices
that he/she is touching intentionally on the screen and moves the finger right
away), a minimum time threshold could be settled to discard those taps and
PwP would always have to press the button above that threshold to have a
valid tap. Additionally, a maximum time threshold could be also settled for
the case that the person is touching on the screen and does not notice it, thus
also discarding this possibility of involuntary tapping.
6.6 Conclusions after the User-Centred Process
This section presents a list of some generic conclusions after the user-centred
design approach process organized in the frame of REMPARK, giving, in this
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way, the opportunity to generate a good solution for the interface implemented
on the used Smartphone along the pilots:
• Concerning the Screen Interaction:
• There were no noticeable difficulties on the accuracy of the tapping
action when buttons size was reduced (elements measuring 10,5 mm
in height were tested).
• Concerning the test on the best approach to scrollable screens speed
(normal or reduced), participants were able to use both. There were
no enough data to conclude something relevant.
• When participants were using button arrows as an alternative to
scroll gestures, they were able to learn and subsequently use the
arrows approach. In principle, it was noticed that it was not intuitive
for them.
• It is not possible to discriminate voluntary taps from involuntary
ones although it might be possible to induce new tap behaviour to
PwP in order to make that distinction possible.
• In general, the users had no problems using spinners either on the
Medication or the Appointments applications under test.
• Concerning the action produced when clicking on “+ and –” buttons,
some users had difficulties using them at first, but after some time
or after getting some hints, they got used to them and were able to
finish the tasks using these.
• Participants were able to use the pop-up dialogues to change date
and time. Some were confused at first and used the down arrows
to increment the values instead of the up arrows; but then quickly
learned from the mistake.
• No user had problems tapping over the checkboxes.
• Concerning the Medication:
• In general, the participants were able to read the medication list
and details. The main difficulty was in reading the intakes list for a
given medicament.
• The most part of participants had no problems reading the medica-
tion that they supposedly had to take for the current day.
• After some hesitation on the options ‘Custom interval’and ‘Custom
week days’, users were able to understand the intake repetition
options.
• Most participants were able to identify the medication that they had
missed.
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• After some interaction with the researchers, users were able to
understand that they can modify a missed intake by inputting the
real intake hour.
• Concerning the Appointments:
• Participants were able to read correctly which days had appoint-
ments, although they missed the current week and the current day
markings.
• It was difficult to understand the tree view of Month > Week >
Day. Nevertheless, they were able to use the calendar and read the
appointments for a specific day.
• Overall participants were able to correctly read the date of the events
presented on a list, although there were some exceptions.
• Users were able to understand that an event can be repeated multiple
times on the calendar by editing it.
• When users tried to add a new appointment, they needed help to
type on the phone, and scroll down to see more options and the save
button.
• In general, it was difficult to use and to add alarms to an event.
6.7 Characteristics of REMPARK Smartphone
Applications
Considering all the previous presented user-centred process and the pre-
liminary conclusions obtained, a final implementation of the smartphone
applications and user interface was organized according with the following
main ideas:
• On Home Screen
In order to avoid scroll and allow users to have a quick overview of
each block of applications, the home screen was divided into three main
blocks: General applications, Favourites and REMPARK applications.
• On Medication
The Medication application retrieves and displays the neurologist pre-
scriptions. At the same time it allows the user to add other medication
which is not Parkinson’s-related. Users can edit this latter medication,
but not the one which has been placed into the system by the medical
doctor.
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The application shows the list of current medications the user is on,
missed intakes, a schedule of intakes and a record of intakes.
The application shows medication reminders at intake time and the
user may choose to keep track of his intakes. In this case, the medication
reminder displays an option reading ‘Taken’. The option for the wording
was to prompt users to press the option ‘Taken’only after they have taken
the medication. This was done to provide users with a mechanism to help
them know whether or not they have taken the medication. If, by some
chance, the user has taken the medication but forgot to record the event
on the smartphone, he or she can go to the ‘Missed Intakes’ list and edit
it by choosing that particular missed intake and editing it by inserting the
hour at which the medication was indeed taken.
• On Appointments
As with the Medication application, this application retrieves the infor-
mation from the REMPARK server on existing appointments made by
the doctor, while allowing the user to add their own. Again, users are
only allowed to edit the information which has been inputted through the
smartphone itself.
The Appointments application allows the users to access a calendar
view (and reach their appointments from there), shows a list of events
ordered by date and allows the user to create new events from the main
menu.
• On Auditory Cueing System Controller
The auditory cueing system controller application has a single screen
and allows the following basic options: turn on/off, change volume and
change rhythm. Users may also choose to change the sound type by
previewing and selecting it and predefine the settings for the auditory
cueing. This is done through the settings application.
• On Medical Questionnaires
Medical questionnaires pop-up as they are fed into the system. Never-
theless, the user may opt to dismiss the questionnaire and answer it later.
In this case, the Questionnaires application icon displays a notification
showing the number of questionnaires waiting to be completed.
Due to the limited available space in a single screen (i.e. without
scroll), there will be limits imposed to the number of characters for
questions and answers. The reasoning behind this choice lays in the
fact that the smartphone is one of the possible ways to answer medical
questionnaires. The use cases predict that more complex or longer
questionnaires may be answered through the web interface.
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• On My Data
The My Data application is meant for emergencies or for a quick overview
of the user’s health data to display, for instance, in a visit to the doctor
who is not part of the REMPARK system. After a pop-up with a warning
about the person’s disease (meant for emergency scenarios), it shows
the smartphone owner’s picture, his or her name and phone number,
along with health information: blood type, medication list, concomitant
illnesses and specific data about Parkinson’s disease.
• On My Day
The My Day application refers to what was at first called ‘Disease Status’
application. The name was changed to a more user friendly working.
It has a single screen displaying information of the user’s state over
the previous day: ON/OFF periods, FOGs, festination episodes, missed
medication intakes, falls and dyskinesia.
• On Quick Emergency Call
This application works as a quick dial to an emergency number and is
displayed both at the Applications and Favourites screens.
• On Calls
The Calls application allows the user to make a phone call through a list
of contacts or by typing in the number using an extra-large dial pad. It
also allows checking missed calls and call history.
• On Contacts
This application displays a regular contacts list and allows the user to
define favourite contacts, call or send a message to a given contact, add
new contacts and delete existing contacts.
• On Messages
This application allows the users to simply read, listen to and send
messages (through text or speech). It also supports sending and receiving
pictures.
• On Settings
The Settings application allows the user to set his or her preferences
regarding Sounds, Vibration, Wi-Fi, Accessibility, Language, Auditory
Cueing Settings, to set a Caregiver (which will show at the Favourites
home screen and to Add a new device. In order to allow for troubleshoot-
ing, this menu shows an option which allows users to check the status of
the sensors and actuators in the REMPARK system.
• On Status Bar, Notifications and Shortcuts
The status bar is shown at the top of all screens and it displays information
about the time, the battery status, the Wi-Fi connection status and strength
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of cellular signal. Furthermore, the status bar is used to host shortcuts for
cueing controllers and to provide users with straightforward information
about their status. When ACS cueing icons is on display in the status
bar, they act as buttons to the applications. The notifications pertaining
to each application will be shown on the home screens, on top of the
corresponding application icon.
6.8 Some Concluding Remarks
The presented interface was completely integrated in the smartphone and used
as part of the whole REMPARK system during the complete trials organized
as one of the main activities at the end of the project. Participants were given
the smartphone along with a user manual and, in the end, were asked to fill in
SUS (System Usability Scale) and QUEST 2.0 (Quebec User Evaluation of
Satisfaction with assistive Technology) questionnaires. Therefore, participants
evaluated the whole system, not just the smartphone user interfaces.
The results indicate that there are some issues in terms of learnability,
which should be looked at in the future. As it was reported during evaluation
of REMPARK, “. . . managing all that REMPARK has to offer at once can be
quite overwhelming, especially if one is using the system for a short period
of time and if the user’s level of familiarity with technology is not very high.
REMPARK is a completely new and innovative system and it is only natural
that these barriers emerge. In the future, however, we could try to work on this
part of introducing the system to new users, covering the unboxing experience
as well. But this is for the future, as it was never part of the goals for our
project”.
It should also be noted that each participant interacted with the system
for four days, which could explain why, at the end of the trials, participants
were not completely familiarised with all the REMPARK apps. Nevertheless,
satisfaction levels, as reported in the scales used, were quite high – for the
participants, the REMPARK system was comfortable, secure and safe.
Finally, one of the most interesting found discoveries during the field trials
had to do with the ‘My Day’ application. The app was not planned at first
and was born from listening to PwP’s conversations about their symptoms.
During the field trials, screen interaction was analysed. The ‘My Day’ screen
showed a high activity with taps on the date and on the elements related to
symptoms. This seems to suggest that participants wanted to interact with their
own data.
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On REMPARK’s final workshop, we had the opportunity of showing
the apps to Sara Riggare, a PD advocate and PwP herself. We commented
on these results and findings, which did not surprise her. However, she
recommended to focus on displaying the positive events, rather than the
negative ones. Further work on the ‘My Day’ app following the field trials
and the experts’ advice was considered by us to be relevant work for the
future
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7.1 Introduction
Patients with Parkinson’s Disease (PD) are usually affected by clinical symp-
toms associated to a reduced motor performance that frequently compromises
their ability to walk independently and safely [1]. While a number of phar-
macological solutions help to manage the symptoms of PD, some gait-related
problems appear resistant to such treatments and, over time, movement-related
disturbances turn out to be the most incapacitating symptoms of the disease [2].
The internal regulation of step length is generally affected, which is
reflected as an inability to generate sufficient amplitude of movement, even
though the control of cadence, or step rate, is intact. This is in fact the
foundation for the use of external rhythmic stimuli, or cueing, as a way to
ameliorate the impact of the disease on rhythmic movement-based tasks, as is
the case of walking [3, 4].
Typically, to compensate for the reduced step length, patients may increase
the stepping frequency. These symptoms are usually referred to as “continuous
gait problems”, since the changes in walking patterns are more or less
consistent from one step to the next. With disease progression, “episodic
gait disturbances” may appear which result in intermittent and occasional
episodes, such as start hesitation, Freezing of Gait (FOG) episodes and
festination [3–5].
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Several cueing strategies, including acoustic and visual cues, can be
applied being capable of modifying movements’ speed and amplitude, as well
as reducing or shortening the occurrence of episodic gait disturbances, such
as FOG episodes [2, 6, 7].
Rhythmic auditory stimulation, in particular, enable people to involuntar-
ily synchronize the rhythm of the steps with the rate of the sounds, therefore,
enhancing the sense of “taking a step”, and the sense of “rhythm”, which are
both affected by the disease [2, 7–10].
Multiple studies have found a positive impact of the rhythmic sounds on
steps length [8, 11, 12], walking speed [9, 10, 12, 13], variability [3, 9] and
FOG episodes [2, 14–16]. In addition to the positive impact observed on gait,
it was found that rhythmic sounds can also enhance the performance of other
tasks involving perceptual and motor timing [17].
Many external cueing approaches are described in the literature; however,
several limitations can be identified. Current solutions typically provide inter-
ventions continuously (i.e., even when no specific gait symptoms are present),
and require cueing to be triggered manually, which limits its applicability in
people’s everyday life [2]. Also, the application of a continuous cueing means
that stimuli are presented without considering whether the patient is suffering
from walking problems or not, which can lead to a possible habituation effect
that reduces cueing efficacy [18].
To address some of the limitations encountered on previous approaches,
an automatic Auditory Cueing System (ACS) was developed throughout the
project REMPARK. The developed solution used a smartphone and a headset
available in the market, and could provide external cues automatically each
time a relevant motor symptom was detected requiring cueing activation. For
that purpose, the REMPARK sensor sub-system was used.
This chapter is focused on the Auditory Cueing System (ACS) developed
for REMPARK as part of the project implementation. Last part of the chapter is
devoted to a technical discussion on the possible future use of the REMPARK
developed sub-systems (mainly, the sensor) for an automatic control of the
dosage of drug (apomorphine) delivered by an infusion pump, when integrated
into the reaction loop around the patient. This technical validation opens the
door to future experiences in the way to a better management of the PD
symptoms, meaning an improvement on patients’ quality of life.
7.2 Cueing Strategies for Gait in Parkinson’s Disease
Human beings are particularly sensitive to the temporal characteristics of
sound, therefore, sonification (generation of data-dependent audio to present
information) suits well for time-related tasks, as is the case of the body
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movement. Other attributes besides rhythm can also be associated to certain
events or processes by listening. Pitch (i.e., the perceptual dimension of
frequency), for example, is related to the perceived urgency of a warning
and, the higher the pitch, the higher the perceived urgency [19].
Multiple types of sounds were explored by different authors as strategies to
guide and provide feedback on walking patterns in people with PD, including,
metronome and music. In all strategies employed, rhythm turns out to be a
key aspect in influencing time-related tasks, as is the case of walking.
The concept of metronome is generally applied to a device that produces
regular, metrical beats with adjustable number of beats per minute (BPM). It
is typically used by musicians as a reference to help keeping a steady tempo
and was also applied in the context of cueing in PD.
The metronome generates temporal expectations that can be intuitively
associated to the cyclic movement of walking. In fact, it allows people with
PD to predict when the next step should occur, which facilitates movement
optimization and execution [17]. Therefore, it is required that an adequate
rhythm is provided to the user, considering his/her normal walking cadence.
The metronome can pace both – right and left – footfalls, by producing a
regular, repeated sound at an adjustable pace defined as the number of beats
per minute (BPM). Several authors showed that the presentation of sounds
with a rhythm that is lower than their natural walking rhythm can be used not
only to influence rhythm but also to indirectly influence the magnitude of the
movement through an increase in the length of the steps, while maintaining
gait speed [9, 20]. A positive impact was also observed in other walking
parameters, including the variability of walking [3, 9] and FOG episodes
[2, 14–16]. Rhythmic sounds could also enhance the performance of other
tasks involving perceptual and motor timing [17].
More complex sounds, including music, have also shown to influence
the organization of movement in time and space. Music, like movement, is
multidimensional, as such it can be naturally linked to spatial, temporal and
force elements of the movement. It can be used as an immediate entrainment
stimuli acting during movement, or a facilitating stimulus for training to
achieve more functional gait patterns. Music therapists are trained to adjust
rhythm, dynamics, and pitch as needed specifically by each patient, according
to their rehabilitation needs [21].
Wittwer, et al. in [22] showed that music produced a significant increase
in gait velocity in healthy older adults, due to a significant increase in stride
length. In contrast, when applied to a group of people with Huntington’s
disease, and contrarily to what would have been expected, music produced
no results, and, in contrast, metronome performed better in this group.
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The authors suggested that participants’ cognitive deficits may have impaired
their ability to discern the beat from the more complex music structure [22].
Besides auditory feedback, other types of external cueing can be applied,
including visual and somatosensory cues. Visual cueing is traditionally
employed using series of strips placed on the floor in transverse line for the
patients to walk over. However, this type of strategy can only be applied in
laboratory context, not being useful during the daily life. Portable solutions,
such as goggles with light emitting diode (LED) or laser-guided walking
canes have been developed, in which the same principles of projecting
parallel lines on the floor are applied (see Figure 7.1). Some of these
solutions can even present the stimuli on demand, for example, when a
FOG episode occurs. However, some issues arise from the use of this kind
of strategies in outdoor environments, especially in bright areas where the
visual information may become less visible. Moreover, this kind of assis-
tive devices may not be practical for real life usage conditions, due to its
obtrusiveness [18, 23].
In addition to these strategies, also rhythmic somatosensory cueing has
been explored. Strategies such as electrical stimulation or rhythmic vibration
have been studied by different researchers, showing also positive effects on
gait [23]. Electrical stimulation, in particular, requires more complex setups
that may not be practical for a daily usage [25].
In [23] it is shown that although all the three types of stimuli (visual,
auditory, somatosensory) were effective in improving gait velocity, step length
and cadence, auditory cueing was in fact the most effective cueing strategy
applied. Moreover, it may provide the easiest setup, being more practical and
realist for a daily everyday usage.
Figure 7.1 Examples of visual cueing strategies (extracted from [24]).
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7.3 State of the Art: Competitive Analysis
A systematic search was conducted on the World Wide Web in order to
capture and analyse relevant information about existing studies, projects
and commercial solutions, with a particular focus on solutions for auditory
stimulation and feedback in PD.
Research included technology being developed and described in published
and publicly available papers and conference proceedings, as well as commer-
cial solutions that are already available in the market. Moreover, a patent search
was conducted to find out innovative solutions for the management of PD.
Search was limited to solutions targeting patients with movement disorders,
in particular, patients with PD and technological approaches mostly based on
auditory cueing aiming to reduce or overcome motor symptoms related to the
disease.
Table 7.1 summarizes the results of said search for R&D and market-ready
products. For each solution, the following parameters were evaluated:
• Current stage of development: R&D or market-ready;
• System Components: e.g. smartphone, headset, dedicated hardware, etc.;
• Types of cueing: metronome, music, verbal cueing and possibly others
(e.g. visual or sensory cueing);
• Modalities and symptoms: identifies whether a system can or not provide
cueing automatically in response to motor symptoms (i.e. the actuation
mode); also identifies whether cueing can or not be manually activated
under specific circumstances/requirements with the purpose of training
(i.e. the training mode); provides a list of motor symptoms that are
targeted by the system;
• History Recording, in case the system is able to record the history of
activations/deactivations;
• Connection with a Disease Management System (DMS), in case the
system is prepared to connect to a server, in which data are recorded
to be then displayed and used by clinicians.
Not many non-pharmacological solutions for actuation in PD can currently
be found in the market. The majority of the solutions found are still in R&D
stage. In particular, related to the auditory stimulation, only one commercial
solution was found, the GAITAID Virtual Walker. This solution can provide
not only auditory stimulation, but also visual stimulation and for that it requires
the use of display glasses with built-in earphones, which are connected to a
proprietary control unit that is responsible for creating images and sounds by
responding to the user’s movements. The system was made in the US, and the
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prices range from 1995 USD (∼1840 €), for orders in US, to 2145 USD
(∼1980 €), for orders outside US and Canada. GAITAID, unlike the
REMPARK solution, is not capable of detecting specific motor symptoms,
neither actuating automatically upon the detection of the symptoms, being
therefore more limited in this sense.
In the study develop by Bächlin, a system for the automatic detection of
FOG episodes was developed. For that, they require the use of multiple sensors,
which are placed on the waist, thigh and ankle. The system is controlled by
a portable processing unit which is placed on the waist and is responsible for
processing sensor data and triggering auditory cueing (metronome sound) as
soon as a FOG episode is detected. It clearly demonstrates the positive and
immediate effects of auditory stimulation in patients’ gait.
The iRACE application, developed for iOS, uses the sensors of the
smartphone to detect steps and estimate steps length. The finger tapping test is
also available in the application. The GaitAssist, which was developed in the
FP7 European project CuPID, also uses the smartphone as a support for the
execution of physical exercises for training, and enable the detection of FOG
episodes through the analysis of the data coming out of two sensors which are
placed in the ankles.
CuePack, which was developed in the context of the European project
RESCUE, enables the application of different types of stimulus, including
auditory, visual and sensory stimulation. Its actuation capabilities are limited
to a training context, since it is not able to detect motor symptoms.
According to Table 7.1, no cueing device is as complete as REMPARK
ACS. While some solutions are not capable of detecting motor symptoms and
actuating accordingly, others, are limited to the detection of FOG episodes.
Also, to detect this type of episodes, both solutions require the use of multiple
sensors, whereas REMPARK needs just one sensor unit to detect a larger
amount of motor symptoms, including FOG episodes, bradykinesia and
dyskinesia events.
Some of the presented solutions are based on the use of specific equipment
for sounds generation and control, as is the case of GAITAID Virtual Walker,
Bächlin and CuePack. In contrast, REMPARK, GaitAssist and iRACE are
based on the use of a smartphone.
Moreover, REMPARK can connect to a DMS, enabling also clinicians
to analyze their patients’ data. As expected, and since the majority of the
systems are still in the R&D stage, no references to the connection to a server
are usually available in the considered systems.
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It was noticed that, to actuate properly, the majority of the systems
aforementioned, including REMPARK, require an initial configuration step,
in which normal gait parameters for a specific patient with PD are identified
and given as an input to the system. This step helps not only to decide when
a gait pattern deviates from the normal, but also to establish the functional
goals that need to be achieved after cueing is applied.
Regarding the type of sounds delivered to the patients, the majority of the
solutions are based on the metronome, i.e. repetitive sounds played with a
certain periodicity. REMPARK also offers the possibility of delivering verbal
cueing (i.e. “one-two-one-two”). Additional solutions are also capable of
providing other types of cueing. CuePack, for example, is able to provide three
different types of cueing, including the metronome, visual cueing and sensory
cueing. GAITAID Virtual Walker can provide both auditory and visual cueing,
which can be used in combination or separately, according to the patient
specificities. However, for this functionality, it requires the use of proprietary
devices that need to be carried by the patient while walking.
Based on this analysis, and considering the limitations of the current solu-
tions encountered on the literature, REMPARK seems to be the most integrated
solution for detection, treatment and management of motor disorders in PD,
being capable of actuating in real time, each time a motor symptom is detected
and cueing is required. Moreover, it can be used either as a gait training device
(at clinics or at home) or during the daily life, at home or outdoors, being
capable of actuating automatically when a motor symptom is detected and
cueing is deemed as required. As it uses mainly components that already exist
in the market, such as the smartphone and a headset, and a single discrete sensor
that needs to be worn in the belt, the solution itself may not be stigmatizing
for its users, being therefore more attractive.
A more throughout analysis of the existing technology was conducted
through the analysis of the patents produced in this area. The most relevant
inventions are described in the following paragraphs:
• US 8409116 B2 (Granted, filing date 2010) presented a device and
method for treating patients with movement disorders. The device
includes a sensor for detecting an akinetic episode (e.g. a FOG episode)
of the person and a receiver that automatically issues a single or multiples
cues to aid in the restoration of the movement. The cue can be of any type,
including verbal, auditory, physical or tactile. Moreover, they propose
sending the information about FOG events wirelessly to a caregiver
and/or an emergency contact [26].
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• EP 2346580 A2 (Application, filing date 2011) disclaims a method for
the improvement of gait parameters comprising determining attributes
of ideal spatial and temporal gait parameters of the subject, measuring
the actual parameters and determining the rhythmic audio cue that may
cause the subject to improve a gait parameter [27].
• US 8961186 B2 (Granted, filing date 2012) presents an ambulation acces-
sory that can also be used as a training device. The invention includes two
balls that illuminate in an alternating fashion to provide a visual target to
each leg. When the user reaches the ball with his foot, the system returns
visual and auditory feedback indicating a successful step [28].
• WO 2012177976 A2 (Application, filing date 2012) presents a method
performed by one or more processing devices that includes generating
a visual representation of an object in the environment, retrieving an
auditory stimulus indicative of the location of a virtual target in the
environment, determining the proximity of the object to the virtual target
and adjusting the auditory attributes based on proximity [29].
As can be perceived, some of these patents describe a system whose operating
mode is basically the same adopted by the systems in Table 7.1. They include
the possibility of detecting movement disorders, the ideal gait parameters and
the cueing strategy/parameters required to overcome said disorder.All the sys-
tems described in the inventions offer the possibility of using auditory cueing
as a feedback mechanism for gait. US 8409116 B2 presents a generic method
that can use just one type of cueing or a combination of several types. EP
2346580 A2, on the other side, is focused on the use of audio cues comprising
a tone and a beat. The last two commented patents (US 8961186 B2 and
WO 2012177976 A2) are mainly focused on the use of visual cues combined
with audio for feedback on gait. As can be understood, these systems lack
practicability, as the delivery of visual stimulus while walking requires the use
of additional equipment, e.g. display glasses. Systems based on the use of audi-
tory cueing can be largely simpler and affordable, since they can benefit from
the use of existing, commercial, equipment that a person may already have,
as is the case of REMPARK ACS using standard headsets and a smartphone.
7.4 REMPARK Auditory Cueing System (ACS)
The ACS was developed in the context of the project REMPARK according
the specifications and characteristics described in Chapter 3. It uses anAndroid
smartphone, which is connected via Bluetooth to a commercial headset.
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The smartphone is responsible for generating cueing sounds, controlling their
rhythm and streaming them to the headset (Figure 7.2).
The headset can be any commercial Bluetooth headset with, at least,
Bluetooth version 2.1 and A2DP profile [30].
The ACS includes multiple types of sounds, which can be chosen through
the smartphone interface. It includes metronome sounds, musical beats,
clapping and verbal cueing (“One-two-one-two”). The patient may himself
select the sound that he/she prefers the most and is more comfortable with.
Each sound, in reality, falls into the category of a metronome, considering
that all sounds produce metrical beats with adjustable number of beats per
minute (BPM). The rhythm of the sounds is provided in beats per minute for a
direct connection with gait cadence or step rate, also defined as the number of
steps per minute (SPM). Both footfalls, right and left, are paced by the system
(Figure 7.3), and some of the available sounds are actually a combination of
different timbres that aim at providing a different feedback for each step.
The ACS takes advantage of the existing modules that are integrated in
the REMPARK solution, including the motor symptoms detection provided
by the REMPARK sensor sub-system. The auditory cueing is activated by the
system as soon as FOG or bradykinesia are detected by the movement sensor.
Once a patient has continued walking without bradykinesia or has stopped
walking, the cueing is discontinued. Nevertheless, each time auditory cues
are activated, a pop-up window appears on the smartphone screen, for a quick
Figure 7.2 REMPARK Auditory Cueing System.
7.4 REMPARK Auditory Cueing System (ACS) 145
Figure 7.3 Cueing rhythm (beats per minute BPM) and cadence (steps per minute SPM).
interaction with the system, which enables the patient to easily stop the sounds,
or manipulating sounds rhythm and volume (Figure 7.4).
The rhythm and volume of cues are pre-configured through the smart-
phone. A clinician may introduce the target rhythm for the cueing sounds
that will target patients’ needs the best as possible. The clinician may also
define the maximum and minimum cueing rhythm that can be provided to
Figure 7.4 Pop-Up window for basic control of ACS when it starts automatically.
146 Actuator Sub-System: The Auditory Cueing
the patient, so that rhythm may never compromise patients’ safety and the
safe synchronization of steps with gait cueing, while still maintaining a good
pattern of walk. The clinician may also help the patient define the minimum
volume accepted by the system, so that it may never go below a level that is
inaudible by the patient.
Voice instructions are also available in the system, to explain what to do,
or how to proceed each time sounds start playing. Both temporal instructions
(“Step in time to the beat”) and spatiotemporal instruction (“Take a big step in
time to the beat”) can be delivered according to the type of symptoms detected.
These instructions can be deactivated through the ACS settings application.
Through this screen, the patient may also preview each sound available, as
well as change the default actuator type of sound.
TheACS can also be activated manually by the patient, and therefore serve
as a training device for gait. This will enable patients to listen to the sounds
as part of a gait training task. The controller application can be opened from
the REMPARK applications list (Figure 7.5).
Moreover, the ACS takes advantage of the capability of recording the
history of activations and deactivations, which can then be analyzed by
clinicians through the disease management system (DMS) [30].
Figure 7.5 Auditory Cueing System application.
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7.5 Outcomes from Field Trials: Future Considerations
The ACS was developed as a module capable of providing auditory stimuli
in real time, to help people with Parkinson’s Disease improve speed and
amplitude of walking. Before developing the final version of the system, which
was then evaluated in the 3 days-long trials stage, a preliminary testing stage
with a first prototype was required to get the first impressions on the feasibility
of the system in stimulating gait, as well as evaluate system’s usefulness and
acceptance.
Preliminary tests were conducted in Spain with 12 people with PD.
During the tests, patients were asked to walk, sometimes with cueing, other
times without cueing, and their walking rhythm was measured against cueing
rhythm. Motor symptoms were identified by observation by a trained medical
doctor or therapist. Patients were asked to walk along predefined distances and
walking circuits, but also to walk at will, being able to choose the trajectory
they wanted to follow. Therefore, both indoor and outdoor conditions were
captured (Figure 7.6).
Despite the reduced number of participants in this preliminary testing
stage, experimental results suggested that better gait patterns could be stimu-
lated when individuals follow rhythmic sounds whose rate is similar to their
natural step rate. The fact that people tended to walk with better walking
patterns and overcome gait problems when feedback rhythm was closer to
their normal walking cadence supports this observation.
Figure 7.6 Preliminary tests with PD patients for the ACS.
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Additionally, people found the volume and quality of sounds adequate,
even in outdoor conditions, where a louder environmental noise could be
found. This is an important requirement for the system, since it is expected
to work in real time, even in outdoor conditions during a person’s daily
routine. Actually, all participants would be willing to use the system during
their everyday life, considering that it would help them in real time during
their daily activities. A complete report of methods and results achieved
in these preliminary tests can be found in reference [31].
After the final ACS prototype has been developed and integrated with
the other REMPARK components, i.e. the REMPARK sensor and the DMS,
the final trials period took place, as it is reported in Chapter 9. During the
trials, 41 people with PD used the system continuously for three consecutive
days and the ACS was put to the test under real life conditions.
After using the system continuously during three consecutive days, people
reported some issues related to the size and comfort of the headset. In fact,
the headset chosen for the trials was an existing commercial device that was
chosen considering mainly its technical specification and price. However, for
a final solution, it is also required to consider its aspect, weight, easiness to put
and remove from the ear, ear fitting, sense of attachment and sound quality,
and take into account also the individual preferences of its users.
In addition, some patients suggested the use of music instead of the
metronome to act as cueing during their daily life, to be more enjoyable and
not so monotonous. In fact, due to the requisite of maintaining a fixed rhythm,
the metronome can become monotonous after a while, therefore challenging
the acceptability and sustainability of the solution. Still, it can be the only
viable cueing solution for some people, for example, people with cognitive
deficits, as suggested by the authors in reference [22].
As a final conclusion, the REMPARK system appears to be usable and
participants seem to be satisfied with the system. Improvements on the system
will, for sure, take into account the valuable input provided by the people who
participated in the trials.
7.6 A Step Further in REMPARK: Automatic Drug
Administration
As it has been already discussed in Chapter 3, one of the project goals was
to technically validate the feasibility of using REMPARK system to create
an automatic or semi-automatic feedback wireless control loop that would
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improve the treatment of PD patients, using some reaction solutions. For this
purpose, a commercial apomorphine infusion pump was modified. The modifi-
cations consisted of incorporating the necessary electronic components so that
it is able to communicate with the smartphone in order to receive commands
related to the drug dosage to be administered. These commands come from
the symptoms’measurements performed by the developed REMPARK sensor.
Additionally, the electronic system added to the pump should permit a manual
user interaction through the smartphone.
REMPARK project proposal discarded, from the beginning, the organi-
zation of a specific pilot action using drug delivery systems control with real
patients because this was out of the real possibilities of the project piloting
activity. The main reason was the required timing for these type of pilots,
where time scales are much more long than those for the rest of scheduled
assessment pilots. The only activity, at this level, was to consider the effective
possibility of a wireless control of these devices, preparing all the requirements
and conditions from a technical and functional point of view.
Apomorphine has been widely used to treat Parkinson’s Disease. One of
its main usages is under Apo-go Pen format. Doses are small injections which
patients can self-administer, with a limited amount of apomorphine. Its active
principle provokes, compared to the levodopa effect, a very quick response
(within few minutes), and the length of the effect is short, which makes this
drug suitable for controlling the symptoms in real time.
At that level, REMPARK project proposed several objectives:
• to technically demonstrate that an automatic drug delivery system can
be remotely controlled and activated by the REMPARK system when an
unexpected OFF period is detected.
• an automatic delivery of the rescue dose is technically possible.
A subcutaneous infusion pump would be included in the system and would
be ready for its automatic activation. This prototype will facilitate functional
laboratory testing of the drug delivery pump for remote operation in simulated
clinical conditions.
After analysing the existing options, the Microjet CronoPAR [37] subcu-
taneous pump manufactured by Canè s.r.l was identified as the unique option
to be adopted. This commercially available pump provides the functional
features associated with the infusion of apomorphine to Parkinson’s Disease
patients. In order to fulfil the project requirements, an electronic control unit
was developed and integrated into the device. Figure 7.7 shows this infusion
pump model as it is commercially available.
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Figure 7.7 Infusion pump to be adapted for a possible use with REMPARK system.
In the original pump, a set of buttons enable the user to command the
behaviour of the pump. A display shows the state of the device. As the device
does not have a battery recharge system, the battery must be replaced and it
may be accessed removing a side tap.
An automatic control requires the substitution of the manual interaction
by an electronic interface, with the equivalent functionality and provided with
a connection to the smartphone using a wireless communication channel. The
strategy for this modification was to replace the PCB (Printed Circuit Board)
integrated in the pump keypad by a much more complex PCB integrating the
interaction with the pump, through the electronic control of the buttons, and
the mentioned wireless connection.
Figure 7.8 shows the modified Microjet CronoPAR, where the controller
has been replaced by a new electronic hardware (PCB). The PCB was designed
to allow a similar aspect of the device, with the same functionality and its
operative LCD display.
The main directive in the PCB design process was the achievement of a
device with reasonable autonomy but keeping the original physical size, allow-
ing the user to wear the subcutaneous pump without undue inconveniences.
The components of the system were restricted to be compatible with an
adjusted power consumption and practical size. Figure 7.9 shows the general
scheme of the PCB device. Internally, the device includes a microcontroller
that handles the different sub-system parts. The microcontroller provides the
system with the capacity of managing the subcutaneous pump and at the same
time to establish a wireless communication.
The control board of the PCB is managed by a microcontroller, which is in
charge of controlling the subcutaneous pump while managing the data received
from the wireless module. The PCB replaces the original control board of the
subcutaneous pump maintaining the same shape, but increasing its thickness.
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Figure 7.8 Modified pump.
Figure 7.9 PCB general scheme.
In order to control the pump behaviour, the control buttons have been replaced
by control signals provided by the PCB. As a feedback, to confirm the proper
operation of the pump, an electronic signal associated with internal acoustic
information is provided.
The Microjet CronoPAR is supplied with a standard and commercially
available 3 Volt type 123 A Lithium non-rechargeable battery with a capacity
of 1400–1500 mAh.As the operating voltage range of the PCB is 2.1 V to 3.6 V,
it can be supplied with the battery of the original pump. This feature allows
152 Actuator Sub-System: The Auditory Cueing
Figure 7.10 System operation overview.
the PCB to work with all the available operating voltage ranges, ensuring that
the system can work with any low battery situation.
The control and supervision functionalities of the modified pump are
achieved with the execution of the microcontroller’s embedded firmware. The
system operation relies on a series of independent but coordinated processes
that manage the behaviour of the subcutaneous pump, taking advantage of its
functional capabilities. The PCB device takes control of the pump behaviour
working as a wireless interface between the subcutaneous pump and the
smartphone (Figure 7.10). The main state machine (firmware) is in charge of
coordinating the commands received from the communication module, giving
the necessary functionality to the system and synchronizing the remaining
processes. Moreover, the subcutaneous pump provides multiple features (e.g.,
administration of the bolus dose). These features have been developed as a
secondary software (state machine), which is managed by the main firmware
software of the device.
It is necessary to confirm that the control of the pump is correctly
performed, and also, it is necessary to acknowledge and monitor the correct
operation of the device. In consequence, an interface was provided giving the
necessary information to the system. This information about the functioning
of the pump is provided by means of an electronic signal, associated with
an internal acoustic confirmation. Using this signal to complete the feedback
loop, the entire system can be managed electronically. As a result, the PCB
interface is connected to the subcutaneous pump through four signals: three
output signals connected to the buttons of the pump, and one input connected
to the beep signal. The connecting diagram between the subcutaneous pump
and the PCB can be seen in Figure 7.11.
In order to manage and control the pump, the input signals generated by the
front buttons are now provided by the PCB. Then, by activating these signals,
the PCB is able to perform all the required actions, for example administer
bolus dose or program the infusion rate.
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Figure 7.11 Connection diagram between the pump and the designed PCB.
In normal operation regime, the ambulatory infusion pump manufactured
by Canè s.r.l. offers two main operative modes: intermittent bolus or contin-
uous apomorphine infusion at variable dose. When operating in a single shot
mode the subcutaneous pump administrates a given quantity of drug only once.
On the other hand, continuous apomorphine infusion consists on continuous
pulses of infusion, where the rate of these pulses depends on the programmed
infusion rate.
In REMPARK, the implemented firmware on the PCB is trying to replicate
this operative in an electronic way, using a state-machine approach. Deploy-
ment of pump behaviour in state-machine based allows a good understanding
of the logic process. In principle, the subcutaneous pump has two independent
states; Pump Switched ON and Pump Switched OFF. Each state has the
possibility to perform specific actions. For example, the pump must be
switched off to program the bolus dose. On the other hand, switching on
the pump allows to administer infusion, bolus dose and to program the
flow rate.
The OFF state starts when the pump finishes an auto diagnostic routine.
Here the bolus dose configuration may be managed. On the other hand,
infusion state starts when the pump has been switched on. This state is in
charge of managing the main actions that can be requested remotely and mainly
the administration of the infusion and the bolus dose. The PCB interprets the
command sent remotely and changes the state of the pump in consequence.
To ensure that actions are correctly performed, a feedback from the pump
is obtained, as it was introduced. The pump confirms all its actions by emitting
a brief sound signal. Then, taking this signal as an input, the PCB is able to
read and analyse the action feedback. As a main characteristic, this sound
signal has different behaviours depending on the action performed by the
pump. For example, the length of the beep signal when the pump changes to
infusion mode is different from that generated when it changes to bolus dose
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administration mode. Reading and processing this signal by the PCB allows
the identification and confirmation of the action performed by the pump at
any time.
As it has been already explained, the aim of REMPARK was not to include
experience with patients around this implementation of an automatic control
loop including the apomorphine pump, but just to demonstrate the technical
viability and its feasibility.
The inclusion of a wirelessly controlled infusion pump in the REMPARK
system would facilitate some future scenarios:
• If on-line symptoms recognition is done correctly, it opens the door to
a better administration of the medication doses, since dosages would be
automatically adapted to the immediate needs of patients.
• Usually the practitioner has difficulties for adjusting a suitable dose for
the pump’s continuous mode, and also to control extra doses administered
by the pump. REMPARK can help the professionals to properly assess
the number of OFF hours that a given patient has experienced with
the aim of judging the effect of the pump therapy through an objective
information.
• Usability from the patient’s point of view. Some patients with Parkinson’s
have OFF phases so severe that they cannot even self-administrate extra
doses. Patients with severe OFFs, which have no caregivers who can
perform this task for them, often cannot choose the treatment with
continuous infusion pumps. REMPARK could contribute to improve the
quality of life of these patients.
7.7 Conclusion
Current chapter has presented the REMPARK activity on PD actuation as
a possible improvement for a more effective management of the disease
symptoms.
Auditory Cueing strategy is already a well-known solution for the
improvement and facilitation of a better gait of people with Parkinson’s
when invalidating symptoms appear. REMPARK tries to improve this tech-
nique with some new characteristics and possibilities derived from an
effective detection of symptoms on-line during the normal activities of the
patients.
In a more speculative scenario, REMPARK has demonstrated the technical
viability and the feasibility of an electronic control to be added to an infusion
References 155
pump of apomorphine, allowing in the future, an automatic delivery of the
drug depending on the patient specific needs.
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Disease Management System (DMS)
Hadas Lewy
Maccabi Healthcare Services, Tel-Aviv, Israel
8.1 Introduction
Parkinson’s Disease is a chronic and progressive neurodegenerative disorder
with a great number of motor and non-motor symptoms [2, 4, 5, 7].The cardinal
symptoms are bradykinesia, rigidity, tremor and postural instability [1, 3, 8].
However, a number of non-motor-related symptoms (e.g., sleep disturbances,
depression, psychosis, autonomic and gastrointestinal dysfunction as well as
dementia) may occur [3–7].
The disease is a great burden as it has a negative incidence on the
quality of life, due to a gradual loss of functionality and decreasing ability
to take care of oneself. For these reasons, the caring process changes along
disease progressions and involves many healthcare professionals. Usually,
these professionals are located in different care services and organizations
(hospitals and the community), and they cover a wide range of medical
care including physicians, nurses, physiotherapists, nutritionists, occupational
therapists and social workers. In addition, there is a need to support the family
and reduce the informal caregiver burden by providing services, information
and knowledge about the treatment.
To cope with the challenging care model of PD patients, the REMPARK
project contributes to the development of a Personalized Health System
(PHS) with detection, response and treatment capabilities for the remote
management of the disease permitting, also, the integration of the generated
data with the patient’s EHR (Electronic Health Record) and the integration
and support of a Disease Management System (DMS), that enable the medical
team to provide integrated care and support to the patient and his family.
One of the main problems in most existing systems for disease manage-
ment is that the data used for treatment is collected on the system overtime
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and is not updated by other systems that are used for treating the patient.
For example, if the patient is treated by the neurologist for the PD and in
parallel he is treated by the general physician in the community for other health
conditions. Usually, no Integration between data is made and there is a lack of
information about the overall condition of the patient. Furthermore, there is
no communication between the healthcare professionals treating the patient.
This way of delivering care results in a fragmentation, slight duplication
and lack of coordination. The DMS creates an integrated environment for data
and knowledge sharing for all care providers without a need to access different
organizational systems by users from different organizations and thus over-
comes the privacy and security barriers. The DMS also includes clinical guide-
lines and a decision support tool for healthcare providers that allow the clinical
team to obtain accurate and reliable information and to decide about the treat-
ment that best suits the patient for improvement of the disease management.
This tool enables treating several conditions at the same time in a coordi-
nated way; therefore, the organization can use several experts to treat a patient
(e.g. psychiatrists, urologists or neurologists) and enable integrated care
between different organizations (e.g. hospital community care and welfare)
which provides flexibility and efficiency treating a patient with changing
conditions, without breaching security constraints of the organization.
For the patient, there is a portal in which he is able to communicate with
the professionals (doctor, nurse...) and obtain information about his condition
and treatment plan. The DMS communicates with the patient’s interface that
can be reached by a home computer, a tablet or a Smartphone, it updates the
data and collects inputs from the patients, such as self-reported questionnaires,
for the evaluation and decision making by the healthcare professionals. These
tools give useful information to the patients and empower them for better
self-management.
The system also has an interface for healthcare organizations to enable
management of the treating teams such as shifts and workload at the call
centre, and reports for the management teams.
This chapter describes the use of the implementations of a DMS within
the REMPARK system, its ability to communicate with REMPARK sensors,
intelligent layer and actuators and reviews the advantages that the DMS
brings to all users involved in the system from a clinical, personal (patient),
organizational and healthcare points of view. At the end of the chapter, the
conclusions from using the system and the vision for its contribution of the
future treatment of PD patient are described, as well as for elderly people
with co-morbidities in a changing era of care models moving from reactive
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to proactive treatment, empowering the patient and creating new services and
relationship between the patient and the healthcare providers.
8.2 Disease Management System Application
Providing integrated care and remotely treating large populations creates
a challenge for the care providers at the clinical and organizational level.
Although the data provided by the sensors and analytical tools are valuable
and the REMPARK system paves the way for its clinical use in the future for
the automatic control of continuous infusion pumps, automatic management
of external cues to guide the gait or for comprehensive and reliable analysis
of changes in motor state, still the use of this type of data in clinical practice is
not implemented. Clinical guidelines for remote monitoring, standardization
of care and risk management of the remote monitoring and care is still not
well-established and requires development of supportive tools as well as
methodological approaches.
The progression of the disease is individual and cannot be predicted, and
the patient and their family need support at different levels and by multiple
caregivers at different stages of the disease. Since the disease is usually related
to elderly people, the associated symptoms may be mistakenly treated as
geriatric symptoms and there is a need to diagnose the source of the symptom
and provide the personalized treatment considering the overall condition of the
patient. The services provided for comprehensive treatment are often provided
by different organizations located in the hospital, community service and
home care. Therefore, the treatment can be complex and involves several
stakeholders.
For these reasons, healthcare system and the industry are interested in the
implementation of technologies for remote care in healthcare. For healthcare
system, the main challenge is to enable the use of these technologies by
changing the model of care and sharing information. Implementation of
these technologies requires collaboration of the healthcare professionals and
patients not just in adoption but also in the process of development and imple-
mentation in new best practice and care pathways and open the way for sharing
information from the patient (self-reported) and other sources (different
organizations), capturing and analysing patient data from dispersed systems.
For the industry, the challenge is to provide solutions that will support
healthcare systems considering constrains of standardization, privacy, reli-
ability, security, existing models of care including healthcare professional
workloads and workflows and adapt the solutions to the system [9]. With these
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challenges in mind, it was proposed and developed the REMPARK system
composed of wearable sensors, analytical layer, decision support tool and a
care platform (DMS) for professional care providers, patients and family.
The DMS system provides various functionalities that support the care by
healthcare professionals and communicate with the patient. It is also adaptable
to the organizational care pathways and workflows and flexible to different
clinical guidelines that are used in different countries and/or can be developed
overtime. It enables to treat the PD patient in a way that changes along
the development of the disease and consider co-morbidities, motor and non-
motor symptoms. In addition to the workflow and/process support, the system
provides the organization tools for risk management, standardization and
data reports that enable a better understanding, control and ways to manage
the treating teams.
The care models are moving from reactive to proactive approach. The
treatment of PD patient involves both approaches since it combines monitoring
of motor symptoms, alerting and responding, as well as overall preventive
assessment and on-going treatment in a proactive way. The REMPARK system
receives data transmitted from the sensors. For each patient, there is a defined
range of normal and abnormal values in each monitored parameter. Any
deviation from normal event creates an alert on the system and consequently
there is a reactive intervention. The alerts can be set not only for a single
event but also for a set of events overtimes. For example, a fall requires
immediate response therefore a single event will create an alert. However,
for the neurologist it is important to know if the drug treatment is effective;
therefore, parameters such as number of dyskinesia events or FoG events in
the last week will be important and indicative for the treatment. In this sense,
it is possible to set an alert whenever a set of accumulative events in a defined
period occurs and to present it to the neurologist.
In addition, each patient has a personalized treatment plan defined by the
doctor that is monitored by the nurse in the centre, who has a concrete list of
tasks to handle. The tasks will be generated automatically from the patient’s
treatment plan or by the doctor/coordinator of the team. This way the patient is
also being treated in a proactive way by the nurse or other care team members.
The nurse can also see the condition of the patient in the last week at a glance
or enter his record. The proactive treatment is driven by the treatment plan that
is observed and followed by all care team members. This allows an integrated
care, team discussion and coordination in providing comprehensive care. The
platform has, also, the ability to communicate between care team through
messaging tool or video call.
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For each patient, participating in the REMPARK pilots, according to the
patient’s evaluation and clinical history, medications and definition of normal
ranges for every measurement, the medical team can add and update the
treatment plan according to changes in condition of the patient. A change
in the treatment plan can be as a result of changes in the patient’s health state
or patient’s environment. Some items create a task for a specific medical team
member according to his profession while all team members can be updated
in the status and given treatment.
The strength of the system also relies on the ability to obtain, analyse
and integrate data from different sources: sensors, patient reported data
and EHR. Wearable sensors provide data monitoring of clinical data about
PD patients motor condition but also behavioral data such as activity levels,
type of activities and social activity. The development of these technologies
that monitor different data types to yield additional information about wide
range of parameters and activities including behavioral, mental and clinical
data that are transmitted in order to assist the treatment process, opens new
opportunities for care providers but also requires integration of care models.
The data can be further analyzed for risk assessment of stratification for
timely intervention. In these cases, data entered by the patient regarding his
condition is pre-defined by the care provider and used as part of the treatment
and for further assessment of the patient’s condition [10, 11]. However, today
the data collected for chronic conditions and specifically patient reported
data in different care programs is partially used in care and are usually not
treated by physicians as clinical data in the EHR as part of the clinical process.
(see Figure 8.1 for a shot view of a screen showing patients’ data. Consider
that data are not real).
The challenge of healthcare system will be to use these data providing
additional information to that existing in the EHR. The REMPARK system
provides a tool for implementation of this approach by using the integrated
care platform to combine heterogeneous data from EHR, sensors, analytical
tools and patients’ self-reported data for comprehensive care of multidis-
ciplinary teams. Furthermore, the data are continuously updated from the
different sources and do not require manual update enabling all stakeholders
to continue using their organizational systems without duplication of work
and bringing added value to the treatment process using intelligent tools
on top of their existing system. The interaction between the patient and the
healthcare professionals will be enabled through the DMS platform as a result
of alerts and/or treatment plan, since the nurse will be able to call the patient
or message him.
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All correspondence is registered on the system for follow-up and risk
management. One of the useful tools presented in REMPARK system
is the clinical protocols tool. A clinical protocol is a document with the aim of
guiding decisions and criteria regarding diagnosis, management and treatment
of PD. It is a set of steps allowing the medical team to make decisions according
to the collected information. It is actually a set of medical instructions for every
situation according to the patient’s medical state.
These protocols can be easily updated or changed from time to time by the
care provider according to the medical considerations or according to organi-
zational procedures. The protocols can guide the medical team how to treat the
patient and co-morbidities. For this purpose, the clinical team of REMPARK
project developed a set of clinical protocols based on the best practices for the
treatment of PD patients. In addition, protocol for other chronic diseases or
geriatric conditions exist in the system and enable the medical team to identify
the clinical situation. The protocols are adapted to the user (e.g. healthcare
organization) and can be generated for doctors, nurses or/and caregivers. By
using the protocols the medical team will provide a standardized treatment
that is in accordance with clinical guidelines (see Figure 8.2).
The protocol is loaded automatically in case of treating a task or an alert.
The clinical protocol automatically guides the medical team user to the next
Figure 8.2 Protocol screen capture for apomorphine pump alert.
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point or stage according to the data, until reaching the final decision or action.
Using the clinical protocol the medical team will be able to send instructions
to the auditory cueing system as described in the external interfaces or make
a decision about any intervention or treatment using future tools that would
be connected to the system.
In order to have an overall understanding about the patient’s condition the
neurologist interviews the patient about their symptoms, frequencies and daily
condition. The patient is usually asked to fill a diary; however, the experience
shows that these diaries are only partially filled in and the information provided
to the neurologist is partial. One of the ways the REMPARK system overcomes
this problem relies on the data obtained and analysed by the sensors and
presented to the neurologist on the DMS platform. This tool is complemented
under some conditions by the use of a questionnaire.
The DMS platform provides a tool of questionnaires that serves as
“patient reported data sensors”. The questionnaires can be filled by the
patient, relative or by a nurse calling the patient in cases the patient is unable
to fill the questionnaire. In addition, some of these questionnaires can also be
responded through the smartphone, which are also received by the DMS. In
either case, the system presents the patient the questionnaire that has to be
filled according to the treatment plan. For each questionnaire, there is a logic
to calculate a score. The medical team and the patient are able to see all history
of previously answered questionnaires.
The questionnaire tool is also combined with the sensors data and can ask
the patient additional questions when the sensor data alerts. The information
can be viewed along time to show a trend even if no alert was raised. This tool
was designed to collect the patient’s reported data and use it with clinical logic
to create alerts and response by the medical team. It integrates the data with the
clinical data in an innovative way that presents the physician the information
they need and simplify the analysis of the patient’s reported data for use in
clinical practice. Figure 8.3 shows, as an example, a part of the questionnaires
section.
As healthcare moves towards proactive treatment there is a need for
changes in relationship between the care provider and the patient. The
proactive concept that involve the patients in self-care requires patient
empowerment. The patient becomes an active partner in care and makes
his own decisions about his health and disease. In order to do so the patient
has to be educated about his disease, aware of the clinical options and learn
how to cope with the disease. Patients who participate in their care process,
cope better with their disease, live healthier lifestyle, have higher quality
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Figure 8.3 Questionnaire’s section detail.
of life and better clinical outcomes [9]. For these reasons, the REMPARK
system adopted this approach and developed a web portal and smartphone
interface for the patient.
Electronic correspondence between the patient and the medical team is
bi-directional. The correspondence can be triggered from the patient (using
the patient web site or the smartphone) or from the medical team or any
DMS user. The patient interface is designed to enable the patient receiving
all the information about his condition. They can view all sensor’s data,
questionnaires and correspondence and perform actions required for the
treatment such as filling questionnaires and for correspondence with their
carers (healthcare providers). The patient is able to add activities into the
treatment plan. The patient’s web interface is used, among the above, to
communicate with the patient either by global message to every person
registered to the REMPARK system or messaging a specific patient/medical
team member. This way the message is personalized to a patient or can
be addressed to a group of patients with the same clinical condition
or need.
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An emphasis was made on patient empowerment and education. Edu-
cational materials are sent to the patient according to their condition, need,
and disease progression such as articles regarding PD, new treatments and
medications or any links to external internet pages and support groups.
Figure 8.4 is showing how it looks the patient’s interface presenting the
personal treatment plan.
The REMPARK system provides additional organizational tools for man-
agement of the care team. The DMS includes a shift management module
that manage the tasks and users that are at each shift. The shift manager can see
the workload and type of activities done in the centre for efficient management
of the care process. They can also receive reports about activities done on the
system.
The above description of the REMPARK system provides an insight
not only to the workflow application but also to the care approach of
REMPARK project for PD patients. The system supports the care approach
and enables the care provider to effectively manage the delivery of integrated
care. The uniqueness of REMPARK system is that it includes a wide
Figure 8.4 Treatment Plan. A patient’s interface view.
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range of functionalities for delivering comprehensive customizable integrated
care by multidisciplinary team, but it also enables the treating physician to
maintain a supervision of the patient throughout the journey; from patient
disease diagnosis, through treatment plan definition, customizing specific
protocols.
Moving from reactive to proactive treatment, involving all care providers,
requires a change in interaction and mode of delivery the care under the
physician coordination. Here, the care is delivered under his supervision
enabling to effectively leverage other providers to pursue a consistent treat-
ment approach and objective. It establishes a way for patient’s personalized
treatment. The application interfaces with the EHR, and the physician receives
on-going alerts, updates and patient’s data. The care team operates as a
supporting envelope to the physician, and maintain constant touch with the
patients according to the treatment plan, protocols and alerts received from
the system.
8.3 DMS Functional Organization
For the already presented functionality, the DMS platform will communicate
with the mobile gateway in both directions through the REMPARK server.
This way, two types of information are distinguished:
• Incoming data: contains the patient’s parameters as they have been
measured by the sensors or/and patient processed information from the
Rule Engine. Furthermore, the DMS will get information from the Rule
Engine through the REMPARK server too.
• Outgoing data: contains updates for the patient’s treatment according
to the patient’s pump or any other command from the auditory cueing
system. These data are sent from the DMS.
The system architecture allows that all the data are stored at the REMPARK
server, so the interaction between the different parts of the system will be
with the REMPARK server. Figure 8.5 shows the main role that the REM-
PARK server has in the communications process. This is the only interaction
point between the REMPARK’s server to the Medical Application – DMS
system.
In general terms, there are two types of communications: telemonitoring
of motor symptoms and another related to patient management issues. These
flows were implemented by sending and receiving different services between
the server and the DMS system. In case of the tele-monitoring of motor
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Figure 8.5 The server acting as a communication hub interfacing the DMA System.
symptoms, the DMS system will receive measures and alerts immediately from
the REMPARK server. On the other hand, regarding the patient’s management
communication, the DMS system will send events regarding the medication,
questionnaires and clinical agenda of the patient.
Figure 8.6 presents the implemented architecture for the Internet interface,
including a web server and a data base server (can be a physical or virtual
server).
8.4 Advantages Using the Disease Management
System (DMS)
8.4.1 Advantages for the Clinical Team
Nowadays, Healthcare delivery systems face problems such as the prevailing
inequities in access to care, resulting from services with availability problems
in different geographic areas, socioeconomic and cultural disparities. In
addition, the system is usually fragmented and a comprehensive patient-
centred care is almost impossible to be delivered with existing systems and
care models. Therefore, even if services exist, it is very complicated for the
clinician to provide the services to many patients that are not located in
the geographical environment and even for these patients, there is a need
of coordination between service provider’s.
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Figure 8.6 The Web interface architecture.
The main health dimensions are described in the SHARE document [14]
and they can be listed as:
• Physical health measured by self-reports on general health, functional
limitations, ADLs, IADLs, diseases symptoms, and health behaviour
• Healthcare use
• Cognitive function test, literacy, numeracy, memory, verbal fluency
• Mental health
• Physical performance measures
The inefficiencies, limited coordination and integration of complex healthcare
systems further complicate the treatment and uneven adherence of patients to
evidence-based medicine becomes a major barrier in treatment efficacy.
The care of PD patients is complex and requires a coordinated care team.
It is possible to consider two approaches for delivering disease management
programs: integrated and non-integrated care. Disease management programs
based on the integrated care model with primary care have shown the most
valuable and effective care and promising results. An integrated approach
requires much deeper involvement from providers, and patients throughout
the process and many health plans are starting to use in-house nurses with data
analytics [12].
New models of integrated health management address member needs
across the organization, offering value and transparency in all member
interactions with the health plan. In order to provide such services there is a
need in predictive modelling health risk assessment, utilization management
and coordination of care. The care delivery model includes capturing and
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analysing patient data from dispersed systems, involving and engaging all
stakeholders, especially primary care providers that are typically left out. An
optimal identification and stratification of patient population is, also, derived
from data integration and physician engagement challenges.
The REMPARK system supports the referred care approach and enables
the clinical team to effectively manage the patient’s disease. The advantage
is that different healthcare professionals can use the same platform without
changing their own system. The data are updated and the workflow is
maintained. It serves for Information and knowledge sharing between all
caregivers of the patient. The REMPARK system provides the care team a way
to overcome the barriers of fragmented care service, overcome organizational
and inter-organizational limitations and focus on patient’s clinical needs
for diagnosis to most advanced conditions, better management of care and
replacement of some of the home visits by remote evaluations as well as better
management of visit scheduling according to need instead of the periodic visits
usually done.
At the PD management level, the system provides information that does
not exist today enabling the neurologist to have better assessment of the
patient’s condition and treatment effectiveness with online information. The
pilot studies done in REMPARK project provided clinical outcomes for
the motor symptom detection. Further studies should be done for assessment
of overall clinical outcomes of the new treatment approach on the PD patients.
However, from previous experience with other chronic disease patients treated
in Maccabi healthcare services, in Israel, using this approach, the following
significant clinical outcomes can be found:
• Significant improvements in the patient’s well-being measured by Qol.
• Patients maintained a healthy lifestyle: diet, physical activity...
• The mental condition of these patients (reported depression) dropped
from 24% before to 15% following the intervention using DMS.
• Patients reported that they have better ability to cope with their disease.
At the level of physicians there was a high satisfaction from the service which
they found very helpful in the treatment process since the system supports
Healthcare professionals in their routine work.
8.4.2 Advantages for the Patients
Daily communication with caregivers, better understanding of the disease,
education and awareness about the disease progression, symptoms and pos-
sible treatments are crucial for PD patients and their ability to cope with
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the disease. At early stages of the disease, there is a need to support the patient
with educational materials and follow-ups, and at more advances stages there
exists a difficulty of the patient to arrive to the clinic as often as needed, to
adjust the medical treatment, provide additional treatments (physiotherapy and
cognitive treatment, for instance) and perform a correct on-going assessment
and intervention of the disease.
The REMPARK system monitors and provides care for PD patients consid-
ering their overall clinical condition including co-morbidities. The patients are
treated by their doctor and do not have to move visiting different doctors and
care providers for the treatment of different conditions. The care coordination
is done within the program and provides them a clear treatment plan and
one contact point. The system aims to enable the patients preserve/enhance
of their physical and mental QoL, performance scores, compliance rates and
satisfaction. It also enables to empower the patients and support them and
their family in the care process.
In summary, the REMPARK system brings an innovative solution to the
patients by involving them in the care process. They are actively participating
in the assessment through the questionnaires and are able to view and follow
their clinical condition. The neurologist can make a remote visit and assess-
ment of the motor condition (administering the UPDRS scale, as demonstrated
during the REMPARK project pilot in Israel) through video conference and
save the need to go to the hospital, especially for patients that are living in
rural areas or have motor symptoms and disabilities at advanced stages of the
disease.
From the cumulated experiences with chronic disease patients adopting the
DMS system approach at Maccabi in Tel-Aviv (Israel), the presented system
clearly helps the patient in all the mentioned aspects. Patients seem less worried
regarding their condition; feel they have the information for the treatment, for
drug regimen and for self-management. It also helps to preserve/enhance their
physical and mental QoL (as measured by PHQ9).
The treatment increases their performance scores and satisfaction,
decrease reported depression and increase healthy behaviour. The effects were
shown also on the whole treatment perception, self-management and treatment
burden healthy lifestyle was assessed by the frequency of self-care activities
of the patient.
• Concerning the diet, physical activity and drug regime, there was a
significant improvement due to the intervention (satisfaction with the
service is very high and is rated 6 in a scale of 1–7).
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• Use of a DMS based service results in a better empowerment of the patient
and caregivers support of the care process. An increase of compliance
and adherence to treatment is also detected.
• Remote- UPDRS was performed in PD patients as part of the pilot.
8.4.3 Advantages for the Organization
It is very well-known that the prevalence of chronic diseases is increasing
around the world, and 50–80% of all global health spending is related to
chronic diseases. Patients suffering from Parkinson’s Disease are part of this
population, since in most cases, PD patients suffer from more than one chronic
disease.
The care of PD patients is complex and the correct treatment should be
handled jointly by General Practitioners (GPs), and the specialized health
service (hospitals or clinics): specialists (geriatrics and neurologist), general
physicians, nurses, physiotherapists, nutritionists, occupational therapists,
social workers, that may be affiliated to different organizations. Rehabilitation
and self-management support should be handled in cooperation with GPs [13].
Disease management programs focus on patient monitoring and interven-
tion. These shift healthcare expenses to less invasive and expensive care, thus,
disease management programs are meant to strive to achieve two seemingly
conflicting goals:
• Improving patient outcomes
• Optimizing resource utilization
In parallel to the increase of the prevalence in chronic diseases, there is a
decrease in number of healthcare professionals. Since the early 1980s there
is a decrease in number of physicians per capita from ∼3 to ∼2 doctors per
1000 people in average in the OECD countries. The number of nurses per
1000 people decreased from 7.5 in the mid-1980s to 5.5 in 2004 in average
in the OECD countries. This trend increases the workload on physicians and
nurses as well as on other healthcare professionals which limit the system in
providing all the services needed.
The healthcare system structure is fragmented and in order to treat PD
and other chronic patients, it is needed to receive services from several
stakeholders. There is a limited accessibility and availability and lack of
treatment uniformity in different areas according to healthcare professionals
and service availability. There is a continuous rise in national healthcare costs
and as a result, the economic stress is rising.
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Nowadays, the healthcare systems face huge challenges. At the level of
the care process there is a need for capturing and analysing patient data from
dispersed systems, involving and engaging all the related stakeholders, espe-
cially primary care providers that are typically left out. Optimal identification
and stratification of patient population derives also from data integration and
physician engagement challenges. Service should be equal to all patients
regardless of their living area (rural or large cities) and involve care teams
and case managers. At the organizational level, there is a need to establish the
process/workflow, the clinical guidelines and protocols for remote treatment,
risk management and cost control.
As it has been already explained, the integrated care workflow application
considered in REMPARK includes built-in alerts, clinical protocols, guide-
lines and treatment plans. The application interfaces with remote monitoring
devices and can be integrated with EHR and other medical systems. The
advantage is that the system does not change the routine work of the healthcare
professional and support them in their work and decisions, enabling knowledge
sharing, online assessment, intervention and follow-up. Using this approach on
PD patients, in REMPARK project, it was received a high level of satisfaction
from both patients and doctors, however it was detected a real need to
drive towards the implementation of the service and to study the success
measurements as it has been already done in other chronic disease patients
populations.
The system is composed of several modules that provide a number of tools
and functionalities to the organization:
• Risk management.
• Control of large teams providing services 24H/7D.
• Management of a large groups of patients that will enable scaling up to
large population management.
• Treating heterogeneous data coming from different monitoring device,
including patient reporting data.
• Ability to treat different conditions from well-being, clinical cognitive
and mental conditions.
• Keep more than one care organization in the loop by sharing data and
knowledge.
• The support of several care models/workflow and therefore the mini-
mization of the number of systems that the organization has to use and
implement.
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8.5 Conclusions, Discussion and Vision
As the healthcare services changes and moves from hospitals to community
care, there is a need to address the need of coordination between the services
provided by specialists in the hospital, such as neurologists, and healthcare
providers in the community and to create a system that will enable continuity
of care, global coordination and integrated care. Furthermore, the treatment of
actual complex patients includes also social care organizations, municipalities
and sometimes private care providers, thus making their care quite complex,
fragmented and with difficulties for sharing relevant information.
On the other hand, the interaction and relationship between patients and
care providers is changing and is moving towards collaboration schemes
and the active involvement of the patient in his care process, including self-
management. This absolutely requires new tools and a different approach for
patient empowerment, guidance and timely response by the care provider.
The REMPARK project developed and experienced a system that aims to
address the challenges of the future model of care for the PD community. The
different levels of sensors, data analytics, decision support tools, integrated
care platform and actuators as well as tools for the patient, demonstrate the
process and care pathway for treating PD patients and chronic patients at home.
The success of the system relies on its ability to adapt to different
organizational and national systems as demonstrated in 3 pilot sites (Spain,
Ireland and Italy) in which the main care of PD is provided by hospitals
and in Israel in which the main treatment is provided in the community. The
reliability of the system also at the level of data analysis provides a powerful
tool when combined with clinical and organizational guidelines and thus pave
the way to treat large populations with different and changing conditions in a
personalized way.
The main barrier in implementing such systems is the need of integration
with organizational systems, which is a slow and partial process. Therefore,
the main challenge of healthcare system is to implement such systems at large
scale and to use them as part of the existing workflows, sharing information
with other organizations, patient and family and to develop methodologies for
interactive treatment.
Healthcare organizations will use these technologies by changing the
model of care, sharing information and advancing the research and deve-
lopment of systems that will bring additional information and knowledge to
that already exist, in order to find the best way to use it in practice to improve
care quality. This will also change the clinical practice and patient involvement
in self-care and decision making.
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9.1 Introduction
In the previous chapters, the REMPARK system has been presented and
discussed, along with its usefulness. According to the initial project spec-
ifications and some important conclusions obtained from the work carried
out during the project, the main characteristics and requirements of the inte-
grating parts and REMPARK sub-systems were initially defined and refined
afterwards.
The present chapter will first describe the final system and, then, its overall
final assessment. This way, first, a description of the communication flows
established in the REMPARK platform (type of information, dataflow and
security issues) is given. Secondly, an overview of the final necessary platform,
ready to be used in the piloting part of the project is provided.
The assessment process was done through a pilot in which the patients
tested the system in ambulatory conditions and during their daily living
activities. More than 40 PD patients participated from four countries (Spain,
Italy, Israel and Ireland).
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9.2 Description of Main Communication Flows
As it has been described in previous chapters, the effectivity of REMPARK
system is based on a couple of interaction loops that define specific communi-
cation data flows. This way, communication between the different sub-systems
of REMPARK is a crucial aspect and the correctness and security of the
information flows must be guaranteed. In order to understand and specify
the characteristics of the communication flows, it must be considered that the
REMPARK system has two differentiated functional parts:
• The first one is related to the monitoring of PD motor symptoms,
including: movement sensors, actuator, smartphone, the REMPARK
server, the Rule Engine, the Disease Management System (DMS) and
a patient’s web interface.
• The second functional part is related to the monitoring of non-motor
PD symptoms. This monitoring strategy is mainly based on the use
of questionnaires and also includes a simple agenda system to interact
with the patient. This part of the system requires the smartphone, the
REMPARK server and the DMS to exchange information.
Thus, two different information flows are distinguished in the REMPARK
system. This differentiation will be used to specify the system according to
either 1) the communication flow due to the monitoring of motor symptoms
and the application of the actuation action or 2) the communication flow due
to non-motor symptoms.
• The monitoring process of the motor symptoms is mainly done in
the immediate loop, around the patient. The mobile phone is acting as
the gateway for the communication of the related sub-systems with the
REMPARK server and the different channels and data type, according to
the definition presented in the next section, are shown in the Figure 9.1:
• The non-motor symptoms mode embraces the communication flows
related to patient management issues, e.g. agenda, treatment, question-
naires, etc. Figure 9.2 presents the REMPARK system parts participating
in non-motor symptoms monitoring and their communication flow.
9.2.1 Type of Transmitted Information
This section details the general specifications of the different information
types sent and received through the communication channels indicated in
Figures 9.1 and 9.2. Four different types of information are considered:
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Figure 9.1 Communication flow of motor symptoms detection and actuation in REMPARK
system.
Figure 9.2 Communication flow of non-motor symptoms management and actuation in
REMPARK system.
(I) Alarms, (II) Data sent within the closed loop of the REMPARK monitor-
ing system, (III) Configuration parameters in the smartphone and, finally,
(IV) Agendas and questionnaires:
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• Alarm specifications
An alarm is defined as an event detected by the REMPARK system that
must be urgently notified to an end-user. For instance, a fall-detection
event is the only alarm provided by the REMPARK wearable system.
Other alarms can be defined within the DMS as a combination of one or
more rules applied to the stored information; for instance, a value from
a questionnaire lower than a specific threshold.
In the communication flow, as a general rule, alarms within the
REMPARK system will be handled as states. This means, for instance,
that when the sensor sends a data packet it will also send the state of all
the alarms, a value 1 meaning an activated alarm and a value 0 meaning
a deactivated alarm. There should be 3 stages for clinical alarms: red,
yellow and green. Therefore, when a low battery level is detected its
corresponding alarm will be set to 1, and its value will not become 0
until an optimum charging level is detected.
• Data sharing between the REMPARK wearable system and the DMS
The sensor sends data every minute to the smartphone. The smartphone
will store the data sent by the movement sensor during a specified time
frame, which usually consists in few hours. Once this time frame is
reached, the smartphone establishes a connection with the REMPARK
server to upload all the data stored since the last connection. The
connection between the smartphone and the server will take place every
1–3 hours, except when the data sent by the sensor contains an activated
alarm or when an alarm is generated at the smartphone. In this case, an
immediate connection with the server is established.
• Configurable parameters
All configurable parameters must be stored in the REMPARK server.
These parameters are used by the machine learning algorithms and the
ACS cueing system, which enable their personalisation to each patient.
They are defined in the DMS and their values are transmitted to the
smartphone, in which they are applied to the sensor’s output provided
every minute. These parameters are, for instance, the patient’s walking
rhythm, the threshold used to detect bradykinesia or the freezing index
level necessary to consider an episode of FOG.
• Questionnaires and agendas
The data associated with the monitoring of non-motor symptoms can be
grouped in three broad categories: the request for a specific questionnaire,
the generation of an event in the agenda and the completion of a
questionnaire. All the questionnaires, including the TAP tests, are stored
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locally in the smartphone and in the DMS. The request for a specific
questionnaire consists in asking for a specific questionnaire number
and a date and time. The results of the questionnaires are sent in an
encoded REMPARK format. As an option, the questionnaires could be
filled in 3 ways:
1. Using the smartphone
2. Through the Patient’s web application
3. By the nurse asking the patient and completing, directly, through
the DMS platform
The data from the questionnaires will be sent to the REMPARK server
from the smartphone or the DMS respectively, they will be analysed by
the Rule Engine and alerts will be then sent to the DMS. The smartphone
will send all data filled by the patient and will be presented to the patient
also on the Web application. An agenda event is generated by the DMS
and sent to the smartphone through the REMPARK server. Even if the
event is stored in the server for record purposes, this information will
not be accessible by the rest of the subsystems (smartphone or DMS)
once the event is transferred to the smartphone. All the data related to the
questionnaires and the agendas must be stored in the REMPARK server.
9.2.2 Security Aspects
Security aspects related to the communication are very important in the appli-
cation of the REMPARK system. The system can be split into two different
domains (the BAN and the platform/server), and different considerations
should be made possible. In the BAN, security issues are related to the
Bluetooth communication between the different sub-systems. In the platform,
security aspects come in the communication between the smartphone and the
server and the rest of the entities of that domain, the Rule Engine and the
DMS. The most relevant security aspects are summarized as follows:
• BAN: All the different devices forming the BAN, i.e. the sensor, the
smartphone and the cueing system, exchange data using Bluetooth 2.1.
Traditionally, using Bluetooth devices was associated to use pin codes
for each device in order to establish communication between devices.
This method required a manual intervention and security is not very
high. REMPARK uses Bluetooth v2.1, which uses SSP. This security
approach uses public key cryptography, which gives a lot of advantages.
It just works without manual intervention; however, a device may prompt
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the user to confirm the pairing process. During the pairing time, if the
devices have a screen, numeric comparison is used, which informs the
user that a device is trying to connect. The number shown in the screen
must be the same as the one in the device. From Bluetooth v2.1 encryption
is required and the encryption key is regularly refreshed.
• Platform/server: The server is interfaced by three different elements,
the Rule Engine, the DMS and the smartphone. Communication with
the server fulfils the European Data Protection Directive (Direc-
tive 95/46/EC), which embraces the different national laws for data
protection.
9.2.3 Final Deployment and Implementation of the REMPARK
Platform
With the already presented specifications and characteristics, the REMPARK
platform was implemented for its use during the last piloting phase of the
project. According to the pilot specification, the system was conceived to be
implemented following a distributed approach, and this is how it was tested
during an early pre-pilot phase. Many efforts were devoted to ensure the
synchronisation, data transmission, processing and representation of the infor-
mation considering different scenarios like a sudden lack of communication,
for instance.
After this early phase, the integration of the Rule Engine into the REM-
PARK server was decided, obtaining in this way a more efficient management
of the communication bandwidth and a mitigation of transmission delays.
The REMPARK system worked steady, secure and with good performance
to carry out the scheduled pilots. The Figure 9.3 shows the final REMPARK
functional view (it was deployed in June 2014 as starting point for the pilots).
In the figure, the Rule Engine is already presented as a part integrated in
the REMPARK server and directly accessing to the information generated by
the patient’s sensor (measures, alerts). All this information is transmitted by
patient’s smartphone in a secure way using a Transport Layer Security (TLS)
channel.
The Rule Engine, then, analyses this information and creates new post-
processed measures, which are stored and forwarded to the DMS system in a
secure way using a TLS channel. Eventually, the DMS shows all the gathered
information to the clinical professionals as well as providing a decision support
system that follows the defined clinical protocols. Furthermore, clinical
professionals can set up treatments and appointments that are forwarded to
patients’ mobile phone.
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Figure 9.3 Final REMPARK platform (ready for pilots) functional view.
In order to guarantee the execution of the pilot, it was decided to implement
four different and equivalent environments. As REMPARK pilot experience
must be distributed among four different countries (Spain, Ireland, Italy and
Israel), it was entailed the deployment of four different servers, one isolated
server per pilot site and the same replica for the DMS system.
In order to guarantee patient’s data privacy, pseudonyms and ID’s instead
of personal information were transmitted. Moreover, to maximise the security
of the pilots, external calls to each environment were forwarded through a
proxy to an isolated Telefónica’s private network which can only be accessed
from inside (Telefónica was the responsible partner for the REMPARK
platform and communications). The Figure 9.4 shows how it looks like
this set up.
In total, four environments were set up assuring this level of security.
Furthermore, any external communication with the server, either from patient’s
mobile phone or the DMS system goes through a TLS channel and each
message includes specific credentials according to the type of user/system
sending the message (i.e. patient, DMS). Moreover, other security mechanisms
have been implemented to assure that there are warning alerts in cases where
there are communication problems between the different devices (i.e. alert
when the smartphone loses communication with the platform, alert if sensor
or actuator connections are lost, presence of a fall detection). Figure 9.5 shows
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Figure 9.4 REMPARK server in isolated network.
Figure 9.5 Final REMPARK system deployment and used for the pilots.
the final set-up implemented and used for REMPARK’s pilots. The secure
connections between the REMPARK server and other external sub-systems,
like the DMS and the smartphones used by the patients are indicated. As a
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proof of concept, the DMS was integrated with the information systems used
by Maccabi in Israel through HL7 protocol.
9.3 Pilot for the REMPARK System Assessment:
Description
This section introduces the details and the execution of the distributed pilot,
executed in REMPARK. The main objective of this pilot was the global
assessment of the system in terms of ON and OFF detection. As a previous
activity, before starting the main pilot, an early pre-pilot was organized with
very few volunteers in order to test the stability and the validity of the overall
system.
In this section, the experimental protocol is described first, followed
by some conclusions after the early trial (pre-pilot experience). Finally, the
analysis of the REMPARK system during the pilots is fully provided, with the
main conclusions regarding the obtained results.
9.3.1 Definition of the Pilots’ Objectives and Eligibility Criteria
The objectives of the pilot activity were divided into primary and secondary.
The complete list to be covered is following:
Primary objectives
• To study the performance and reliability of the REMPARK system under
real conditions on a significant group of patients.
• To study the validity of the ON/OFF motor phase detection by the system
on a significant group of patients.
Secondary objectives
• To study the functionality of cognitive tests administered through the
smartphone in detecting ON/OFF states on a pilot group of patients.
• To check the operation of an auditory cueing system, activated by the
output of an algorithm, in improving the gait on a pilot group of patients.
• To assess both usability and user’s satisfaction referring to the REM-
PARK system under real daily living conditions on a pilot group of
patients.
• To study the validity of the fall detection algorithm of the REMPARK’s
system on a pilot group of patients.
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• To verify the safety of the REMPARK in individuals with Parkinson’s
disease on a pilot group of patients.
Population and eligibility criteria
The reference population is that formed by a pilot group of patients with
moderate to severe Parkinson’s Disease, presenting ON/OFF phases, FOG
or dyskinesia (Hoehn and Yahr greater than 2 in ON phases and lower
than 5 in OFF phases). Candidates found to be eligible to participate in the
study immediately were provided with the Patient Information Sheet and
the Informed Consent Form. The Principal Investigator or a co-investigator
met the subjects and explained the study purpose, procedures, possible
risks and benefits and subject responsibilities to the potential participants.
The subjects had the opportunity to evaluate these documents in detail and
were allowed to ask the investigators any question regarding the study. The
subject’s willingness and ability to meet the follow-up requirements were
determined.
Patients fulfilling the following criteria were candidates to be included in
the study:
• Clinical diagnosis of Idiopathic Parkinson’s Disease according to the UK
Parkinson’s Disease Society Brain Bank [1].
• Disease in moderate-severe phase, with a Hoehn and Yahr greater than
2 in ON phases and lower than 5 in OFF phases, or with a scale
greater or equal to 2.5 (in ON state) with motor fluctuations comprising
bradykinesia, FOG and/or dyskinesia [2].
• Able to walk unaided in OFF state.
• Age between 50 and 80 years.
• Sufficient literacy capacity to answer questionnaires.
• Willing to participate in the study (in writing-sign informed consent)
and wanting to co-operate in all its parts, accepting the performance
regulations and procedures provided by the researchers. The patients’
family members and responsible doctors should fulfil, also, this inclusion
criteria.
Patients fulfilling the following criteria were excluded from the study:
• Other health problems that hamper physical activity and gait: rheumato-
logic, neuromuscular, respiratory, cardiologic problems other neurolog-
ical disorders- (Post stroke, Polio), mental disorders, significant pain.
• Alcohol and/or drug abuse.
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• Being treated with duodopa or apomorphine pump, or deep brain
stimulator.
• Patients who are participating in another clinical trial.
• Dementia according to clinical criteria -DSM-IV-TR [3].
• Unable to fully understand the potential risks and benefits of the study
and give informed consent.
• Unable to recognize the ON and OFF fluctuations, after proper training.
• Subjects who are unable or unwilling to cooperate with study procedures
(for example- unwilling to carry the sensors during the study hours).
All participants in the pilot presented motor fluctuations, according with
the inclusion criteria, and at least 25% of the total of the sample had FOG
problems. Family members and responsible doctors of the participants were
included in the study and they were allowed to consult patient’s health data
through the web information system.
9.3.2 Design of the Study
The REMPARK pilot was designed as a longitudinal pilot study in which
each participant was using the REMPARK system under real conditions
(ambulatory conditions) during 4 consecutive days. An additional pre-trial
day (day 0) is necessary for customizing the system to the user, and a day 1,
to train the user in the system’s use. This pre-trial day was scheduled at least
1 week prior to the trial start. The organization of the study design is shown
in Figure 9.6.
In the pre-trial day (day 0), the thresholds for the bradykinesia detection
algorithm, the FOG detection algorithm and the TAP test parameters were
adjusted for each individual participant. For doing so, three short specific
experiments were conducted: walk in OFF, walk in ON, FOG provocation test
and TAP test. During the trial days (day 1–day 4), patients were wearing and
using the REMPARK system under real conditions. The system was recording
Figure 9.6 Timing of the methodological study design.
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motor and non-motor symptoms, which were also video recorded by standard
means (video cameras or smartphones).
The pilot study started after getting the approval of the corresponding
Ethics Committees and the competent authorities in the four countries
(i.e., in Spain the Spanish Agency for Drugs and Medical Devices, AEMPS
gave the corresponding permission). The following data and records from each
participant were obtained and integrated into the pilot database:
• Personal identification data: name, address, phone number.
• Socio-demographic variables: date of birth, gender, educational level,
cohabitation.
• Clinical assessment questionnaires:
• Parkinson’s diagnosis: according Brain Bank criteria by Hughes
et al. [1].
• Parkinson’s severity: measured by Hoehn and Yahr scale [2].
• Questionnaire assessment of motor fluctuations, FOGs, and
dyskinesia.
• Basal health status: list of chronic conditions, list of current
medications.
• ON/OFF current phase: The current motor phase was established
by using three different instruments. 1) Patient’s report: patients
who were previously trained for recognizing their ON/OFF phases
2) report whether they are in ON or OFF phase every 60 minutes,
or 3) when they detect a change.
• Unified Parkinson’s Disease Rating Scale (UPDRS) [4], which
was administered by a trained researcher to participants several
times during the pilot.
• Video recording and posterior analysis by an expert was used for
confirming the motor phase of the patient.
• TAP-test: This test was designed to objectively assess changes in
movement, such as slowing and rigidity which are effects com-
monly related to the OFF state. In this test the subject is requested
to repeatedly press a button on the touch screen of the smartphone
representing a white arrow in order to fill up a vessel as soon as
possible according to ten predefined levels (each target level is
marked by a green bar). The ten levels represent the number of
button presses needed for the level to be fulfilled. The subject has
to press the button by using his forefinger of the dominant hand
(i.e., right hand).
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• Cognitive status: Assessed by Folstein Mini-Mental [5] and
applying the criteria of DSM-IV TR dementia.
• Freezing of Gait (FOG) episodes and severity, measured by two
different standard methods:
• Video recording and subsequent analysis by a trained observer,
was used for identifying the section of the sensor signal’s
corresponding to FOG episodes.
• Freezing of Gait Questionnaire (FOG-Q) [6]: This instrument
was used for establishing the basal (over the last 4 days week)
severity of freezing of gait in the participants, and also its
severity during the 4 days of the REMPARK’s system use.
• Gait quality:
• Video recorded timed Up & Go test [7]: This instrument is
a timed test of standing and walking. It is a gait-speed test
used to assess a person’s mobility and requires both static and
dynamic balance.
• Non-motor symptoms:
• Non-Motor Symptom Questionnaire: NMSQuest [8].
• Usability: The usability instruments were used to assess separately
the usability of each device, and also the whole system.
• System Usability Scale (SUS) [9].
• Quebec User Evaluation of Satisfaction with Assistive Tech-
nologies (QUEST) [10].
The REMPARK system for these pilots included all the already described
sub-systems:
• Sensor sub-system (located in the waist). μSD cards were used on day 0
to collect the raw data from the sensor in order to perform the user
particularization. The remaining days, the sensor shared the results of
the algorithms with the smartphone once per minute.
• Smartphone: The smartphone used in the experiments is the Samsung
Galaxy Nexus. The specific software running in the smartphone was
developed within the framework of the REMPARK project.
• Headset for auditory cueing: The headset chosen for the REMPARK
experiments was the Samsung HM3500 Bluetooth earphone.
• REMPARK Platform (according the description in precedent text).
• Web Server – Disease Management System (application for managing
the patient’s health by the medical staff).
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9.3.3 Pre-Pilot Conclusions
As it has been mentioned, a preliminary pre-pilot activity was scheduled with
the participation of a limited number of patients, and with the objective of
checking the stability of the overall REMPARK system to be used. It was also
intended to evaluate its performance in terms of correct detection of the motor
state of few PD patients in ambulatory conditions.
During the pre-pilot, regarding the system stability, it must be noted that
the data gathered by the REMPARK sensor were correctly sent through the
different communication layers so that no information loss due to commu-
nication errors were detected. Although some packet losses were observed
during the experiment, they were due to the fact that the user didn’t remember
to have the smartphone always in coverage range of the sensor. In this respect,
it was concluded that, during the user training session, emphasis to keep both
devices as close as possible during the whole duration of the experiments had
to be done.
It was also found with these pre-pilot tests that the performance of the
REMPARK system when detecting the motor state of a patient is in line
with the original specifications, even if the gold standard available to validate
the results is not always accurate enough. The existing issue is the fact
that the only available gold standard is the self-reporting of the patients using
a diary. Figure 9.7 presents the diary filled by one of the participants in the
pre-pilot experience, during the first day of experimentation (day 1). It can be
observed that the patient, as it is commonly done in motor states self-reporting,
writes down the motor state for each hour of the day.
Reporting the motor state in this manner presents the following two issues:
• The time in which the motor state is reported has been shown to be inac-
curate in some cases. More specifically, it is unclear when exactly
changes among motor states occur. In contrast, the information obtained
by REMPARK system is known with seconds’ accuracy.
Figure 9.7 Motor states section of the diary filled by one patient during the first day of
experimentation. Third row corresponds to the ‘intermediate state’.
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• Some PD patients are not able to recognize their motor state. This risk
could be mitigated in the recruitment phase, since neurologists only
should select those patients able to recognize ON and OFF states.
In order to evaluate the ability of the REMPARK system for the detection of
ON and OFF motor states, a set of three main performance measures are used:
specificity, sensitivity and correlation with a gold standard. These measures
can be severely affected by the two inaccuracy issues presented above:
• Concerning specificity and sensitivity measurements: These measure-
ments may be strongly affected by the described issues, since the
REMPARK system provides an estimation of the motor state once
every 10 minutes. First, given a patient who constantly switches among
different motor states, a big difference between the time assumed in self-
reporting and the time provided by the REMPARK system could lead to
very low specificity and sensitivity values. Second, if the patient does not
correctly recognize the motor state, a similar effect would be obtained.
• Concerning the correlation between REMPARK system output and
patient diary (used as gold-standard), it must be pointed out that
these measurements would be affected similarly to the specificity and
sensitivity ones.
Two possible options appear when comparing the self-reported motor state of
a patient and the REMPARK system output:
• It is possible to consider the correct REMPARK system output as the
output that is closest to the time of the self-reported motor state by the
patient. Results for this option were presented as ‘exact time’.
• It is possible to consider the correct REMPARK system output as the
mode (most frequent value) among the outputs obtained within the one-
hour period that corresponds to the self-reported motor state. Results for
this option were presented as ‘mode’.
Finally, it should be noted that patients can report to be in ON, OFF or interme-
diate state (see Figure 9.7). However, REMPARK system only provides ON
and OFF predictions. In consequence, those periods in which intermediate
state was reported will not be included in the performance analysis.
Table 9.1 shows results for two patients, who participated in the pre-
pilot. No valid conclusions can be extracted from this pre-pilot phase, but the
identification of the discussed issues and the technical validation of the system.
In the results of the first patient, it can be observed that only 8 hours were
analysed, given that most of the reported states correspond to the ‘intermediate
state’.
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Table 9.1 Pre-pilot results on motor state detection
Patient
REMPARK
System
Output
Selection Specificity Sensitivity VPP VPN Correlation
Number
of Hours
Analysed
1 Mode 0.6 0.3 0.33 0.6 –0.07 8
Exact time 1 1 1 1 1 8
2 Mode 0.91 0.71 0.71 0.90 0.62 29
Exact time 0.73 1 1 0.54 0.7 29
9.4 REMPARK Pilots’ Execution and Obtained Results
Pilots with REMPARK system were conducted in accordance with the protocol
presented above. It must be remembered that the main objectives of the
study were to analyse the performance and reliability of the REMPARK
system under real conditions, and to study the validity of the ON/OFF
detection by the system. A list of secondary objectives was also focused (see
Section 9.3.1).
The recruitment was carried out following a convenience sampling among
patients assisted in the different centres participating in the study, following
the methodology described in the above Section 9.3.1. Fifty-four (54) patients
were initially contacted, 44 of them met inclusion criteria and agreed to
participate. Three of the included patient did not complete the study days. One
of them discontinued participation voluntarily. Two patients were removed
from the study by the researchers, the first of them due to lack of adherence to
the study protocol, the second patient was removed due to a health condition,
which required hospitalization, apparently not related to study devices or
procedures. Finally, 41 patients completed all study days and evaluations.
Table 9.2 shows recruitment and follow-up data by participant entity.
Table 9.2 Recruitment and follow-up data by participant entity
Medical Partner
Contacted
Patients
Included
Patients
Lost-Dropout
Patients
Completed
Protocol
NUI Galway
(Ireland)
7 7 1 6
TEKNON
(Spain)
18 15 0 15
FSL (Italy) 16 10 0 10
MACCABI
(Israel)
13 12 2 10
Total 54 44 3 41
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Concerning the socio-demographic and health data of the partici-
pants, twenty-eight participant patients were men (68.3%) and 13 were
women (31,7%). The average age of participants was 71.3 years (SD 7.3;
range 56–84).
All the participants had been diagnosed of Parkinson’s Disease according
to the UK Parkinson’s Disease Society Brain Bank [1]. The average time
from diagnosis was 11.3 years (range 2–26). As per inclusion criteria, all
participants had a Hoehn and Yahr scale equal or greater than 2.5 [2], being
median stage of the sample 3 (range 2.5–4). The motor section of the Unified
Parkinson’s Disease Rating Scale (UPDRS) was in average 28.2 (SD 1.7) [3],
when the patients were in OFF phase and 12.2 (SD 1.5) when the patients
were in ON phase. The median of the Freezing of Gait (FOG) questionnaire
of all participants was 13 (IQR 6) [4], this scale explores gait disturbances of
the patients and ranges from 0 through 24, being the higher scores related to
worse gait disturbances.
Participants with dementia and acute medical conditions were not included
in the study. Mini-Mental State Examination (MMSE) [5] results of the par-
ticipants are shown in Table 9.3, along with other medical chronic conditions
of participants.
Table 9.3 Mental and chronic disease condition of the participants
Condition
Number of
Participants (n) %
High blood pressure 15 36,6
Heart conditions 3 7,3
Arthritis, osteoarthritis or rheumatic conditions 11 26,8
Back ache 13 31,7
Asthma or COPD 1 2,4
Diabetes 10 24,4
Urinary incontinence 14 35
High cholesterol 12 29,3
Depression 9 22,5
Anxiety disorder 3 7,3
Stroke, cerebral embolism, cerebral infarct or
cerebral bleeding in the past
0 0
Cancer (malignant tumours) 5 12,2
Osteoporosis 2 5
Thyroid disease 1 2,4
Cognition (MMSE) 29 (Median) 5 (IQR)
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9.4.1 Performance of the System
The assessment of the system performance was done considering and
analysing the data received and stored in the REMPARK server.
One of the main problems that was detected in the system and that was
widely repeated in many users is related to the communication structure
of the BAN and the usage received from patients. REMPARK wearable
system is composed of a smartphone, a wireless headset and the waist-worn
movement sensor. Bluetooth is employed among them to communicate. More
concretely, the movement sensor and smartphone communicate once per
minute (every 60 seconds). In consequence, given the short-range reached
by this type of communication, whenever patients placed the sensor and
smartphone at a certain distance (e.g. in different rooms) communication could
be lost. Some measures would not be received by the smartphone which, then,
would not be received by the server. These periods of lost information were
mainly addressed and analysed as an objective measurement of the system
performance.
In order to distinguish them from those in which the sensor is turned off,
it was used the first packet after the communication between the smartphone
and the sensor is established, which contains specific values that make this
situation recognisable.
The performance analysis process of the REMPARK system was organized
according the following procedure. First, presenting a summary of the most
relevant data sent and stored in the server during the pilots, distinguishing them
according to the different sources and types of information. Then, data received
in each day of the pilot were analysed in order to evaluate the performance
of the system communications. In ideal conditions, in every minute during
which the patient wore the system, the corresponding set of samples should
be stored in the server.
Table 9.4 shows just a summary example of the kind of data stored in
the REMPARK server. This table includes the source of the information (in
this example, only data corresponding to the sensor and the smartphone are
shown), a description of the variable (between parentheses, the internal code
assigned to the variable in the database is appearing) and the amount of data
samples for each variable stored in the server.
Along the complete pilot execution, a total of 949 hours of raw data were
stored in the system. This assumes that an average of 6.6 hours of raw data per
user per day were collected. It is noted that this average number of monitoring
hours is obtained on a minute basis, that is, the number of values in which
the movement sensor sent information, meaning that missing values are not
included.
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Table 9.4 Example of data stored in the REMPARK server
Information Source Information Variable Quantity
Movement sensor BRADYKINESIA – NUM STEPS (106) 56955
BRADYKINESIA – BRADY MEAN (107) 56955
BRADYKINESIA – BRADY STD (108) 56955
DYSKINESIA – DISK PROBABILITY (110) 56955
DYSKINESIA – DISK CONFIDENCE (111) 56955
FOG – MAX FI (112) 56955
ACTIVITY – SMA (901) 56955
ACTIVITY – CADENCE (902) 56955
Smartphone BRADYKINESIA (201) 56955
FREEZING OF GAIT (202) 56955
DYSKINESIA (203) 56955
TAP RESPONSE TIME MEAN (204) 99
TAP RESPONSE TIME STD (205) 99
LAST TAP RESPONSE TIME MEAN (206) 99
LAST TAP RESPONSE TIME STD (207) 99
TAP TEST RESULT DECISION (208) 99
In order to estimate the amount of missed data, it must be considered
that if the sensor did not communicate with the smartphone during a given
period of usage, missing packets are reflected with time intervals higher than
60 seconds. More concretely, it is considered that some packets have been
missed when two consecutive movement-sensor measurements were received
by the smartphone with more than 100 seconds of difference.
It was observed that some packets were lost in most patients (only in
5 patients there were not any missed packets). Moreover, it was calculated
that the average number of missed packets was only of 6 minutes. Finally,
the error rate was considered in terms of missed packets vs. total number of
measurements received. According to this, it was observed that less than 4%
of the packets were missed among all patients.
These missed short periods are not relevant since motor symptoms
algorithms, require sensor measurements on a time interval of 60 minutes,
allowing to have missing values in the analysed period, which means that
these short-time missed packets do not influence the information provided to
clinicians.
Given these considerations, Table 9.5 provides the performance analysis
of REMPARK system related to a very few patients participating in the pilot
(shown patients are randomly selected from the complete set and must be
considered only as an illustrative example).
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Table 9.5 Performance analysis of the REMPARK system (some examples)
Patient
Number ID
Number of Time
Intervals of
Missing Packets
Average Number of
Missing Packets Per
Time Interval
Number of
Time
Intervals
> 10 min.
1 TEKNON 1 1 2,67 0
2 TEKNON 2 18 10,55 6
16 MACC 1 37 19,74 8
24 FSL 1 6 3,28 0
25 FSL 2 11 7,64 2
34 NUIG 1 21 20,11 10
Total
pilot
average
– 8,64 6,70 2,16
9.4.2 Validity of the ON-OFF Detection Algorithm
REMPARK system would be very useful enabling neurologists to adjust
the medication regime based on detailed information of ON/OFF states
fluctuations, which is provided in real-time by the wearable sensor sub-
system (a waist-worn inertial sensor), with the concurrency of a smartphone.
Final adjustment is then performed with the help of the specifically designed
Disease Management System (DMS), which is a server-based service that
allows neurologists, patients and caregivers to follow the disease evolution
and communicate among them. This section presents the validation of the main
objective of the REMPARK: the monitoring of ON/OFF motor fluctuations.
The presented validation consists in the evaluation of the REMPARK system in
detecting motor states in PD patients, who used the system over 4 consecutive
days, as part of the described pilot.
9.4.2.1 The methodology
The system assesses, in real-time, objective ON/OFF motor states based on the
inertial signals given by the waist-worn device, treated with different machine
learning algorithms that provide the presence or absence of specific symptoms,
from which PD motor states are then determined. In the following part, the
ON/OFF detection methodology is described.
Accelerometer measurements obtained by the waist-sensor are analysed
with two different algorithms: a bradykinetic-gait detector [11] and a dysk-
inesia (choreic-dyskinesia) detector [12]. The bradykinetic-gait detector is
based on the patients’ strides analyses, only after identifying that the patient
is walking. Each stride is characterized by a measure of its fluidity: high
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fluidity measurements correspond to non-bradykinetic gait and vice-versa.
On the other hand, the dyskinesia algorithm has two main outcomes: first, a
probability value that represents the chances of having obtained the signals
from a patient suffering dyskinesia and, second, a confidence value that
represents the degree of certainty on such probability. The outputs of both
algorithms on a period of T minutes are then processed.
The inferred motor state is ON when bradykinesia is not present in gait or
when dyskinesia output is present. This is due to, on the one hand, a lack of
symptomatic gait in ON states and, on the other hand, because of peak-dose
dyskinesia detection, also is associated to ON states. OFF state is determined
as the detection of bradykinesia and the absence of dyskinesia. Finally, the
intermediate state is defined by an intermediate detection of the bradykinesia
algorithm and lack of dyskinesia. A not evaluated (NE) state is provided in
case of not detecting dyskinesia and if the patient did not walk in the period
under analysis.
A final refinement is performed to the sequence of ON-OFF detections
obtained from the evaluation of 10 consecutive 1-minute periods. Those
periods determined as not NE are changed according to the following rules:
• If a NE period is found between two periods whose states are equal (either
ON or OFF), that period is set to be the same state as adjacent periods.
• If adjacent periods of an empty period correspond to different motor
states, an intermediate state is then inserted.
9.4.2.2 Validation of the ON-OFF diaries: available data
As it was introduced in above Section 9.3.3, the only possible and available
gold-standard for the validation of the ON and OFF states detection algorithms
are the patients’ diaries with the self-reported states and all the inherent
and already described inaccuracies. In order to stablish a methodology, two
strategies were followed to ensure the validity of the gold-standard:
• First, the validity of motor state diaries was evaluated based on clinicians’
expertise through UPDRS. In each scale that clinicians administered, it
was annotated the state in which the patient perceived to be.As it has been
described in many works devoted to study the factors involved in UPDRS,
scores obtained in OFF state are higher than the scores obtained in ON
states [13]. Thus, the validity of the gold-standard has been evaluated
based on an objective measure consisting in the correlation between
UPDRS scores and motor states provided by patients at the moment of
administration. Motor state is represented with 2 = OFF, 1 = Intermediate
200 REMPARK System Assessment: Main Results
and 0 = ON, so positive correlations are expected. It is noted that, in some
cases, negative correlations have been obtained. In order to also avoid
those situations in which there is not any relation between UPDRS and
the annotated motor state (i.e. nearly-zero correlation), patients whose
correlation was lower than 0.20 were not included in the study since
their ON/OFF diaries were considered not reliable enough to be used as
gold-standard.
• A second aspect taken into account is the timeframe during which
annotations are valid. More concretely, in order to consider a motor state
annotation to be valid, this motor state has to appear two consecutive
times in the diary, being the time interval of 1 hour between both annota-
tions its corresponding valid timeframe. In case the motor state changes
between two consecutive annotations, both annotations are excluded
from the analysis since the time in which the motor state changed cannot
be established. Although this strategy reduces the number of annotations
used from patients, it ensures that the annotations employed to validate
the system are temporally reliable. Results obtained when this procedure
is applied are presented under the name Strict diary. On the other hand,
when this procedure is not applied, results obtained are reported as
Original diary.
The complete validation of the ON/OFF detection algorithm requires the usage
of the data stored in REMPARK server during the pilots, the ON/OFF diaries
filled in by patients and the CRF’s administered by clinicians. Finally used and
useful data for these purposes were obtained from a total of 36 patients, after
two drop-outs and the exclusion of 5 diaries due to incoherencies (15 patients
administered by Teknon in Spain, 10 patients from Italy administered by FSL,
8 patients from Israel under the supervision of Maccabi and 3 patients from
Ireland administered by NUIG).
9.4.2.3 Results of the ON/OFF state detection
Among the initial 36 patients, data from 3 of them were removed due to a low
correlation between UPDRS scores and the movement state reported by the
patient (correlations were –0.62, 0.06 and 0.2, respectively), as discussed in
the previous section.
Table 9.6 presents the average results of REMPARK system in detecting
motor states in the 33 patients under real-life conditions, being the sys-
tem adjusted without using data from artificially induced OFF states. The
average specificity and sensitivity achieved by the system in recognizing
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Table 9.6 Average results according to the Original diary method and time-ensured method
(Strict)
Validation
Method
Average
Specificity
Per Patient
Average
Sensitivity
Per Patient
Average Number
of Validated
Hours Per Patient
Average Number of
ON/OFF Monitoring
Hours Per Patient
Original
diary
82% 57% 9.73 81.25
Strict
diary
89% 98% 6.42 81.25
ON/OFF motor states is 89% and 98%, respectively. These values dramatically
decrease when the described time ensuring is removed: specificity is 82% and
sensitivity falls to 57%.
In overall, the system generates an average of 35.3 hourly-based motor
state detections per patient over the 4 days (11.8 hours in ON, 4.9 hours in
OFF and 18.6 hours in an intermediate state). Thus, in average, for each of
the four days, almost 9 hours of monitoring per day have been provided by
the system.
Performance obtained by the system provides excellent results (sensitivity
of 98% and specificity of 89%). Although the minimum sensitivity achieved
is 75%, some specificity values are presented in the range of 50–70%.
The lowest values are obtained due to a very low number of validated
estimations for some of the participating patients. It must be noted that
in some cases validation was not possible due to a lack of annotations, which
is noted with NE in both Specificity and Sensitivity (main reason was because
patients did not fill in the diary).
Regarding the method used to set the thresholds of the bradykinetic-gait
measurement algorithm, the distribution-based approach reveals to suitably
set the algorithm parameters, according to the excellent results obtained.
The novelty of this approach relies on the fact that the approach does not re-
quire any OFF-induced data. In contrast, other works such as [14] employ
OFF-induced states, obtained by skipping medication intakes, to train machine
learning algorithms. Following the method described here, patients would not
be required to skip medication intakes to adjust the algorithms. Moreover,
patients do not have to follow any specific set of scripted activities as in [14],
either at home or in a lab, to particularize the detection method.
One of the main limitations of the system is that, in order to estimate
the motor state, it requires the patient either to walk or to present choreic-
dyskinesia. However, this is compensated by a reasonable high number of
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monitored hours with enough number of correct detections and a correct
selection done for the kind of patients recruited (H&Y greater than 2 and
lower than 5 in OFF state). On the other hand, one of the main advantages of
the motor states detection offered by REMPARK system is in the fact that the
evaluation method only requires patients to wear a single sensor.
9.4.3 Non-Motor Symptoms Descriptive Analysis
The REMPARK system was designed for the administration of questionnaires
to the participants in the pilots [15], through the mobile phone interface. One
of these questionnaires was a patient-based 30-points, used to determine the
non-motor symptoms experienced by the patient during the past month. It had
thirty items answered by the patient with a dichotomous answer: yes or no.
The following two questions were added to enquiry other non-motor
symptoms:
• Difficulty to speak.
• Have you had unusually strong urges that are hard to control? Do you
feel driven to do or think about something and find it hard to stop (Such
gambling, cleaning, use the computer, obsessing about food or sex)?
In addition to the standard dichotomous answers (yes or no), the REMPARK
system was given the option of rating each symptom by using an analogical
10-points scale (0–10).
All the 41 patients answered the non-motor symptoms questionnaire
(NMSQ). Among them, 63.4% presented mild non-motor symptoms, 36.6%
presented moderated non-motor symptoms and no patient had a result within
the “severe” range of the questionnaire. The median of the questionnaire
answers was 8 (over the 30 points) and IQR was 9.0.
Table 9.7 shows a random selection of answers (five of them) with the
most frequent positive answer. In addition, the two new introduced questions
are also shown.
9.4.4 Efficacy and Effectiveness of the Cueing System
The efficacy of the cueing system to improve walk was tested by comparing
the timed UP and GO test [16] with and without the cueing system activated,
according the protocol of the study established in REMPARK.
The average time performing the timed UP & GO (TUG) test with the
cueing system activated was 25.8 seconds, and without the cueing system was
25.7 seconds. Thus, no significant or clinical difference was found.
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Table 9.7 Non-motor symptoms selected answers sorted by frequency
Question Positive Positive
Number Question Text (n) (%)
8 A sense of urgency to pass urine makes you rush to
the toilet
27 69,5
9 Getting up regularly at night to pass urine 27 69,5
5 Constipation (less than 3 bowel movements a week)
or having to strain to pass a stool (faeces)
17 41,5
12 Problems remembering things that have happened
recently or forgetting to do things
17 41,5
15 Difficulty concentrating or staying focused 17 41,5
Added Difficult to speech 26 63,4
Added Have you had unusually strong urges that are hard to
control? Do you feel driven to do or think about
something and find it hard to stop (Such gambling,
cleaning, use the computer, obsessing about food
or sex)?
2 4,9
Several sub-analyses selecting participants were performed with severe
gait problems according their FOG questionnaire. Some improvement in the
average time in completing the timed UP and GO test was found then, but
it was still no significant from a statistical point of view. Results of these
sub-analyses are shown in Table 9.8.
The effectiveness of the ACS cueing system to improve walking problems
was tested by comparing the results of two administered FOG questionnaires
(before and after the REMPARK system testing).At the beginning of the pilots,
participants answered the FOG questionnaire [6], which measures walking
related problems (higher values in the results of this questionnaire means more
Table 9.8 Results of the cueing systems for participants with severe gait problems
FOG
Questionnaire
Filter* n
TUG with Cueing:
Average Seconds
TUG without Cueing:
Average Seconds
Mean
Differences
(seconds) Comment
Questions
4 > 2
11 24,7 27,0 –2,4 Ns
Questions
5 & 6 > 2
9 26,9 29,5 –2,5 Ns
Questions
4 or 5 or 6 > 2
16 24,5 26,0 –1,5 Ns
*FOG questionnaire question 4 > 2: longest FOG episodes lasting > 10 seconds
*FOG questionnaire question 5 > 2: starting hesitation episodes lasting > 10 seconds
*FOG questionnaire question 6 > 2: turning hesitation episodes lasting > 10 seconds
Ns: no significant.
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severe gait problems), regarding the last 4–5 days. After the pilot experi-
ments, the participants answered again the same questionnaire, regarding the
pilot days.
The mean of the FOG questionnaire before using the REMPARK system
was 12.8 and after the use of REMPARK system was 12.3, not being the
difference clinical or statistically significant. The results did not signifi-
cantly change in the sub-group of patients with worse walking problems.
Thus, we cannot conclude with the data obtained in the study that the cueing
system of the REMPARK system helped the patients to reduce their walking
problems in real conditions.
9.5 Health-Safety of the REMPARK System
In all health interventions, there is a risk that intervention entailing unexpected
negative effects that counteract the possible benefits from it. It is important
to notice that, according to the operative definition, and adverse event is “any
untoward medical occurrence, unintended disease or injury, or untoward
clinical signs (including abnormal laboratory findings) in subjects, users
or other persons, whether or not related to the investigational medical
device”.
During the experimental time, 7 participants presented health “adverse
events”, one of them had a “serious adverse event” consisting in condi-
tion deterioration that led to hospitalization. The most frequent adverse
events were limbs pain (three cases) and depressive symptoms (3 cases);
cervical pain was also reported (1 case). All adverse events, including the
serious adverse event, were considered as “unrelated to the investigational
device”.
In conclusion, we can’t identify special health-risk associated with the
use of the REMPARK system in this pilot, although the study timeline and the
lack of comparison group makes difficult to detect any health-risk associated
with the use of the system. Further studies on safety are warranted.
9.6 Usability and User Satisfaction of the REMPARK
System
The usability and user satisfaction with the system were measured by using two
standard instruments: the System Usability Scale (SUS) [17] and the Assistive
Device sub-scale of the Quebec User Evaluation of Satisfaction with Assistive
Technologies (QUEST) [18].
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The SUS is a 10 items Likert scale in which the respondent indicates the
degree of agreement or disagreement with the statement on a 5-point scale
(Figure 9.8). To calculate the SUS score, first the score contributions from
each item are summed. Each item’s score contribution ranges from 0 to 4. For
items 1, 3, 5, 7 and 9 the score contribution is the scale position minus 1. For
items 2, 4, 6, 8 and 10, the contribution is 5 minus the scale position. Finally,
the sum of the scores is multiplied by 2.5 to obtain the overall value of SUS.
SUS scores have a range of 0 to 100.
Results over 50 are considered acceptable, and over 68–70 are considered
good [19, 20]. The median SUS score of the REMPARK system in the pilots
was 70 (IQR 25).
Figure 9.8 System Usability Scale.
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The results can be considered good, according with standard interpre-
tations of the scale. However, the results must be interpreted with caution,
as the researchers administered themselves the SUS to the participants, who
knew that the answers were not anonymous. This could have biased the results,
because participants could have tried to please the researchers, offering a more
positive vision of the usability than they would have given under anonymous
circumstances.
Concerning the evaluation of user satisfaction, a subset of the QUEST
questionnaire was used. The QUEST scale as it is described in [18] contains a
number of items related to device characteristics and several questions related
to the service characteristics. All the answers must be done according the
following scale:
1. not satisfied at all
2. not very satisfied
3. more or less satisfied
4. quite satisfied
5. very satisfied
For evaluating REMPARK system, the 6 following items of the device
subscale were used, together with a general question (number 7):
1. The dimensions (size, height, length, width) of your assistive device?
2. The weight of your assistive device?
3. The ease in adjusting (fixing, fastening) the parts of your assistive device?
4. How safe and secure your assistive device is?
5. The ease in using your assistive device?
6. The comfort of your assistive device?
7. What is your overall satisfaction with the assistive device?
Obtained results are shown in Table 9.9. The results can be considered good,
being comfort the worst rated item and safety the best rated item. Overall
satisfaction is good, being not satisfied 5% of the participants, and quite
satisfied or very satisfied 75% of the users.
9.7 Summary and Conclusions
Forty-one (41) Parkinson Disease patients, under real conditions, participated
in the test of the REMPARK system. Overall results show that the system has
a good performance and reliability, with few data loss (4% of data), which
does not impact the main information provided by the system, as it comes
from several data slots, grouped and presented in 60 minutes’ periods.
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Table 9.9 Results for the QUEST questionnaire
Not Satisfied Not Very More or Less Quite Very
At All Satisfied Satisfied Satisfied Satisfied
n % n % n % n % n %
Dimensions 0 0 3 7,3 10 24,4 13 32 15 36,6
Weight 0 0 2 4,9 6 14,6 14 34 19 46,3
Ease in
adjusting
1 2,4 1 2,4 15 36,6 11 27 13 31,7
Safe 0 0 0 0 7 17,1 22 54 12 29,3
Ease in
using
0 0 2 4,9 8 19,5 22 54 9 22
Comfort 3 7,3 2 4,9 11 26,3 18 44 7 17,1
Overall
satisfaction
0 0 2 4,9 8 19,5 19 46 12 29,3
The validity of the REMPARK system to detect motor fluctuations is
very good. When all possible errors of the gold-standard timeline (the diary
completed by the user) are excluded, by using the so called “strict method”,
the sensitivity reaches 89% and specificity reaches 98%. These seems very
good results, given the fact that they have been achieved in real life conditions,
which are very demanding; in real life, there are many situations which could
cause false positive or false negative detections. We consider this an important
outcome, as it opens the door to a possible clinical use of the REMPARK
system in the future.
The study has also demonstrated how difficult it is for patient to fill
their diaries. In this respect, the REMPARK system constitutes a promising
candidate to evaluate the correlation between the medication intake and the
motor state in real life conditions. This can also constitute an invaluable help
as a quantitative assessment instrument in clinical trials.
Additionally, during the REMPARK pilots, users could answer non-
motor symptoms questionnaires using the mobile-phone interface. We did
not measure the validity of this way of administration of questionnaires,
but we really didn’t expect a decrease in validity of the questionnaires
when administered in this electronically way. This, again, suggested that
the REMPARK system could be successfully used by clinicians, to remotely
gather non-motor symptoms information from their patients.
Although the usefulness of the cueing system to improve gait in PD patients
have been previously demonstrated by other groups, we failed to show any
benefit of the REMPARK system in improving gait, during this specific pilot.
No benefit was noticed when performing the timed Up and Go test under
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controlled conditions (efficacy), though a tendency to improvement was shown
in the subgroup of patients with severe gait problems. These results did not
reach statistical significance, possibly due to the small sample size, which
pose problems of statistical power. In addition, the FOG questionnaire did
not improve after using the system during the testing days (effectiveness).
We think these results are inconclusive, as they were secondary outcomes
of the pilot, which was not specifically designed to address these issues. If
REMPARK system can improve gait problems or not, should be tested in
longer experiments, specifically designed for measuring the effectiveness of
the ACS sub-system.
The REMPARK system appeared to be safe, as no health adverse events
were noticed, which could be related to the system. However, this result has
to be interpreted with caution, as the small sample size and short observation
period, pose again problems of power to detected adverse events. Safety of
the system should be tested in additional research studies.
Finally, REMPARK system appears to be usable and participants seem to
be satisfied with the system. Although this is a very encouraging conclusion,
a possible bias in the usability results has to be taken into account, as the
participants’answers were not anonymous and the researchers where not blind
to their answers.
Overall, we consider that the REMPARK system piloting was successful,
demonstrating good performance and validity to detect motor fluctuations,
and good usability characteristics. The system is prepared for further testing
in its way to commercialization and medical use.
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10.1 Summary of PD Symptoms and the Influence on QoL
As it was extensively presented along Chapters 1 and 2, Parkinson’s Disease
(PD) is a major, chronic, non-communicable disease and the second most
frequent neurodegenerative disorder worldwide. There is currently no cure for
PD, but treatments are available to help relieve the symptoms and maintain
individual’s Quality of Life (QoL) at least for the first years.
It has been already debated the impact on the QoL of the Parkinson’s
Disease due to an enormous number of motor and non-motor symptoms:
bradykinesia, rigidity, tremor, postural instability, reduced gait speed, freezing
of gait, sleep disturbances, depression, psychosis, autonomic and gastroin-
testinal dysfunction as well as dementia. As already explained, the majority
of patients will develop an increasing number of more complex symptoms
over time.
The treatment in the early stages of the disease, focused on the use of
levodopa in pills, is very effective. Nevertheless, different problems related
with the treatment may start to appear depending on the advance of the
disease. Thus, it might be the case of motor complications: motor fluctuations
such as the wearing-off phenomenon, involuntary movements known as
dyskinesia, abnormal cramps and postures of the extremities and trunk known
as dystonia, and a variety of complex fluctuations in other motor and non-
motor functions. In these cases, the correct adjustment of the therapy is crucial
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for avoiding to decrease the QoL of the patient. The motor symptoms are
especially responsible of falls and gait impairments and negatively impact
on QoL by reducing the ability to perform many activities of daily living.
They are the major causes of institutionalisation and to lose the capability to
live independently. Daily tasks at home: self-care, food preparation, hygiene,
become difficult, as do many activities outside the home (shopping, visiting
friends/family, leisure activities . . .).
The global management of this disease has to be based on a simultaneous
treatment and consideration of different symptoms that usually are treated in
different by different specialists. Unfortunately, many times no integration
between data is made and there is a lack of information about the overall
condition of the patient and, furthermore, there is not enough communication
between the healthcare professionals treating the patient.
REMPARK system, discussed along the present document is a good
example of the recent advances in technologies for people with neurological
diseases, focused on the development and validation of tools, techniques and
overall solutions for the effective management of PD. The system exhibits
the combination of two technologies that promise to radically change the
daily management of PD: the so-called wearables technology (WT) and the
machine-learning based algorithmic approach.These technologies can provide
objective, high frequency, sensitive and continuous data on motor and non-
motor phenomena in PD. Thanks to the technology, it is possible to solve
one on the major existing problem: the data acquisition over a continuous
time period. An important aspect of a WT system is that it allows remote
monitoring of symptoms with its obvious potential advantage for patients and
health economics.
10.2 Existing Barriers of PD Management
In order to preserve their quality of life and allow them to live independently for
longer while experiencing their burdens, PD patients fully resort on tailored
treatments that can address the symptoms as they appear or prevent/delay
the onset of other symptoms and co-morbidities. Emerging systems, like
REMPARK, try to improve the efficacy of disease management and treatments
in the current clinical practice that presents the following major obstacles:
• Barrier 1: Lack of accuracy and completeness when reporting about
own symptoms. Due to the cognitive impairments, distress or the evasive
nature of some of the symptoms caused by PD, the patients often
10.2 Existing Barriers of PD Management 213
find difficulties or lack sufficient ability to provide reliable/consistent
clinically relevant information about the symptoms they experience in
order to optimise the treatment. In particular, often the patients are not
aware of the onset of dyskinesia and sometimes it is even difficult for
them to distinguish between ON/OFF periods. However, these are key
information items for the doctor to adjust the treatments.
• Barrier 2: Missing information about the PD symptoms and signs
of disease progression at clinical level. The current available means to
report and monitor the symptoms are modest as compared to the huge
challenge posed by the variety of PD symptoms and their fluctuations.
The patient’s visits and self-reporting may not throw reliable or complete
evidence for the physician to cope with the entire picture and overall
phenomena surrounding their patient’s day-to-day. Most of the evidence
used builds on reporting provided by the same patients and they often
lack the ability to undertake this task.
• Barrier 3: Compromised self-care and adherence to treatments.
Treatment regimens (medications, times, doses) and adherence to treat-
ment are crucial for a correct PD management and the QoL of the
patients. PD patients resort to prescribed regimes, but this seemingly
simple commitment may represent a non-trivial feat, since patients must
add on top of the overall burden the challenge of self-care, which is
often difficult to achieve due to the many impairments and distresses
linked to the disease. Cognitive deficits such as attention, communication,
memory, and executive functions; depression and impulsive behaviours
play a key role in the common lack of adherence and self-efficacy in
co-management of the disease.
• Barrier 4: Symptoms recognition in time to better administrate
the medication dose. Another related barrier is the capability of the
professional to properly assess the number of OFF hours the patient has
experienced to judge, based on that information, the therapeutic effect
of the administered therapy, since it is based on daily or patient recall.
Thus, the practitioner has difficulties for adjusting the continuous dose
and control the administration of extra doses, mainly when an infusion
pump therapy is used.
• Barrier 5: Usability from the patient’s point of view. Some patients
with Parkinson’s have OFF phases so severe that they cannot even self-
administrate extra doses. Patients with severe OFFs, which have no
caregivers who can perform this task for them, often cannot choose the
treatment with continuous infusion pumps.
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10.3 The Role of the REMPARK System in the Context
REMPARK system was proposed and has been developed as a personal
health system for the remote and autonomous management of PD. It is
composed of wearable sensors for the detection and measurement of motor
symptoms, a high level analytical layer and decision support tool, and a
care platform (DMS) for professional care providers, patients and family. It
enables the real-time, continuous and quantitative identification of the patient’s
motor symptoms in ambulatory conditions. The novelty and added value of
REMPARK relies on using just one inertial sensor located and fixed to the
patient’s waist and a mobile interface to constantly read and send to the remote
server a wealth of key relevant motor symptoms related to PD.
After symptoms’ identification, the system is also able to provide some
degree of actuation, like gait guidance mainly with an auditory cueing system,
automatic fall detection and alarms, and assistance for self-management
during daily life activities. Further development of the system should also
include an automatic control of an infusion pump for a more accurate dosage
or a delivery of an extra dose, when necessary.
The remote computing platform underneath REMPARK provides auto-
matic data storage, processing, analysis and visualization tool so that other
relevant actors, doctors and caregivers, can be included in the loop and can
provide the best-informed, evidence-based and personalized action for therapy
and healthcare management. In particular, REMPARK can be used to extract
indicators of the disease evolution and open the possibility of a better adjust
of the medication and treatments.
One of the main advantages of REMPARK is its alignment with the actual
evolution of the care models, that are moving from reactive to proactive
approach. The strength of the system relies on the ability to obtain, analyse
and integrate data from different sources: sensors, patient reported data and
healthcare professionals.
The system is able to receive the data transmitted from the sensors. For each
individual patient, it is possible to define a range of normal values, permitting
to stablish some levels of alarms according the thresholds defined by the
professionals. Any deviation from normal event creates an alert on the system
and consequently there is a reactive intervention. The DMS includes a shift
management module that manages the tasks and users that are at each shift.
The shift manager can see the workload and type of activities done in the
centre for efficient management of the care process.
The REMPARK system is an interesting solution that includes a wide range
of functionalities for delivering comprehensive and customizable integrated
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care by a multidisciplinary team, but it also enables the treating physician to
maintain a supervision of the patient throughout the journey; from patient
disease diagnosis, through treatment plan definition, customizing specific
protocols. One of the main problem in most existing systems for disease
management is that the patient’s data used for treatment is collected on the
system overtime and is not updated by other systems that are used for treating
the patient. This problem is particularly relevant when the patients are affected
by a multimorbidity.
Multimorbidity is commonly defined as the presence of two or more
chronic medical conditions in an individual and it can present several chal-
lenges in care particularly with higher numbers of coexisting conditions and
related polypharmacy. For this reason the patient is treated by the neurologist
for the PD and in parallel he is treated by the general physician in the commu-
nity for other health conditions. Typically, a completeintegration between data
doesn’t exist and there is a lack of information about the overall condition of the
patient. Furthermore, the communication between the healthcare professionals
treating the patient is quite limited. This way of delivering care results in a
fragmentation, some duplication and lacks of coordination.
REMPARK, offers an integrated environment for data and knowledge
sharing for all care providers and also it provides clinical guidelines and
a decision support tool for healthcare providers helping in management of
patient’s disease. This tool enables treating several conditions at the same time
in a coordinated way avoiding the interaction among drugs and the negative
impact on the patients compliance.
Another additional value is the available integrated platform, allowing
the stablishement of improved communication channels among patients and
professionals (doctor, nurse, etc.)
Some advantages for the patients are the increase of their treatment
performance scores, the improvement of the patients’ empowerment and a
good degree of satisfaction.
10.4 Limitations of the REMPARK System
The characteristics and advantages of REMPARK system would contribute,
for sure, to the mitigation of the barriers analysed in the Section 10.2. It is
obvious that some limitations exist, and because a main part of REMPARK
is the sensor (a wearable device) for the detection and measurement of the
motor symptoms related with PD, part of the inherent limitations are in line
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with those of different wearable products developed for their use in e-Health
domains.
There is a need to improve the cost-to-benefit ratio of WT strategies and
their effectiveness for chronic disease and rehabilitation therapy management.
Innovative research is still needed to continue developing the best combination
of wellness, special needs and technologies in order to assist and maintain the
preferred QoL for individuals with chronic disabilities and older adults.
A further limitation is the need of a refinement of the technology to
correctly measure and monitoring non-motor symptomatology of the dis-
ease. Patient priorities and sources of disability often arise from non-motor
deficits, such as: depression, anxiety, fatigue, orthostatic hypotension, sleep
disturbance. There is a need for developing unobtrusive systems to monitor
non-motor end points in the home environments and community settings.As it
has been presented along the chapters, REMPARK was designed as a complete
system, where in a limited way, the consideration of the non-motor symptoms
was already included and worked-on. Further versions of REMPARK system
must, for sure, consider and emphasize these aspects.
Usability of the REMPARK system was a challenge from the beginning
of the project and quite good results are reported in Chapter 9. A problem that
the consortium was working-on and tried to solve is the PD patient’s adapted
smartphone interface. The special adapted interface (see Chapter 6) is a good
point for the usability and acceptability of the system.
After the REMPARK project finalization, relevant experiences would be
used for an improved version of the different parts of the system, but always
some common issues related with the acceptability of wearables in general
would be encountered.
Systems are often not as user friendly or compelling to adopt as they should
be. Currently, patient and care giver engagement with wearable and mobile
technology is modest, as shown by recent studies.
A lack of motivation to use wearables and monitoring systems should not
be underestimated, particularly in the absence of meaningful feedback pro-
vided to their users. Preliminary evidence suggests that patient empowerment
and their inclusion as active players in the development of research activities
may favourably impact on compliance. As a preliminary conclusion, it could
be stablished that additional research is needed to determine the characteristics
and the feasibility of wearable systems for long-term monitoring of motor and
non-motor symptoms that would be acceptable to patients.
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The power and usefulness of the devices and systems based on ICT technolo-
gies are still under-recognized by a part of the physicians and professionals
participating in the treatment and management of the PD patients. Its potential,
considered as an aid to the patients, is also under-exploited.
In the case of REMPARK, the system is based on non-obtrusive elements
worn by the patient: the waist inertial sensor, a smartphone and an auditory cue-
ing system. The elements seamlessly communicate with each other and with
the server platforms providing further service and capabilities. REMPARK
is an interoperable standalone solution that can be easily integrated in
Hospital Management Systems and external eHealth services operated by
third parties.
The REMPARK system core is a sensor device placed on the patient’s
waist that it is able, as it has been already explained, to identify and quantify
the main motor symptoms of PD (bradykinesia, dyskinesia and FOG) in real
time. This sensor also recognizes and registers the patient’s motor fluctuations
(ON and OFF motor states) in ambulatory conditions in a very reliable and
automatic way while patients are performing their normal activities. Finally,
the device wirelessly transmits this information to a server.
Furthermore, the use of these devices with the described characteristics
would enable the doctors to accurately personalize medication intakes and,
thus, improve the patient’s response to the treatment. A system with the
REMPARK characteristics would result an invaluable tool in the diagnosis
and management of PD. A correct detection of the symptoms would help
to, on one hand, enhance the effectiveness of the oral medication through a
better regimen adjustment; on the other hand, to automatically control the
administration of an extra dose when the patients are using infusion pumps
(apomorphine or duodopa). These new approaches are aimed at significantly
improve the QoL of patients and, it will allow a deeper understanding of the
personalized evolution of the disease.
An additional benefit is represented by the contribution of the system to the
real and effective implementation of a multidisciplinary care. In fact, clinical
experience suggests that optimal management requires a multidisciplinary
approach, with multifactorial health plans tailored to the needs of each
individual patient. In case of PD patients, the multidisciplinary team includes
physiotherapists, occupational and speech-language therapists, dieticians and
social workers.
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The use of systems highly based on ICT technology, like REMPARK,
contributes to alleviate and facilitate the organization of the multidisci-
plinary approach improving communication between the different health
professionals, the patients and the caregiver.
Another area that would benefit from a tool, like the sensor developed in
REMPARK is the clinical and epidemiological research. This kind of studies
are expensive and highly laborious. Sometimes, they suffer economic limita-
tions that can affect the methodological rigor of the studies carried out. In gen-
eral, the studies based on movement disorders are especially complicated, on
the one hand by the lack of well-established markers to establish a clear diag-
nosis and, on the other hand, by the lack of uniformity in diagnostic criteria.
Finally, it must be pointed out that REMPARK system technological
innovation can be an interesting challenge for companies developing business
based on the commercialization of new e-health home based services for
PD patients. Such tools would provide the unique opportunity to objectively
monitor and control the treatment efficacy of any given therapy on an individ-
ual basis, which would sustainably change traditional health care methods.
10.6 As a Concluding Remark
We can conclude that REMPARK system is a big step to a new approach
to a new approach of the PD treatment where the technology contribution is
helping to provide a different and complimentary view of the symptoms of
the disease by offering clinicians a complete map and evolution.
The provided information will not only be useful from a diagnosis but
rather would contribute to a better and more effective management of the
disease.
This kind of systems, when completely developed, will be relevant because
the possible supervision and measurement of the evolution of the symptoms
and the appearance of new ones. This will permit a rapid action when
necessary, facilitating among others the establishment of preventive polices
according patients’ individual needs.
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Parkinson’s Disease (PD) is a neurodegenerative disorder that manifests 
with motor and non-motor symptoms. PD treatment is symptomatic 
and tries to alleviate the associated symptoms through an adjustment of 
the medication. As the disease is evolving and this evolution is patient 
specific, it could be very difficult to properly manage the disease.
The current available technology (electronics, communication,  computing, 
etc.), correctly combined with wearables, can be of great use for obtaining 
and processing useful information for both clinicians and  patients allowing 
them to become actively involved in their condition.
Parkinson’s Disease Management through ICT: The REMPARK 
Approach presents the work done, main results and conclusions of the 
REMPARK project (2011 – 2015) funded by the European Union under 
contract FP7-ICT-2011-7-287677. REMPARK system was proposed 
and developed as a real Personal Health Device for the Remote and 
Autonomous Management of Parkinson’s Disease, composed of 
different levels of interaction with the patient, clinician and carers, 
and integrating a set of interconnected sub-systems: sensor, auditory 
cueing, Smartphone and server. The sensor subsystem, using embedded 
algorithmics, is able to detect the motor symptoms associated with 
PD in real time. This information, sent through the Smartphone to the 
REMPARK server, is used for an efficient management of the disease.
Implementation of REMPARK will increase the independence and 
Quality of Life of patients; and improve their disease management, 
treatment and rehabilitation.
